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ABSTRACT 
 
 
ANDREA MARY MURPHY. Nonsegmented negative strand RNA viruses: viral RNA 
cap methylation and potential applications as an anticancer therapy. (Under the direction 
of DR. VALERY GRDZELISHVILI) 
 
 
The viruses of the order Mononegavirales include important human, animal, and 
plant pathogens and additionally, have great potential as vaccine, oncolytic and gene 
therapy vectors. This dissertation focuses on two prototypic Mononegavirales, vesicular 
stomatitis virus (VSV) and Sendai virus (SeV), their virus-encoded cap methylation 
function, and potential applications as an anticancer therapy. The L protein of 
Mononegavirales has six conserved domains postulated to constitute the specific 
enzymatic activities of this multifunctional protein. We conducted a comprehensive 
mutational analysis by targeting the entire SeV L protein domain VI, creating twenty-four 
infectious L mutants. Our analysis identified several residues required for successful cap 
methylation and virus replication. This study confirms structural and functional similarity 
of this domain across different families of the order Mononegavirales. Additionally, the 
oncolytic potential of VSV was analyzed for the first time in a panel of human pancreatic 
ductal adenocarcinoma (PDA) cell lines and compared to other oncolytic viruses. VSV 
showed superior oncolytic abilities; however, cells were heterogeneous in their 
susceptibility to virus-induced oncolysis and several cell lines were resistant to all tested 
viruses. Four cell lines that varied in their permissiveness to VSV were tested in mice, 
and in vivo results closely mimicked those in vitro. While our results demonstrate VSV is 
a promising oncolytic agent against PDA, further studies are needed to better understand 
the molecular mechanisms of resistance to oncolytic virotherapy.  
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CHAPTER 1: INTRODUCTION 
 
The nonsegmented negative strand (NNS) RNA viruses of the order 
Mononegavirales include many important human, animal, and plant pathogens such as 
rabies virus, Ebola and Marburg viruses, measles, mumps and respiratory syncytial virus. 
Most of our current understanding of the biology of Mononegavirales comes from 
studying two prototypic members of this order, vesicular stomatitis virus (VSV, Family 
Rhabdoviridae) and Sendai virus (SeV, Family Paramyxoviridae) (Lamb and Parks 2007; 
Lyles 2007). There are several advantages to using VSV and SeV as research models for 
the less tractable members of this order including: i) the ability to safely study them in the 
laboratory ii) their simple genome structure; iii) their ability to replicate in a wide range 
of cell types; iv) the development of in vitro systems for the study of RNA synthesis; and 
v) available reverse genetic systems (Lyles 2007). Further study of the molecular biology 
of these viruses is important because it can lead to the development of new effective 
antiviral therapies for medically related viruses. Moreover, VSV and SeV have great 
potential as vaccine, gene therapy and oncolytic vectors (von Messling and Cattaneo 
2004; Finke and Conzelmann 2005; Bukreyev et al. 2006). This dissertation focuses on 
both the basic molecular biology of VSV and SeV, more specifically 5’ cap methylation 
of viral mRNAs, and additionally, potential applications of these viruses as an anticancer 
therapy. 
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Mononegavirales and eukaryotes share a similar 5’ mRNA cap structure. 
Viruses of Mononegavirales encode only 5-10 proteins and utilize the host cell 
machinery for a successful replication cycle to occur. Therefore, similar to eukaryotic 
mRNA, viral mRNA requires a 5’ cap structure that is methylated for efficient translation 
and mRNA stability (Abraham et al. 1975). Viral mRNA mimicks the host’s mRNA 
thereby utilizing all the necessary components of the translation machinery for the 
efficient production of viral proteins. This viral mimicry may also play a role in evading 
host antiviral responses (Daffis et al. 2010; Zust et al. 2011). While this dissertation 
focuses on the methylation of viral mRNA 5’ cap structures, it is important to describe 
the different mechanisms of 5’ cap addition between Mononegavirales and eukaryotes, 
both ending up with identical mRNA 5’ cap structures which are required for successful 
translation (Fig. 1).  
The process of mammalian transcription centers around RNA polymerase II and 
requires a multitude of transcription factors to aid in all aspects of this important cellular 
process. RNA polymerase II consists of 12 subunits and is responsible for catalyzing 
mRNA synthesis of all genes that code for proteins (Alberts et al. 2002). As the mRNA 
molecule is being synthesized, other mRNA processing reactions are occurring co-
transcriptionally (Cowling 2010). These reactions include RNA splicing to remove intron 
sequences from the RNA transcript, the addition of a 5’ cap structure, and 3’ 
polyadenylation (Cowling 2010). The enzymes that catalyze these modifications interact 
with the RNA polymerase II tail known as the C-terminal domain (CTD) (Alberts et al. 
2002; Cowling 2010). The CTD is highly phosphorylated during transcription elongation 
which allows for a high amount of protein association (Alberts et al. 2002; Cowling 
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2010). Four enzymes are involved in creating the 5’ cap structure of all eukaryotic 
mRNAs and these enzymes all associate with CTD during transcription elongation and 
are transferred at certain time points to the nascent RNA molecule for the addition of the 
5’ cap (Alberts et al. 2002; Cowling 2010). First, a triphosphatase removes a phosphate 
from the 5’ end of the nascent RNA molecule (Cowling 2010). Secondly, a 
guanylyltransferase transfers a GMP from GTP in an unusual 5’ to 5’ linkage (instead of 
5’ to 3’) (Cowling 2010). For mammals, the phosphatase and guanylyltransferase activity 
is catalyzed by a single polypeptide known as capping enzyme (CE) or also known as 
RNA guanylyltransferase and 5’ triphosphatase (RNGTT) (Pillutla et al. 1998; 
Tsukamoto et al. 1998; Yamada-Okabe et al. 1998). Lastly, methyltransferases (MTases) 
add methyl groups to the guanine-N7 (G-N7) position (Cap0) and the 2’O-ribose of the 5’ 
penultimate nucleotide residue (Cap1) (Cowling 2010). The G-N7 (RNA guanine-7 
MTase, RNMT) and 2’O-ribose MTases are distinct proteins (Pillutla et al. 1998; 
Tsukamoto et al. 1998; Cowling 2010). It has been well established that methylation of 
the 5’ cap at the G-N7 position is absolutely required for efficient translation, but 
significance of methylation at the 2’O-ribose has remained unclear (Daffis et al. 2010; 
Zust et al. 2011). Recent studies have demonstrated that the presence or absence of 2’O-
ribose methylation has an evolutionary basis and plays a role in distinguishing self from 
non-self mRNA (Daffis et al. 2010; Zust et al. 2011). 
The 5’ cap structure of mammalian mRNA plays several important roles in the 
cell cycle and because viruses hijack the cell’s translational machinery, it is important for 
viruses to mimic cellular mRNA structure. The 5’ cap structure of the newly synthesized 
mRNA is bound by a cap-binding complex (CBC) in the nucleus which aids in further 
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RNA processing and transport to the cytoplasm (Alberts et al. 2002). In the cytoplasm, 
eukaryotic initiation factor 4E (eIF4E) directly binds to the 5’ cap and then associates 
with eIF4G (Alberts et al. 2002). The small ribosomal subunit recognizes eIF4E/eIF4G 
and then moves along the mRNA until it identifies the first AUG start codon (Alberts et 
al. 2002). The initiation factors dissociate from the small ribosomal subunit which allows 
the large ribosomal subunit to assemble and translation proceeds (Alberts et al. 2002). 
The 5’ cap structure plays an important role in exit from the nucleus and entry into the 
cytoplasm in addition to efficient translation initiation (Alberts et al. 2002; Cowling 
2010), but it also has other important functions. Fully methylated 5’ caps provide mRNA 
stability by protecting mRNA from degradation by exonucleases (Murthy et al. 1991). 
The guanylyltransferase reaction is reversible, and uncapped mRNA created by the 
reverse reaction is rapidly degraded. There is evidence that the methylation reaction is 
irreversible and therefore the guanylyltransferase cannot use methylated cap structures as 
substrate for the reverse reaction, and this allows for stabilization of mRNA (Furuichi et 
al. 1977; Murthy et al. 1991). The mRNA 5’ cap structure in eukaryotes and 
Mononegavirales are identical so that viral mRNAs can be recognized and utilize the host 
cell translational machinery however the mechanisms of 5’ cap addition differ greatly.  
The unusual mechanism of Mononegavirales 5’ mRNA capping and cap methylation. 
All members of Mononegavirales share a similar genome organization and 
common mechanisms of genome replication and gene expression (Lamb and Parks 2007; 
Lyles 2007). The L protein, whose large size (more than 2,000 amino acids in a single 
polypeptide chain) reflects its multifunctional nature, plays a central role in virus RNA 
replication and transcription. This protein has six sequence regions (“domains”) with a 
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high degree of homology among all Mononegavirales. Although there is no protein 
structure data available for any part of the L protein, these domains have been postulated 
to constitute the specific enzymatic activities of the viral RNA polymerase involved in 
transcription, mRNA 5’ capping, cap methylation, mRNA 3’ polyadenylation, and 
replication of viral RNA (Whelan et al. 2004; Lamb and Parks 2007; Lyles 2007). 
The mRNA 5’-cap structures of Mononegavirales are methylated by the virally 
encoded L protein at the guanine-N7 and 2’-O-adenosine positions (Abraham et al. 1975; 
Moyer et al. 1975; Rhodes and Banerjee 1975; Gupta et al. 1979; Barik 1993; Takagi et 
al. 1995). The single multifunctional L polypeptide is responsible for all enzymatic 
capping reactions because this process takes place in the cytoplasm of host cells whose 
capping enzymes are localized to the nucleus. The viral capping reaction is different from 
the eukaryotic capping mechanism (described above); however, both reactions lead to 
identical mRNA 5’ cap structures (Ogino and Banerjee 2011). The capping mechanism of 
Mononegavirales is beyond the scope of this dissertation; however, it is a required 
precursor to the methylation reactions and will be briefly described (Fig. 1). The first step 
requires a GTPase activity of the L protein (to date this activity has not been mapped to a 
specific region of L) to remove the γ-phosphate group of GTP to generate GDP (Ogino 
and Banerjee 2007; Ogino and Banerjee 2008). The α and β phosphates of the nascent 
mRNA are therefore derived from a GDP donor instead of a GMP (as seen in eukaryotes) 
and the enzymatic activity responsible for this reaction is a RNA:GDP 
polyribonucleotidyltransferase (PRNTase) activity (Ogino and Banerjee 2007; Li et al. 
2008). The PRNTase activity has been mapped to a specific motif (GxxT[n]HR) in 
domain V of the VSV and Chandipura virus (also Family Rhabdoviridae) L proteins (Li 
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et al. 2008; Ogino and Banerjee 2010). The PRNTase domain of L interacts with the 
triphosphate of the newly synthesized mRNA which has a specific start sequence (L + 
pppAACAG → L-pAACAG +PPi) (Rhodes and Banerjee 1976). More recently, Ogino et 
al. has described an alternative mechanism for the addition of guanosine to the 5’ ends of 
viral mRNA (Ogino and Banerjee 2008). In this mechanism, the PRNTase domain of L 
interacts with the triphosphate of the newly synthesized mRNA which has a specific start 
sequence (L + pppAACAG → L-pAACAG +PPi). GTP (GDP is not efficiently generated 
from GTP using their experimental conditions) is then transferred to the L-pA 
intermediate to form a guanosine-tetraphospho-adenosine cap structure (GppppAACAG). 
This process occurs at a much lower efficiency than the originally described VSV 
mechanism of 5’ cap addition; however, both of these mechanisms differ greatly from 
eukaryotic and other viral capping reactions (Ogino and Banerjee 2008). 
Currently there is no structural data available for any portion of L, however 
independent computational analyses (Bujnicki and Rychlewski 2002; Ferron et al. 2002) 
propose that, while L proteins share a very low degree of homology with other known S-
adenosylmethionine (AdoMet) dependent MTases at the aa level, their domain VI has a 
prototypical MTase fold; a glycine-rich motif shared by all members of the AdoMet-
dependent MTase superfamily and directly involved in AdoMet binding (Ingrosso et al. 
1989; Martin and McMillan 2002); and several potential catalytic residues. Although all 
these studies suggest that a conserved domain VI is the MTase domain of L, many 
important questions remain including the MTase specificity of domain VI (G-N7, 2’-O-
adenosine, or both?), and there have been no reports for the L protein in VSV or any 
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other Mononegavirales that directly demonstrate the location of the L protein region 
physically binding AdoMet. 
The MTase function of L was originally shown by Sue Moyer and coworkers 
through the characterization of two host-range (hr) mutants of VSV. It was shown that 
these mutants were defective in viral mRNA cap methylation (Horikami and Moyer 
1982; Horikami et al. 1984), and that purified wild-type (wt) L protein was able to 
complement their defect during transcription in vitro, demonstrating that the VSV L 
protein possesses cap MTase activities (Hercyk et al. 1988). In addition to defective cap 
methylation, a link was documented between L protein MTase activities and the 
phenotype of the VSV mutants. Specifically, VSV mutants defective in cap methylation 
were temperature sensitive (ts) and, more interestingly, hr restricted as manifested by 
their inability to grow in certain nonpermissive cell lines (e.g., HEp-2 cells) while 
retaining their ability to grow to high titers in permissive cells (e.g. BHK-21) (Horikami 
and Moyer 1982; Horikami et al. 1984; Grdzelishvili et al. 2005; Grdzelishvili et al. 
2006).  Previous studies linked the inability of VSV cap methylation defective mutants to 
grow in HEp-2 cells to nontranslatability of primary VSV transcripts (Horikami and 
Moyer 1982; Horikami et al. 1984) and showed that host cells methylate viral mRNA in 
permissive cell lines through an unknown mechanism (Horikami et al. 1984). 
 A more recent analysis of the VSV hr1 mutant showed that a single aa 
substitution (D1671V) in this putative AdoMet-binding glycine-rich motif, completely 
eliminated viral mRNA cap methylation at both the guanine-N7 and 2’-O-adenosine 
positions (Grdzelishvili et al. 2005), thus experimentally supporting the above 
computational predictions (Bujnicki and Rychlewski 2002; Ferron et al. 2002). In 
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addition, it has been demonstrated that substitutions at other positions within the VSV L 
protein domain VI (including an invariant lysine 1651 and aa 1670 and 1672 within the 
glycine-rich motif) also resulted in various defects in mRNA cap methylation 
(Grdzelishvili et al. 2005; Li et al. 2005; Grdzelishvili et al. 2006; Li et al. 2006; 
Galloway et al. 2008). These data suggest that domain VI catalyzes both G-N7 and 2’O-
ribose methylation and uses a single AdoMet binding site (order of methylation is 
discussed below) (Li et al. 2006). The exact mechanism of these two methylation 
reactions is unclear; however, it is possible that other regions of L have varying affects on 
these two activities through allosteric interactions (Li et al. 2007). For example, Li et al. 
demonstrated that aa substitutions in domain II and III of the VSV L protein can affect 
cap methylation (Li et al. 2007). Both MTase activities do require specific cis acting 
signals in the viral RNA (Wang et al. 2007). As transcription proceeds, the viral mRNA 
has a conserved 5’ sequence (pppAACAGNNAUC) that is thought to be the substrate for 
the capping and cap methylation enzymatic activities of the L protein (Rhodes and 
Banerjee 1976; Wang et al. 2007). Substitutions at aa positions 1, 2, 3, and 5 inhibit cap 
addition and it is thought that the conserved residues at positions 8, 9, and 10 are required 
for cap methylation (Ogino and Banerjee 2007). Therefore the length of the mRNA 
substrate for capping and cap methylation differs (Ogino and Banerjee 2007). To further 
analyze the cap methylation function of the VSV L protein, Zhang et al. identified two 
highly conserved aromatic aa residues in domain VI of the VSV L protein that play a role 
in mRNA substrate recognition (Zhang et al. 2010). Together, these data confirm and 
support the role of domain VI of the L protein in many of the aspects of cap methylation 
in VSV and potentially other Mononegavirales.   
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Studies with VSV also identified a region upstream of domain VI important for 
cap methylation (Grdzelishvili et al. 2006). Interestingly, it has been shown that VSV 
tolerates an insertion of the GFP gene between domain VI and this upstream region, and a 
recombinant virus with such insertion showed a normal growth in cell culture but no 
virion-associated activity in vitro (Ruedas 2009). The upstream region has not been 
studied in SeV as there is no homology in this variable region between rhabdoviruses and 
paramyxoviruses, although the L protein of measles virus (a paramyxovirus) was also 
reported to tolerate GFP insertion in a region just upstream of domain VI (Duprex et al. 
2002). 
The cap methylation order for Mononegavirales is controversial with some 
evidence pointing to the conventional order GpppA → m7GpppA → m7GpppAm and 
some evidence pointing to GpppA → GpppAm → m7GpppAm. The in vitro results using 
detergent-activated VSV (Indiana strain) virions proposed the following order of MTase 
reactions:  GpppA + AdoMet (low concentration) → GpppAm  + AdoMet (high 
concentration) → 7mGpppAm (Testa and Banerjee 1977; Li et al. 2006). Rahmeh et al. 
demonstrated that aa substitutions in the positions of the KDKE catalytic tetrad inhibit 
methylation at both positions most likely because efficient G-N7 methylation requires 
2’O-ribose methylation to occur first (Rahmeh et al. 2009). They also speculate that 
KDKE residues, in addition to catalyzing 2’O-ribose methylation, play a role in 
positioning the RNA substrate for G-N7 methylation to occur (Rahmeh et al. 2009). 
However, the previous in vitro data on VSV (Indiana strain) mRNA synthesis in the 
presence of the methylation inhibitor cycloleucine (Moyer 1981) and in vitro 
transcription data on VSV New Jersey serotype (Hammond and Lesnaw 1987) suggest 
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that the reverse order of VSV mRNA methylation (GpppA→7mGpppA →7mGpppAm) 
can also occur.  
While most of the cap methylation studies were conducted using VSV, limited 
studies using SeV and other Mononegavirales demonstrated similarities as well as 
differences in the cap methylation function of L between these distantly related viruses. 
SeV produces mRNA that is capped and methylated at both the G-N7 and 2’-O positions 
(Takagi et al. 1995), but interestingly, purified SeV L protein or just its C-terminal 
portion retaining domain VI, catalyzed only G-N7, but not the 2’-O cap methylation 
(Ogino et al. 2005). Also, a previous study showed that Newcastle disease virus (NDV), 
another paramyxovirus, produces viral mRNAs that are not 2’-O-methylated at all 
(Colonno and Stone 1976). While much is known about VSV cap methylation, there are 
very few studies with other members of Mononegavirales; therefore, we chose to analyze 
cap methylation function in the SeV L protein, which is distantly related to VSV, to 
determine if cap methylation function is similar across different families of this order. 
11 
 
Figure 1. Proposed 5’ capping mechanisms for viruses of Mononegavirales (A) and 
eukaryotes (B). Adapted from Ogino and Banerjee (2011). 
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The role of viral mRNA cap methylation in a successful replication cycle. 
 In general, the viruses of Mononegavirales have similar strategies when it comes 
to a successful infection/replication cycle. Viral mRNA 5’ capping and cap methylation 
is an important part of replication because of the utilization of host cell translational 
machinery and the necessity of production of viral proteins. Virus infection begins with 
attachment and entry into host cells. Protruding from the host-derived viral envelope, are 
varying proteins that recognize certain aspects of the cell membrane. For members of 
Mononegavirales, viruses are recognized by specific cellular receptors, sugar moieties or 
interactions with certain cell membrane properties. Sialic acid moieties serve as receptors 
for SeV and are found on both membrane glycoproteins and lipids (Markwell et al. 1984; 
Markwell et al. 1985). Anchored in the SeV envelope are hemagglutanin/neuraminidase 
(HN) proteins that interact with sialic acid residues and fusion (F) proteins that facilitate 
envelope-membrane fusion (Scheid and Choppin 1974; Lamb and Parks 2007). Upon 
recognition and attachment of SeV, the viral envelope fuses with the cell membrane at 
neutral pH and ribonucleoprotein (RNP) complexes are released into the cytoplasm 
(Scheid and Choppin 1974; Lamb and Parks 2007). RNP structures consist of the viral 
RNA genome tightly surrounded and protected by virally encoded nucleocapsid (N) 
proteins. The single VSV envelope glycoprotein (G) is not recognized by a known 
receptor and because VSV has a wide host range, it is thought that VSV can enter host 
cells through electrostatic interactions at the host cell membrane (Schlegel et al. 1983; 
Bailey et al. 1984; Coil and Miller 2004). To date it is unclear the actual mechanism of 
VSV attachment. Following attachment, VSV enters host cells via clathrin-dependent 
endocytosis and passes through the stages of early to late endosomes in the cytoplasm 
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(Matlin et al. 1982; Cureton et al. 2009). As the endocytic pathway progresses, the pH 
drops within the endosome, triggering fusion of the viral envelope with the endosome 
membrane and the release of the viral RNP complexes into the cytoplasm (Matlin et al. 
1982). Following attachment and entry into host cells, VSV and SeV have very similar 
strategies for a successful replication cycle. Because all aspects of the Mononegavirales 
life cycle take place in the cytoplasm of host cells, the RNA-dependent RNA polymerase 
(RdRp), consisting of two viral subunits (the cofactor phosphoprotein (P) and the 
enzymatic large (L) polymerase protein) is packaged into mature virions (Whelan et al. 
2004). The RdRp is associated with N, and the matrix (M) protein initially surrounds all 
components beneath the viral envelope (Whelan et al. 2004).Upon entry into the 
cytoplasm, the M protein spontaneously dissociates from the RNP structure, allowing for 
primary transcription to proceed (Rigaut et al. 1991). Primary transcription is defined as 
transcription from the original RNA templates that have entered the cell. The RdRp 
always initiates transcription at the 3’ leader sequence and proceeds down the genome, in 
what is known as the start-stop model, to transcribe the mRNAs encoded by VSV and 
SeV (Whelan et al. 2004). The RdRp will pause at intergenic regions and either dissociate 
or continue on to transcribe the next gene (Abraham and Banerjee 1976). Transcripts are 
co-transcriptionally modified (capped, methylated and polyadenylated) and created in a 
gradient fashion with genes encoding proteins that are needed at higher levels located 
closer to the 3’ end of the genome and genes that encode for proteins that are needed in 
lesser amounts located closer to the 5’ end (5’-N-P-M-G-L-3’ for VSV and 5’-N-P/V/C-
M-F-HN-L-3’ for SeV) (Abraham et al. 1975; Abraham and Banerjee 1976; Ball and 
White 1976; Ball 1977; Whelan et al. 2004). In addition to mRNAs, a leader RNA is 
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always synthesized prior to N mRNA; however, this RNA is neither capped nor 
polyadenylated and is thought to play a role in evading antiviral responses (the exact 
functions remain unclear) (McGowan et al. 1982; Grinnell and Wagner 1985; Whelan 
and Wertz 1999). For most Mononegavirales the N protein is the first gene to be 
transcribed because a large quantity of N is needed for genome and antigenome 
encapsidation throughout the replication cycle (Bishop and Roy 1971; Emerson and 
Wagner 1972). The genomes and antigenomes of these viruses never exist without being 
tightly associated with N and therefore a sufficient amount of N must be synthesized 
prior to viral replication and secondary transcription (Bishop and Roy 1971; Emerson and 
Wagner 1972; Patton et al. 1984). SeV primarily transcribes monocistronic mRNAs 
similarly to VSV; however, the SeV P gene also undergoes mRNA editing to produce 
accessory (V and C) proteins that play roles in inhibiting host antiviral responses (Garcia-
Sastre 2004; Conzelmann 2005; Lamb and Parks 2007). Once sufficient amounts of N 
have been synthesized, the RdRp switches from transcriptase to replicase, catalyzing 
synthesis of antigenomes and negative strand genomes from antigenomes (Wertz 1983; 
Lyles 2007). Accumulation of progeny genomes triggers the RdRp to proceed with 
secondary transcription (Whelan et al. 2004; Lyles 2007). RdRp can now transcribe from 
the progeny genomes and virion assembly most likely takes place at the same time 
(Whelan et al. 2004; Lyles 2007). Viral proteins associated with the envelope are 
localized to (Bergmann et al. 1981) and inserted into the host cell membrane in 
microdomains known as lipid rafts (Brown and Lyles 2003). The M protein is also 
localized to the cell membrane (Knipe et al. 1977; Ohno and Ohtake 1987; Flood and 
Lyles 1999) and interacts with the progeny RNPs (Odenwald et al. 1986; Flood and Lyles 
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1999). Infectious virus particles, with all viral protein components and RNA genomes, 
bud through the host cell membrane and can go on to infect adjacent host cells (Harty et 
al. 1999; Jayakar et al. 2000; Harty et al. 2001; Irie et al. 2004).    
Virus infection results in recognition by host cell innate immune molecules, an 
adaptive response, and viral clearance. VSV and SeV are recognized by cytoplasmic 
sensors, RIG-I and MDA5, which signal the production of Type I IFN and other antiviral 
cytokines (Fig. 2) (Kato et al. 2006; Onoguchi et al. 2011). Recognition of viral RNA by 
RIG-I and MDA5 results in a cascade of signaling molecules that ultimately lead to the 
activation of the IFN-β promoter and production of IFN-β (Fig. 2) (Gerlier and Lyles 
2011). IFN-β is then secreted and acts in a paracrine manner by binding to IFN-αβ 
receptors on neighboring cells (Fig. 3). Binding of IFN-β to its receptor leads to a 
signaling cascade of adapter molecules and the production of IFN-stimulated genes (ISG, 
Fig. 3) (Gerlier and Lyles 2011). ISGs play an important role in creating an ‘antiviral 
state’ in cells surrounding uninfected cells, and this state allows them to resist further 
virus infection. While host cells are equipped with virus recognition tools, VSV and SeV 
have evolved strategies to evade host antiviral responses. These viruses inhibit host gene 
expression and translation as evasion mechanisms (Lamb and Parks 2007; Lyles 2007). 
The leader RNA and M protein both play a role in inhibition of host antiviral responses. 
There is evidence that the leader RNA inhibits host RNA synthesis (McGowan et al. 
1982; Grinnell and Wagner 1985) and the M protein, in addition to its role in virus 
assembly and budding, inhibits the transport of host mRNA from the nucleus to the 
cytoplasm thus downregulating production of Type I IFN and interferon-stimulated genes 
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(ISGs) (Black and Lyles 1992; Lyles et al. 1996; Ferran and Lucas-Lenard 1997; Ahmed 
and Lyles 1998). As mentioned earlier, SeV encodes additional accessory proteins (V and 
 
 
 
Figure 2. Recognition of viral RNA by RIG-I and MDA5 results in production of IFN-β. 
Adapted from Gerlier and Lyles (2011). 
 
 
 
C) that antagonize host IFN production. The V protein has been shown to bind directly to 
MDA5 and block IFN-β production (Andrejeva et al. 2004). The C protein interferes with 
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STAT (signal transducers and activators of transcription) phosphorylation which 
obstructs IFN signaling (Gotoh et al. 2003). There is new evidence that cytoplasmic 
innate immune receptors recognize viral RNA that lack cap methylation at the 2’O-ribose 
position (Daffis et al. 2010; Zust et al. 2011). This was shown for positive strand RNA 
viruses and has not been investigated in any NNS RNA viruses. We performed some 
preliminary experiments to explore whether SeV cap methylation defective mutants 
induced greater immune responses in primary mouse cells. 
 
 
 
 
Figure 3. IFN-α/β is recognized by IFNAR and a subsequent signaling cascade leads to 
the production of ISGs. Adapted from Gerlier and Lyles (2011). 
 
 
 
Practical implications of Mononegavirales cap methylation studies. 
A better understanding of the biology of the viruses of Mononegavirales can lead 
to the development of new effective antiviral therapies and the rational design of live-
attenuated viruses for their use as vaccine (von Messling and Cattaneo 2004; Finke and 
18 
Conzelmann 2005; Bukreyev et al. 2006), oncolytic (von Messling and Cattaneo 2004) 
and gene therapy (Finke and Conzelmann 2005) vectors. The cap methylation function of 
L, while important in a successful virus replication cycle, is not essential and is therefore 
thought to be a promising target for drug development and rational attenuation. 
Adenosine analogues that inhibit the host cell enzyme, S-adenosylhomocysteine (SAH) 
hydrolase, and thereby inhibit cap methylation have shown success against 
paramyxoviruses, rhabdoviruses, and filoviruses (De Clercq 1998; Bray et al. 2000). 
SAH is the byproduct of AdoMet-dependent MTase reactions and the SAH hydrolase 
eliminates the buildup of SAH allowing for further methylation to proceed (De Clercq 
1998; Bray et al. 2000). Blockage of SAH hydrolase causes increased concentration of 
SAH which competes with AdoMet binding to MTases and interferes with 5’ cap 
methylation ultimately leading to decreased efficiency in translation (Bray et al. 2000). 
Similarly, sinefungin, a natural AdoMet analogue generated by Streptomyces griseolus 
inhibits MTase activity and successfully interferes with VSV replication (Li et al. 2007). 
Remarkably, cap methylation defective viruses (VSV, SeV or any other 
Mononegavirales) have never been tested in any animal system. It is possible that cap 
methylation defective viruses will be attenuated in vivo; however, it is unclear if 
infectious viruses carrying these specific mutations will exhibit any unusual tissue 
specificity as compared to their wild type counterpart. Further studies of cap methylation 
defective viruses can lead to the rational design of vectors for vaccine, gene therapy and 
oncolytic virotherapy development.  
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VSV as an oncolytic agent against pancreatic ductal adenocarcinoma. 
It was first observed in the early 1900s that some cancer patients suffering from 
viral infections exhibited tumor regression or stabilization (Sinkovics and Horvath 2008). 
With this observation came the development of oncolytic virus (OV) therapy which 
utilizes replication-competent viruses to specifically target and kill tumor cells (Russell 
and Peng 2007; Vähä-Koskela et al. 2007; Breitbach et al. 2010). Such selectivity is 
possible because many tumors are characterized by defective innate immune responses or 
tumor-related abnormalities in regulation of mRNA translation or certain cellular 
signaling pathways, facilitating selective replication of viruses in cancer cells. For 
example, many cancer cells have defective Type I IFN responses, which provides growth 
advantages to tumor cells; however, it also makes them more susceptible to viral 
infections (Stojdl et al. 2000; Naik and Russell 2009). As a result, OV can infect, 
replicate within and kill tumor cells. Successful virus replication in cancer cells leads to 
the release of newly formed infectious virus particles that go on to infect neighboring 
tumor cells.  
In the field of OV therapy, several members of Mononegavirales have shown 
preclinical success with VSV being the most successful against a variety of malignancies, 
including prostate (Ahmed et al. 2004; Chang et al. 2010; Moussavi et al. 2010), breast 
(Fernandez et al. 2002; Obuchi et al. 2003; Shi et al. 2009; Ahmed et al. 2010), 
melanoma (Fernandez et al. 2002; Galivo et al. 2010), colorectal (Huang et al. 2003; 
Shinozaki et al. 2005; Edge et al. 2008), liver (Wu 2008; Altomonte et al. 2009; Ausubel 
et al. 2011), glioblastoma (Ozduman et al. 2008; Wollmann 2010; Cary et al. 2011) and  
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Figure 4. Schematic of oncolytic virus (OV) therapy. 
 
 
 
other cancers (Barber 2004). There are several advantages of using VSV as an anticancer 
therapy. VSV is the prototypic NNS RNA virus (order Mononegavirales, family 
Rhabdoviridae), and its basic biology and interactions with host immune responses have 
been extensively studied (Lyles 2007). While VSV is very sensitive to IFN-mediated 
antiviral responses (and therefore unable to productively infect healthy cells), it can 
specifically infect and kill tumor cells, the majority of which are believed to be defective 
in Type I IFN production and responses (Barber 2004; Lichty et al. 2004). Also, the 
mechanisms of VSV-mediated killing by apoptosis have been established (Gaddy and 
and Lyles 2007). In addition to tumor specificity, VSV has several important advantages 
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as an OV: (i) replication occurs in the cytoplasm of host cells with no risk of host cell 
transformation, (ii) cellular uptake in many mammalian cell types occurs rapidly and 
there is no cell cycle dependency, (iii) the genome is easily manipulated with the 
possibility for strong and adjustable levels of foreign gene expression to enhance 
oncolysis and specificity, and (iv) there is no preexisting immunity against VSV in 
humans (Barber 2004). While VSV is not considered a significant human pathogen, it can 
cause neurotoxicity in mice, nonhuman primates and even humans (Quiroz et al. 1988). 
However, several VSV mutants have been generated which are not neurotropic but retain 
their oncolytic activity (Ahmed 2008; Kelly et al. 2010; Wollmann 2010). In addition to 
improving the safety of VSV, several groups have engineered VSV to enhance specificity 
and oncolysis by introducing specific mutations to the viral genome, or by arming the 
virus with cytotoxic genes or cytokines that can elicit a more robust immune response. 
Because of its preclinical success, at least two VSV OV have been considered for 
clinical trials by the NIH Recombinant-DNA Advisory Committee (Cary et al. 2011). 
However, VSV oncolytic potential has never been studied in any pancreatic cancer 
models. OV therapy with several viruses, including adenoviruses (Kuhlmann et al. 2008; 
He et al. 2009; Huch 2009), herpesviruses (Sarinella et al. 2006; Kasuya et al. 2007; 
Nakao et al. 2007; Watanabe et al. 2008; Eisenberg et al. 2010), measles virus (Carlson 
2009; Penheiter et al. 2010; Bossow et al. 2011) and reoviruses (Etoh et al. 2003; Himeno 
et al. 2005; Hirano et al. 2009), has recently shown promise in several PDA tumor 
models. About 95% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDA) 
which are highly invasive with aggressive local growth and rapid metastases to 
surrounding tissues (Stathis and Moore 2010). PDA is considered one of the most lethal 
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abdominal malignancies with annual deaths closely matching the annual incidence of the 
disease (Lindsay et al. 2005; Farrow et al. 2008), resulting in a 5-year survival rate of 
merely 8-20%. PDA begins with mutations in oncogenes and tumor suppressor genes. 
These alterations progress through a series of pre-invasive stages known as pancreatic 
intraepithelial neoplasias (PanINs) ultimately resulting in invasive and metastatic PDA 
(Farrow et al. 2008). These PanIN lesions secrete numerous soluble factors that result in a 
local inflammatory response and the recruitment of immune cells (Farrow et al. 2008). 
Unfortunately, the locally secreted factors recruit regulatory T cells (Treg), myloid-
derived suppressor cells (MDSCs) and tumor-associated macrophages (TAM) all of 
which play a role in immunosuppression (Ben-Baruch 2006; Farrow et al. 2008). 
Therefore the site of the PanIN lesions becomes a site of immune-privilege and the 
progression to the devastating PDA disease (Ben-Baruch 2006). Several cancer therapies 
proven successful in other tumor types have shown little efficacy in treating PDA. 
Chemotherapy is the primary treatment available; however, patients exhibit little 
improvement or develop chemoresistance (Stathis and Moore 2010). Therefore, 
development of new treatment strategies for patients suffering from PDA is of utmost 
importance and OV therapy using VSV has great potential (Kasuya et al. 2005).  
Hypotheses and Present Study 
In the present study we have focused on the cap methylation function of SeV, the 
prototypic member of the Paramyxoviridae family of the order Mononegavirales; and 
evaluating VSV as an oncolytic agent against pancreatic ductal adenocarcinoma.  
The large (about 2200 amino acids) L polymerase protein of Mononegavirales has 
six conserved sequence regions (“domains”)  postulated to constitute the specific 
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enzymatic activities involved in viral mRNA synthesis, 5’ capping, cap methylation, 3’ 
polyadenylation, and genomic RNA replication (Whelan et al. 2004; Lamb and Parks 
2007; Lyles 2007). Similar to eukaryotic mRNA, viral mRNA requires a methylated 5’ 
cap structure for mRNA stability and efficient translation of viral proteins (Abraham et 
al. 1975). Virus-encoded cap methylation function, which is distinct from host cells, can 
be a target for drug development and rational attenuation. The majority of previous cap 
methylation studies were done with VSV and identified aa residues within the L protein 
domain VI required for mRNA cap methylation (Grdzelishvili et al. 2005; Li et al. 2005; 
Grdzelishvili et al. 2006; Li et al. 2006; Galloway et al. 2008). While most cap 
methylation studies have been done using a VSV experimental system, we wanted to 
determine if the aa residues required for VSV cap methylation had similar importance in 
other members of Mononegavirales. Therefore we chose to study SeV (distantly related 
to VSV) to investigate the importance of the L protein domain VI in paramyxovirus cap 
methylation function.  We hypothesized that domain VI of paramyxoviruses has similar 
cap methylation function as rhabdoviruses. Initially, four aa residues within domain VI of 
the SeV L protein were analyzed and our data indicated that there could be differences in 
L protein sequence requirements for cap methylation in two different families of 
Mononegavirales - rhabdoviruses and paramyxoviruses. To further analyze domain VI of 
the SeV L protein, we conducted a more comprehensive mutational analysis by targeting 
the entire SeV L protein domain VI, creating twenty-four L mutants, and testing these 
mutations for their effects on viral mRNA synthesis, cap methylation, viral genome 
replication and virus growth kinetics. Our analysis identified several residues required for 
successful cap methylation and virus replication and clearly showed the importance of a 
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putative catalytic tetrad and methyl donor binding site in SeV cap methylation. This study 
is the first extensive sequence analysis of the L protein domain VI in the family 
Paramyxoviridae, and it confirms structural and functional similarity of this domain 
across different families of the order Mononegavirales.  
VSV is also one of the most promising oncolytic viruses against a variety of 
malignancies and we have analyzed for the first time the oncolytic potential of VSV 
against pancreatic ductal adenocarcinoma (PDA).  PDA is the most common form of 
pancreatic cancer with highly aggressive local growth and rapid metastases to 
surrounding tissues. Currently there are few treatments options available to patients 
suffering from this disease therefore there is a great need to develop alternative therapies. 
VSV has shown preclinical success in several cancer models, however VSV has never 
been studied in any form of pancreatic cancer. We hypothesized that VSV can be an 
effective oncolytic virus against PDA and set out to determine the ability of VSV to 
infect and cause cell death in pancreatic cancer cell lines in a nude mouse model of 
tumorigenesis. The oncolytic potential of several recombinant VSVs were analyzed in a 
panel of 13 clinically relevant human PDA cell lines and compared to conditionally 
replicative adenoviruses (CRAds), SeV and respiratory syncytial virus (RSV). VSV 
variants showed superior oncolytic abilities compared to other viruses, however, PDA 
cells were highly heterogeneous in their susceptibility to virus-induced oncolysis and 
several cell lines were resistant to all tested viruses. For resistant cells we demonstrated 
low levels of very early VSV RNA synthesis, indicating possible defects at initial stages 
of infection. In addition, most of the resistant cell lines were able to both produce and 
respond to Type I interferon (IFN), suggesting that intact IFN responses contributed to 
25 
their resistance phenotype. We selected certain cell lines that varied in their 
permissiveness to VSV and tested them in nude mice, and in vivo results closely 
mimicked those in vitro. Our results demonstrate VSV is a promising oncolytic agent 
against PDA, and further studies are needed to better understand the molecular 
mechanisms of resistance to oncolytic virotherapy.  
 
CHAPTER 2: SEQUENCE-FUNCTION ANALYSIS OF THE L PROTEIN DOMAIN 
VI OF SENDAI VIRUS 
 
2.1 Objective of the study 
Viruses of the order Mononegavirales include diverse human, animal and plant 
pathogens that share structurally similar NNS RNA genomes with similar strategies for 
viral RNA genome replication, transcription and posttranscriptional modifications of viral 
mRNAs (Whelan et al. 2004; Lamb and Parks 2007; Lyles 2007). All members of this 
order encode the large (L) polymerase protein which has six highly conserved regions 
(“domains”) postulated to be responsible for the specific enzymatic activities of the viral 
polymerase complex which include viral genome replication, transcription, mRNA 5’ 
capping, cap methylation and 3’ polyadenylation. Currently, there is no structural data 
available for the entire L or any region of L. However, site-directed mutagenesis and 
computational analyses support the multifunctional nature of the L protein as targeted aa 
substitutions in the different L domains were able to inactivate individual functions of 
viral polymerase (Poch et al. 1990; Sidhu et al. 1993; Sleat and Banerjee 1993; Schnell 
and Conzelmann 1995; Cortese et al. 2000; Smallwood et al. 2002; Cartee et al. 2003; 
Grdzelishvili et al. 2005; Li et al. 2005; Li et al. 2008; Ogino and Banerjee 2010; Ogino 
et al. 2010). 
Similarly to eukaryotic mRNA, most of Mononegavirales synthesize mRNA 
containing a 5’ cap structure methylated at the G-N7 and 2’O-ribose positions. The 5’ 
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cap is required for mRNA stability, and cap methylation, especially at G-N7 position, is 
required for efficient mRNA translation (Horikami and Moyer 1982; Horikami et al. 
1984; Gingras et al. 1999).  The MTase activity was originally mapped to the L protein 
following the characterization of two vesicular stomatitis virus (VSV, family 
Rhabdoviridae) hr mutants. These mutants exhibited severe defects in cap methylation 
(Horikami and Moyer 1982; Horikami et al. 1984), but this function was successfully 
complemented with purified wt L protein in vitro, demonstrating that L possesses the 
viral mRNA MTase activities (Hercyk et al. 1988). More recently, computational 
analyses predicted that the L protein domain VI has a typical 2’O-ribose MTase fold and 
identified a putative KDKE catalytic tetrad and a glycine-rich motif (GxGxG) as the 
putative AdoMet binding site (Bujnicki and Rychlewski 2002; Ferron et al. 2002; Martin 
and McMillan 2002). These predictions were experimentally confirmed by several 
studies with the VSV L protein leading to the identification of the aa residues important 
for cap methylation within domain VI (Grdzelishvili et al. 2005; Li et al. 2005; Li et al. 
2006; Galloway et al. 2008). Grdzelishvili et al. (2005) showed that one of the VSV hr 
mutants, hr1, had a single substitution D to V within the glycine-rich motif (GDGSG in 
VSV) and was completely defective in cap methylation. Further site-directed mutagenesis 
of the glycine-rich motif and putative KDKE catalytic tetrad by Li et al. (2005, 2006) 
showed that they are important for mRNA cap methylation at both the G-N7 and 2’O 
positions. Most of previous studies suggest that the L protein uses a single AdoMet 
binding site for both G-N7 and 2’O MTase activity, and that, at least in VSV, 2’O 
methylation precedes G-N7 methylation (Testa and Banerjee 1977; Rahmeh et al. 2009).    
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While most of the cap methylation studies were conducted using VSV, limited 
studies using Sendai virus (SeV, family Paramyxoviridae) demonstrated similarities as 
well as differences in the cap methylation between these two distantly related viruses. 
SeV produces mRNA that is capped and methylated at both the G-N7 and 2’O-ribose 
positions (Takagi et al. 1995), but interestingly, purified SeV L protein or just its C-
terminal portion retaining domain VI, catalyzed only G-N7, but not the 2’O-ribose cap 
methylation (Ogino et al. 2005).   
To dissect the L protein sequence requirements for cap methylation in SeV in 
more detail, we conducted a more comprehensive analysis by targeting the entire SeV L 
protein domain VI and created twenty-four L mutants by site-directed mutagenesis at 
highly conserved positions within this domain, using sequence conservation between L 
proteins in Mononegavirales as a guide (Bujnicki and Rychlewski 2002).  The L 
mutations were analyzed in the context of infectious mutant viruses for their effect on 
viral mRNA cap methylation and virus growth in vitro, and we found a good correlation 
between attenuation in cell culture and defects in MTase activity for most of SeV 
mutants.  Our analysis experimentally confirms previous computational predictions 
suggesting the importance of the glycine-rich motif and KDKE catalytic tetrad in cap 
methylation across different families of the order Mononegavirales. In addition, the 
majority of L mutants were tested for their ability to synthesize viral mRNA and replicate 
viral genomic RNA. This study is the first detailed analysis of the L protein domain VI in 
the family Paramyxoviridae.  
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2.2 Materials and Methods 
Cell lines and viruses. 
African green monkey (Vero, ATCC# CCL-81), human epidermal carcinoma 
(HEp-2, ATCC# CCL-23), human lung carcinoma (A549, ATCC# CCL-185) and BSR-
T7/5 cells [derived from baby hamster kidney (BHK-21) cells and constitutively 
expressing bacteriophage T7 polymerase (Buchholz et al. 1999)] were used for virus 
infections and plasmid transfections. Monolayer cultures of these cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Cellgro) supplemented 
with 9% fetal bovine serum (FBS, Gibco). Mouse embryonic fibroblasts (MEFs) were 
kindly provided by Dr. Takemasa Sakaguchi (Hiroshima University, Japan) and were 
maintained in DMEM supplemented with 9% FBS. Wild-type C57BL/6 MEFs and RIG-I 
knock-out (KO) MEFs, MDA5 KO MEFs, IRF-3 KO MEFs, and IRF-7 KO MEFs 
(C57BL/6 background) were used in immune response studies. 
Recombinant wt (rWT) SeV (Fushimi strain) (Leyrer et al. 1998) and SeV-GFP-
Fmut (rWT-GFP) with an enhanced green fluorescent protein (eGFP) upstream of the NP 
gene (Wiegand et al. 2007) were kindly provided by Dr. Wolfgang J. Neubert (Max-
Planck-Institute of Biochemistry, Germany). All viruses were approved by the IBC at 
UNCC. To grow and purify SeV wt or mutants, Vero or BSR-T7 cells were infected with 
wt or mutant viruses at a multiplicity of infection (MOI) of 0.1 CIU/ml in MegaVir 
HyQSFM4 (SFM) serum-free medium (Hyclone) and in the presence of 4 µg/ml 
acetylated trypsin (Leyrer et al. 1998), and incubated for 48-120 hours (h) at 34°C. 
Cleavage by a cellular protease is necessary for the SeV fusion (F) protein to be 
biologically active in vivo, making the viral particle infectious and allowing for multiple 
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rounds of virus replication. SeV-GFP viruses were grown similarly but without acetylated 
trypsin in the medium, as they have a wt monobasic trypsin-dependent cleavage site in 
the F protein mutated to an oligobasic cleavage site, allowing F activation in any cell type 
through an ubiquitous furin-like protease (Wiegand et al. 2007). The released viruses 
were purified from the medium as described previously (Grdzelishvili et al. 2005), 
suspended at about 5 mg/ml in 1 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10% DMSO, and 
stored at -80°C. Recombinant VSV wt (Indiana serotype) and its derivative VSV rHR1-1 
(referred to as hr1) with a single aa substitution D1671V in the L protein were described 
in (Grdzelishvili et al. 2005). 
For the immune response studies, SeV wt and the following SeV mutants - 
K1782A, E1805A, and G1806A were propagated in eggs as described in (Kiyotani et al. 
1990) and titered on LLC-MK2 (ATCC CCL-7) cells.  
Plasmids and mutagenesis. 
The pGEM plasmids containing wt genes for SeV NP, L, and Pstop (expressing P 
but not C due to a stop codon in the C open reading frames, and referred to here as wt P), 
under the control of the T7 promoter have been described previously (Curran et al. 1991). 
The pGEM-L plasmid and mutagenic primers were used for the L protein domain VI 
deletion and for site-directed mutagenesis (Table 1). Primers also contained silent 
restriction sites (Table 1) for screening and confirmation purposes. Using an overlapping 
PCR approach (Higuchi et al. 1988), two rounds of PCR were done using wt pGEM-L 
plasmid as a template, common flanking primers VG19 and VG20, and two specific 
primers designed for aa substitutions (Table 1). The final PCR products were digested 
with XhoI and MfeI and cloned into XhoI-MfeI digested pGEM-Lwt plasmid.  All L 
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plasmids were tested for the presence of silent sites by digestion with the appropriate 
silent site enzymes, followed by sequence analysis to confirm the presence of the desired 
mutations and absence of any spontaneous secondary mutations. The SeV pTM-NP, 
pTM-P and pTM-L plasmids, the pRS3Gg (Leyrer et al. 1998) full length SeV 
antigenomic plasmid and the SeV pRSIdeFmut plasmid (a full length SeV antigenomic 
plasmid with the GFP gene inserted upstream of the NP gene) used for the rescue of 
recombinant SeV viruses were kindly provided by Dr. Wolfgang J. Neubert (Max-
Planck-Institute of Biochemistry, Germany). 
Recovery of recombinant SeV. 
The recombinant virus rescue was done using the reverse genetics system for SeV 
described by Leyrer et al. (Leyrer et al. 1998) using plasmids with SeV wt NP, P, and L 
genes and SeV full-length genomic cDNA (wt or mutant L gene) all under the control of 
the T7 promoter. For this study we used the BSR-T7 cell line stably expressing the T7 
RNA polymerase (Buchholz et al. 1999) for initial plasmid transfections and Vero cells 
for consequent virus passages. All mutations were introduced into the full length genomic 
SeV plasmid, pRS3Gg. To obtain a mutant plasmid, pGEM-Lmut was digested with KpnI 
and NheI and the fragment containing the L mutation was cloned into KpnI-NheI cut 
pRS3Gg. Similarly, K1782A, E1805A and G1806A mutations were introduced into the 
pRSIdeFmut plasmid to generate recombinant SeV-GFP viruses. To rescue recombinant 
viruses, 10 µg of full length pRS3Gg or pRSIdeFmut plasmid containing wt or a mutant L 
gene along with 1 µg of  pTM-L, 3 µg of  pTM-P and 5 µg of pTM-NP plasmids were 
transfected into BSR-T7 cells in 35-mm dishes using Opti-MEM medium (Gibco) and 
Lipofectamine (Invitrogen) in a total of 2 ml according to the manufacturer’s protocol.  
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All transfection reactions were incubated for 24 h at 34˚C.  After 24 h, the transfection 
medium was aspirated and 1.5 ml of SFM medium and 4 µg/ml acetylated trypsin were 
added to each well (SeV-GFP viruses were grown without trypsin).  The cells were then 
incubated at 34˚C for 2 days.  On day 3 post transfection (p.t.), 500 µl of BSR-T7 
supernatant was collected and passed (Pass1) onto a fresh monolayer of Vero cells in 1 
ml of fresh SFM with 4 µg/ml acetylated trypsin. Between 2-5 days following Pass1, 
there were noticeable cytopathic effects (CPE) and cellular debris was pelleted and the 
medium harvested. The recombinant SeV mutants were titered on Vero cells with an agar 
overlay with 4 µg/ml acetylated trypsin, and individual infectious foci were picked and 
grown on Vero cells. Recombinant viruses were purified as in (Grdzelishvili et al. 2005) 
and all mutations were confirmed by RT-PCR and digestion with the appropriate silent 
restriction enzymes, and by sequence analysis for the presence of the desired mutations 
and absence of any spontaneous secondary mutations in the L gene.   
Virus growth analysis. 
SeV infectivity, expressed as cell infectious units/ml (CIU/ml), was measured by 
virus titration on Vero cells and counting infectious foci visually using light microscopy 
and/or immunofluorescence (IF) assay for SeV mutants, or by GFP-based fluorescence 
for SeV-GFP viruses. For IF, SFM media from 6-well plates was aspirated 2 or 3 days 
post infection, cells were washed with PBS, fixed with 3% paraformaldehyde (Sigma) for 
10 minutes, and permeabilized for 2 minutes on ice with 20 mM HEPES pH 7.5, 300 mM 
sucrose, 50 mM NaCl, 3 mM MgCl2, and 0.5% Triton-X-100.  Cells were then blocked in 
PBS with 5% bovine serum albumin (BSA, Sigma) for 20 minutes and incubated with 
anti-SeV primary antibodies (1:100) for 1 h.  Cells were washed, incubated with goat 
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anti-rabbit IgG-FITC antibodies (Santa Cruz) for 1 h in the dark, and viewed under a 
fluorescent microscope to determine virus titer.  
For multistep growth analysis, Vero or HEp-2 cells in 6-well plates were infected 
at an MOI of 0.001 CIU/cell in 1.5 ml SFM per well.  One h post infection (h p.i.), media 
was aspirated, cells were washed with PBS and 1.5 ml SFM with 1 µg/ml acetylated 
trypsin was added to each well.  Supernatants were harvested at 12 h (for Vero) or 24 h 
(for HEp-2) intervals and flash frozen at -80˚C. Virus titers were determined using a 96-
well plate format by infecting Vero cells with the serial dilutions (1:8) of wt or mutant 
SeV (collected at various time points) and incubating at 37°C with shaking.  At 1 h p.i., 
viruses were aspirated, and cells were overlaid with 100 µl SFM with 2 µg/ml of 
acetylated trypsin, and cells were analyzed at 48 h p.i. 
For one-step growth kinetics, Vero cells were incubated for 1 h with SeV wt or 
mutants at an MOI of 3 CIU/cell in 24 well plates.  At 1 h p.i., unabsorbed viruses were 
aspirated, cells were washed two times with PBS and SFM with 4 µg/ml acetylated 
trypsin was added to each well.  Plaque assays were performed on Vero cells using 
supernatants collected at different time points.   
For superinfection experiments, virus infectious foci were detected by IF as 
described above or by 4 CN Peroxidase Substrate colorimetric staining (KPL). Briefly, 
cells were fixed in 3% paraformaldehyde for 10 min and permeabilized for 2 min on ice. 
Cells were blocked in PBS with 5% BSA for 20 min and incubated with anti-SeV 
primary antibodies (1:100) for 1 h. Cells were then washed, incubated with goat anti-
rabbit IgG-HRP (Jackson ImmunoResearch) secondary antibodies (1:500) for 1 h. To 
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visualize infectious foci, cells were washed and incubated with equal volumes 4 CN 
Peroxidase Substrate and Peroxidase Substrate Solution B (KPL). 
In vitro transcription with T7-expressed L proteins. 
For virus-driven expression of the bacteriophage T7 RNA polymerase, Vero or 
A549 cells were infected with T7-expressing vaccinia virus (VV-T7) (Fuerst et al. 1986). 
To express SeV wt P and wt or mutant L proteins, 60-mm dishes of A549 or Vero cells 
were infected with VV-T7 at MOI of 2.5 PFU/cell for 1h at 37°C, washed with Opti-
MEM (Gibco), transfected with 1.5 µg of SeV pGEM-Pstop and 1 µg of pGEM-L (wt L 
or one of the mutant L genes) plasmids using Lipofectamine, and incubated at 34°C in 
Opti-MEM. At 18 h p.t., cytoplasmic extracts were prepared exactly as described 
previously (Chandrika et al. 1995; Grdzelishvili et al. 2005). To assay for SeV mRNA 
synthesis, 1 µg of wt SeV polymerase-free RNA-N template and 20 µCi of [α
32
P]CTP 
were added to each extract, and reactions were incubated for 2 h at 30°C. Total RNA was 
purified using RNeasy columns (Qiagen) or Quick RNA Miniprep (Zymo Research) and 
analyzed by 1.5% agarose/6 M urea gel electrophoresis. The gels were fixed in 7% acetic 
acid, dried, and exposed to Kodak X-OMat film for 18 h at -80°C, and quantitated using a 
Typhoon 8600 PhosphorImager and ImageQuant software (Molecular Dynamics).  
DI RNA replication with T7-expressed L proteins. 
To produce cell lysates containing SeV wt NP, wt P and wt or mutant L proteins 
for in vitro replication of SeV defective interfering (DI) RNA, 60-mm dishes of A549 
cells were infected and transfected as above using 5 μg of SeV pGEM-Pstop, 2 µg SeV 
pGEM-NP and 0.5 μg of pGEM-L (wt L or one of the mutant L genes).  At 18 h p.t., 
cytoplasmic extracts were prepared as for in vitro transcription. To assay for SeV genome 
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synthesis, 2 μg of detergent disrupted DI-H (Carlsen et al. 1985) and 18 μCi of [α 
32
P]CTP were added to each extract, and reactions were incubated for 2 h at 30°C and 
then treated with micrococcal nuclease to digest unpackaged RNA (mRNA).  Total RNA 
was purified and analyzed as described above for in vitro transcription.  
In vitro transcription using purified SeV virions. 
SeV in vitro transcription by detergent-activated purified virions was conducted 
essentially as described in (Mizumoto et al. 1995). For [α
32
P]UTP-labeled RNA, 10 µg of 
purified virus was incubated at 30°C for 6 h in a 50 µl reaction containing: 30 mM 
HEPES-KOH (pH 7.9), 75 mM NaCl, 50 mM KCl, 6 mM MgCl2, 2 mM dithiothreitol, 2 
mM spermine, 0.1% NP-40, 500 µM  each of ATP, CTP and GTP, 50 µM UTP, 50 U of 
RNasin (Promega), 12 µg of purified tubulin (>99% pure) from bovine brain 
(Cytoskeleton Inc.) and 20 µCi of [α
32
P]UTP. Total RNA was purified using RNeasy 
columns (Qiagen) and analyzed by 1.5% agarose/6 M urea gel electrophoresis. The gels 
were fixed in 7% acetic acid, dried, and exposed to Kodak X-OMat film for 4-18 h at -
80°C, and quantitated using a PhosphorImager. To test for viral mRNA cap methylation, 
in vitro transcription by detergent-activated purified SeV wt or mutants was conducted as 
described above, but RNA was synthesized in a 200 µl reaction with cold NTPs (1 mM 
each) and 11 µCi of [
3
H]AdoMet (55 Ci/mmol, 1 µM AdoMet final concentration) in the 
presence or absence of 100 µM of the methylation inhibitor S-adenosylhomocysteine 
(AdoHcy). Total RNA was purified using RNeasy columns (Qiagen), diluted in 25 µl of 
H2O, and used for measurement of [
3
H]Met incorporation by scintillation counting (20 
µl) or analyzed by Northern blot to measure mRNA levels (5 µl).  
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Cap methylation analysis of purified SeV virions. 
To generate viral mRNA for cap analysis using tobacco acid pyrophosphatase 
(TAP), SeV rWT and VSV rWT in vitro transcription by detergent-activated purified 
virions was performed as described above using [
3
H]AdoMet and the same reaction 
conditions for SeV and VSV. VSV mRNA was synthesized in a 100 μl reaction. To 
obtain sufficient amounts of SeV mRNA for this analysis, ten 200-μl transcription 
reactions were used for SeV rWT, and viral mRNA products were isolated and pooled 
together for TAP treatments.  For preparation of synthetic mRNA controls, uncapped 
SeV NP mRNA was synthesized in vitro with the MAXI-Script T7 kit (Ambion) using 
SeV pGEM3-NP plasmid digested at the BamHI restriction site located immediately after 
the stop codon for the NP gene as a template. This RNA was divided to generate: i) Cap 0 
containing mRNA (m
7
GpppA...) labeled with [
3
H] only at the G-N7 position, or ii) Cap 1 
containing mRNA (m
7
Gppp[m
2’-O
]A...) labeled with [
3
H] only at the 2’-O position. To 
make synthetic mRNA containing Cap 0, uncapped mRNA transcripts were capped and 
G-N7 methylated in the presence of 1.75μM [
3
H]AdoMet using the ScriptCap m
7
G 
Capping System (Epicentre Biotechnologies) based upon the tri-functional vaccinia virus 
capping enzyme, and purified using Spin-50 Sephadex G-50 mini-columns (USA 
Scientific).  To make synthetic mRNA with Cap 1 but [
3
H]-labeled only at the 2’-O 
position, uncapped mRNA transcripts were first capped in the presence of 100μM cold 
AdoMet using the ScriptCap m
7
G Capping System to make mRNA with the unlabeled 
Cap 0 structure (which is the template for 2’-O methylation by the vaccinia virus 2’-O 
MTase). After purification using Spin-50 Sephadex G-50 mini-columns, the unlabeled 
Cap 0 mRNA was 2’-O methylated in the presence of 1.75μM [
3
H]AdoMet using 
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ScriptCap 2’-O-MTase (Epicentre Biotechnologies) based upon the vaccinia virus 2’-O 
MTase, and purified again using Spin-50 Sephadex G-50 mini-columns.   
For TAP analysis, virion-produced viral mRNA (SeV or VSV) and synthetic (G-
N7 or 2’-O labeled) mRNAs were normalized by [
3
H] counts and digested by TAP 
(Epicentre Biotechnologies) in 10 µl reactions in the presence or absence of 5 units of 
TAP for 1 h at 37°C. All reactions were then adjusted to 25 µl and passed through Spin-
50 Sephadex G-50 mini-columns. Spin columns were then placed in new microfuge tubes 
and 25 µl diH2O was passed each column to retrieve the residual column-bound RNA. 
Separate optimization experiments demonstrated effective separation of RNA from 
nucleotides using this procedure (data not shown). [
3
H]AdoMet incorporation into the G-
N7 or 2’-O cap position was measured by scintillation counting of the entire flow through 
(contained mRNA) and the Sephadex G-50 column material removed from mini-columns 
after separation (contained removed G). 
Northern blot analysis. 
For Northern blot analysis, mRNA products of in vitro transcription reactions 
with [
3
H]AdoMet were separated in a 1.2% agarose/formaldehyde gel system, transferred 
to a Hybond-N+ nylon membrane (GE Healthcare) and incubated with an RNA probe 
complementary to the SeV NP gene. The probe was synthesized by digestion of the SeV 
pGEM3-NP plasmid at the EcoRV restriction site and transcribed in vitro in the presence 
of [α-
32
P]-CTP using the MAXI-Script SP6 kit (Ambion). Radioactive signals were 
measured using a PhosphorImager and ImageQuant software. 
For analysis of RNA synthesized during superinfection, both supernatants and 
cells were collected at 48 h p.i. Virus particles in the supernatant were pelleted by 
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centrifugation at 50,000 rpm for 1 h using a Beckman TLA 100.2 rotor and total RNA 
was extracted from both cells and pelleted virions using the Zymo Research Quick-RNA 
MiniPrep kit.  Total RNA (0.7 μg or 7 μg) from the supernatant or cells respectively was 
separated on a 1.5% agarose formaldehyde gel and transferred to a nylon membrane. 
Membranes were originally probed for full length and DI genomic RNA using an 
oligonucleotide [5’-
ACAAGAAGACAAGAAAATTTAAAAGAATAAATATCTCTTAAACTCTTGTCTG
GT-3’ (Integrated DNA Technologies)] complimentary to the first 54 5’-nucleotides of 
the SeV genomic RNA. The primer was  labeled with [γ-
32
P]-ATP using bacteriophage 
T4 polynucleotide kinase (New England Biolabs). Membranes were then reprobed for NP 
mRNA using the riboprobe described above.  Radioactive signals were measured using a 
Typhoon 8600 Phosphorimager and ImageQuant software (Molecular Dynamics). 
Western blot analysis. 
To compare the amounts of P and L proteins in cell lysates used for in vitro 
transcription, total protein samples from transfected cytoplasmic lysates (5 µl of a total of 
100 µl of lysate) were separated by 7.5% SDS-PAGE and electroblotted onto a PVDF 
membrane (Sigma). Membranes were blocked with 5% non-fat dry milk in TBST [0.5 M 
NaCl, 20 mM Tris pH (7.5), 0.1% Tween 20] and antibodies were diluted in the same 
buffer. The blots were initially incubated with a mixture of rabbit antibodies against SeV 
L protein [a-TrpE-SeV-L #5 (“1-19-90”) and a-TrpE-SeV-L #1 (“10-23-89”)] (Horikami 
et al. 1992) and developed with a horseradish peroxidase conjugated secondary antibody 
using the Enhanced Chemiluminescence Plus (ECL+) protein detection system (GE 
Healthcare) according to the manufacturer’s protocol. Blots were then reprobed with a 
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rabbit anti-SeV antibody (“1-4-83”) (Carlsen et al. 1985) and developed in the same 
manner. Protein bands were quantified using VisionWorksLS software (UVP). 
 For immune response studies, 6 well plates of MEFs were infected at an MOI of 
10 CIU/cell and cells were harvested for lysates at 24 h p.i. Lysates were prepared 
directly in the 6 well plates in 1X SDS sample buffer and 5 µl (of a total of 150 µl) of 
each sample was separated by 10% SDS-PAGE and electroblotted onto PVDF 
membranes. Membranes were blocked with 5% non-fat dry milk in TBST and 
membranes were incubated with rabbit anti-SeV antibodies (1:5000) followed by 
incubation with goat anti-rabbit IgG-HRP secondary antibodies (1:5000). Membranes 
were developed as described above. Lysates were also probed for IFIT-1 (ISG56, Santa 
Cruz, Cat. # sc-134949, 1:500) and membranes were developed as described above. 
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2.3 Results 
Site-directed mutagenesis of the SeV L protein domain VI and recovery of infectious 
SeV mutants. 
To date, all the domain VI mutagenesis studies have been carried out using the 
VSV (Family Rhabdoviridae) experimental system (Grdzelishvili et al. 2005; Li et al. 
2005; Grdzelishvili et al. 2006; Li et al. 2006). Based on these studies and computational 
predictions (Bujnicki and Rychlewski 2002; Ferron et al. 2002), it has been postulated 
that the glycine-rich motif (L aa positions 1670-1674 in VSV, 1804-1808 in SeV) 
constitutes an AdoMet-binding site of L, while a KDKE motif (aa position K1651, 
D1762, K1795, and E1833 in VSV; K1782, D1901, K1938,  and E1975 in SeV) is the 
putative active MTase site (Bujnicki and Rychlewski 2002; Ferron et al. 2002; Li et al. 
2006).  Because the L proteins of Mononegavirales are conserved and all have a glycine-
rich motif and KDKE motif at the same positions as VSV (Fig. 5), it has been suggested 
that these aa residues are likely to have similar importance in all Mononegavirales 
(Bujnicki and Rychlewski 2002; Ferron et al. 2002; Li et al. 2006). To test this hypothesis 
experimentally, we initially targeted by site-directed mutagenesis the SeV L protein aa 
residues homologous to those that are important for cap methylation in VSV. Figure 5 
shows sequence alignments comparing domain VI of the L protein (including the glycine-
rich motif and KDKE motif) between various paramyxoviruses and other 
Mononegavirales. Using the SeV pGEM-Lwt plasmid (SeV L wt gene under control of 
the T7 promoter), in addition to targeting the glycine-rich motif (the putative AdoMet 
binding site) and the putative catalytic tetrad KDKE, which also is conserved in other 
known 2’-O MTases including NS5 protein of flaviviruses (Fig. 5), we also targeted 
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residues D1799 and Y1802 located just upstream of the glycine-rich motif and conserved 
only in some paramyxoviruses (Fig. 5). Many classes of MTases of known structure 
contain either a conserved aspartate or glutamate, or a tyrosine residue within the beta 
strand that precedes the conserved glycine-rich motif, but rarely do they contain both 
these residues. A polar residue in this position has been implicated in reaction mechanism 
as the fifth catalytic entity (Kozbial and Mushegian 2005), and we were interested in 
determining whether one or both of these aa may play a functional role in SeV MTase. 
We also targeted the DKDKD sequence located immediately upstream of the residue 
D1799. Although this DKDKD sequence is present only in some paramyxoviruses, we 
wanted to determine whether such high concentration of aspartates and lysines and its 
close proximity to the glycine-rich motif may play some role in cap methylation catalysis. 
In addition to single aa substitutions, several double and triple alanine substitutions were 
created, and the glycines within the glycine-rich motif were changed to leucines to 
address a possibility that this motif is possibly more tolerant to single glycine-to-alanine 
substitutions as compared to VSV. Also, additional mutants were generated: i) E1805V, 
based on an analogous D1671V mutation in the VSV hr1 mutant (Grdzelishvili et al. 
2005) and ii) L-∆VI  with a deletion of the entire domain VI to confirm that the presence 
of this region is critical for L transcriptional activity as it was previously shown for a 
VSV L protein mutant (Canter and Perrault 1996). All together, twenty-nine SeV L 
mutant genes were generated. 
To examine the abilities of L mutants to synthesize viral genomic negative-
stranded, as well as viral mRNA, we used a VV-T7-based (vaccinia virus expressing T7 
polymerase) mammalian expression system previously described in (Chandrika et al. 
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1995; Grdzelishvili et al. 2005). These assays do not depend on the viability of SeV 
mutant viruses and are based on the exogenously provided polymerase-free wt genomic 
(for transcription) or DI (for replication) RNA-N template and cell extracts containing T7 
RNA polymerase-expressed SeV L (wt or mutant), P and NP (for DI replication only) 
proteins as described in Materials and Methods.  Briefly, A549 cells were infected with 
vaccinia virus (VV) expressing T7 polymerase (VV-T7), transfected with SeV P wt and L 
(wt or mutant) and NP wt (only for DI replication), and incubated at 34°C. At 18 h post 
transfection, cytoplasmic extracts, containing P-L or NP-P-L complexes, were prepared 
and supplied with the exogenous wt SeV polymerase-free RNA-N template (genomic or 
DI, isolated from wt SeV virions) and [α
32
P]CTP to assay for mRNA or DI RNA 
synthesis. The transcription and replication products were analyzed by 1.5% agarose/6M 
urea gel electrophoresis, visualized by autoradiography and quantitated using a 
PhosphorImager. As shown in Figure 6 for A549 cells (similar results were obtained with 
Vero cells, data not shown), most tested proteins were transcriptionally active except for 
the L-∆VI deletion mutant and L-E1805V where mutations completely inactivated L. The 
L-E1805V result is rather unexpected as a similar substitution in the VSV L protein 
(D1671), while abolishing cap methylation, had little effect on VSV transcription 
(Grdzelishvili, Smallwood et al. 2005). Additionally, two L mutations - E1805L and 
G1808L, produced no detectable mRNA and were also defective in genomic RNA 
replication (<5% of rWT) (Fig. 6). The E1975A mutant L protein, had wt-like levels of 
transcription in the VV-mediated system, but replication levels were 10% of rWT. 
Several other mutant L proteins had transcription levels higher than 50% of rWT but 
lower levels of replication (<40% of rWT) including D1901A, E1903A, and 
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K1938A/I1938L (but not K1938S), all of which are members of the KDKE catalytic 
tetrad. G1804L, E1805A, G1806L, and G1804A/G1806A/G1808A, all members of the 
glycine-rich motif, had similar levels of transcription and replication ranging from 30 to 
60% of rWT. This indicates that the intactness of the primary AdoMet-binding site and 
the majority of the catalytic residues are required for multiple functions of L protein, 
most likely including synthesis of the negative-strand genomic RNA and its transcription 
into mRNAs. Only two mutant L proteins, S1777A and K1782A, had rWT levels of 
transcription and replication, indicating a more limited role of the predicted first helix in 
the Rossmann fold in SeV RNA synthesis. 
Interestingly, we observed that many aa substitutions negatively affected L 
protein accumulation in the plasmid based expression assays. Some of these mutations 
could potentially affect L gene expression or L protein stability of the protein, which 
could impact viral RNA synthesis. However, we did not see any clear correlation 
between L protein levels and transcriptional activities for most mutant proteins (Fig. 6). 
The lowest protein accumulation (26% of wt) was shown for the K1938A/I1939L 
mutation; however, it had 107% transcriptional activity. At the same time, this mutant 
showed only 14% DI replication activity suggesting a possibility that L protein 
accumulation may specifically affect replication (but not transcription) activity of viral 
polymerase. However, two other mutations, E1903A and E1975A, which had 
disproportionally low DI replication activities (relative to transcription), did not show any 
dramatic decreases in protein accumulation (Fig. 6).  
Nevertheless, as most mutations passed the in vitro transcription/replication test 
(Fig. 6), they were cloned into the SeV full-length infectious cDNA plasmid to generate 
44 
mutant viruses using the BSR-T7 cell line stably expressing the T7 RNA polymerase 
(Buchholz et al. 1999) for initial plasmid transfections and Vero cells for consequent 
virus passages. Although BSR-T7 cells are derived from BHK-21 cells (Buchholz et al. 
1999) which support replication of cap methylation defective VSV mutants (Horikami et 
al. 1984; Grdzelishvili et al. 2005), we wanted to confirm that BSR-T7 were suitable for 
recovery of SeV mutants potentially defective in cap methylation. Similarly, we wanted 
to verify that potential cap methylation defective viruses can be passed on Vero cells 
which support robust replication of wt SeV. Therefore, prior to the rescue attempts, we 
tested VSV wt and the cap methylation defective mutant VSV hr1 (Grdzelishvili et al. 
2005) for their ability to grow on BSR-T7 and Vero cells and compared it to their growth 
on HEp-2 cells which do not support replication of VSV hr1 or any other tested cap 
methylation defective VSV mutants (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). 
VSV hr1 was unable to grow in HEp-2 cells as expected (Table 2) but was only 
moderately attenuated in Vero cells (2.4 x 10
9
 PFU/ml for VSV wt and 6.0 x 10
7
 PFU/ml 
for VSV hr1) (Table 2) and grew normally in BSR-T7 (2.4 x 10
9
 PFU/ml for VSV wt and 
1.1 x 10
9
 PFU/ml for VSV hr1). Therefore, we concluded that a BSR-T7/Vero recovery 
system could be successfully used to rescue SeV mutants even if they are defective in cap 
methylation. Using this approach, we successfully recovered 24 infectious SeV mutants 
using a reverse genetics system (Table 3). Infectious virus particles could not be recovered for the 
remaining five mutant L genes (indicated as NR in Table 3). All viruses were confirmed for 
the presence of the desired mutations and absence of any spontaneous secondary 
mutations by virus purification followed by RT-PCR amplification of the L gene and 
sequence analysis using primers VG19 and VG20 (Table 1).  
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Growth analysis of SeV L mutants in cell culture. 
Previously studied VSV cap methylation mutants exhibited host range (hr) and 
temperature sensitivity (ts) (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006), therefore 
we tested our initially recovered recombinant SeV mutants (r1782A, r1804A, r1805A, 
r1806A, r1804A/1806A) for their possible hr and ts phenotypes. The wt and mutant SeV 
were titered on Vero and HEp-2 cells at 34°C and 40°C (Table 2).  In addition, we used 
rVSV wt and rVSV hr1 viruses as convenient controls for the conditions used in these 
studies. rVSV hr1 grew to high titers on Vero cells (permissive cells) at 34°C (permissive 
temperature) but, unlike rVSV wt, displayed more than 60,000-fold reduction in growth 
in HEp-2 cells at 34°C (nonpermissive cells) and in Vero cells at 40°C (nonpermissive 
temperature). Therefore, we predicted that SeV mutants defective in cap methylation 
would be moderately attenuated in Vero cells (as VSV hr1 compared to wt), but be 
severely attenuated in HEp2 cells. As shown in Table 2 and Figure 7A, SeV r1782A 
mutant showed a hr phenotype with a Vero/HEp-2 titer ratio of 100 (compare to 2.3 for 
rWT), which supported a possible role of the SeV L protein lysine 1782 at the active 
MTase site. This ratio was much smaller than in VSV hr1 (Table 2) because rK1782A 
was also attenuated in Vero cells reaching a maximum titer of only 4.0 x 10
5 
CIU/ml at 
120 h p. i. compared to 2.0 x 10
8 
CIU/ml for rWT at 48-72 h p. i. (Table 2). Also, 
infectious foci counted for r1782A in HEp-2 cells were noticeably smaller than in rWT 
(Fig. 7A). 
Unexpectedly, all tested SeV mutants with aa substitutions in the glycine-rich 
motif produced similar numbers of infectious foci in Vero and HEp-2 cells with a 
Vero/HEp-2 titer ratio of about 2.5. However, r1805A displayed slow growth in both 
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Vero and HEp-2 cells with about a 24 h delay in infectious foci formation and noticeably 
smaller foci on both Vero and HEp-2 cells.   
To independently confirm these observations, we cloned three representative 
mutations, K1782A, E1805A and G1806A, into a plasmid with the full-length SeV 
genome additionally encoding the GFP gene, and successfully rescued two of the three 
recombinant viruses (r1805A-GFP and r1806A-GFP) containing the appropriate L 
mutations (Fig. 7B).  Ten separate attempts were made to rescue r1782A-GFP, but no 
infectious virus was ever recovered and no GFP signal was visible during these attempts. 
We think that the combination of negative factors, the K1782A mutation and GFP 
insertion, made this virus too attenuated for recovery, at least using our standard rescue 
conditions. For successfully rescued GFP viruses, virus titrations were conducted on 
Vero and HEp-2 cells and virus infection sites were compared between rWT-GFP, 
r1805A-GFP and r1806A-GFP using fluorescent microscopy. As shown in Figure 7B for 
both Vero and HEp-2 cells, rWT-GFP and r1806A-GFP viruses had similarly sized foci 
with similar GFP signal at 48 h p.i. The r1805A-GFP virus at 48 h p.i. had smaller 
infectious sites on both Vero and HEp-2 cells. However, we did not observe differences 
in the relative ability of r1805A-GFP to grow on HEp-2 cells versus Vero cells (by CIU 
counts). Together, these data using SeV-GFP viruses confirmed that the G1806A 
mutation had no effect on SeV growth in Vero or HEp-2 cells, while the E1805A 
mutation similarly attenuated virus replication in Vero and HEp-2 cells.  
In addition, virus titration experiments were performed with the wt or mutant SeV 
(and SeV-GFP) viruses on Vero cells at 34°C and 40°C to determine possible ts 
phenotypes of these viruses as previously shown for VSV hr1 and other cap methylation 
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defective mutants (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). As shown in Table 
2, rVSV hr1 was clearly ts with a 34°C/40°C titer ratio in Vero cells of more than 60,000 
compared to 75 for rVSV wt. However, only two SeV mutants displayed a ts phenotype, 
r1782A and r1805A. In agreement with this result, the GFP signal was present in Vero 
cells at 40°C for the rWT-GFP and r1806A-GFP viruses as early as 48 h p.i. (Fig. 7B). 
However, there was no GFP signal in cells infected with r1805A-GFP virus at 40°C at 
any time point (Fig. 7B).  
Our titration experiments demonstrated that, unlike the r1782A mutant, all 
recombinant SeV with the aa substitutions in the glycine-rich motif did not display hr 
phenotypes. We wanted to confirm this result using a separate assay testing for the ability 
of these mutants to generate infectious particles in HEp-2 versus Vero cells (rather than 
their ability to form infectious foci as in our titration experiments). Therefore, we 
conducted a multistep growth kinetics assay for these viruses by infecting Vero cells at 
low MOI, harvesting cell supernatants at various time points, and assaying them on Vero 
cells to determine viral titers for each time point. As shown in Figure 8, most 
recombinant viruses, except for SeV r1782A, displayed similar growth kinetics in Vero 
cells with all titers peaking at 60 h p.i. The r1782A mutant grew very slowly in Vero cells 
producing about 2.5 x 10
2 
CIU/ml at 72 h p.i. (Fig. 8) and reaching only 4.0 x 10
5 
CIU/ml 
at 120 h p. i. While r1804A, r1806A and r1804A/1806A viruses all behaved similarly to 
rWT, r1805A had about 12 h delay in virus production. In HEp-2 cells, r1782A could be 
detected only at 96 and 120 h p. i. (maximum titer 2 x 10
3 
CIU/ml at 96 h p. i.) and the 
r1805A infection of HEp-2 cells was clearly delayed with viral titers beginning to 
increase after 72 h p.i. In addition, two SeV mutants, r1804A and r1806A, behaved very 
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unusually in HEp-2 cells with r1804A growing considerably faster than rWT and r1806A 
slower than rWT. The presence of both mutations in r1804A/1806A produced an 
intermediate growth phenotype suggesting that these mutations had a reciprocal effect 
when present together. Despite these differences in growth kinetics, all initially rescued 
recombinant viruses, except for r1782A, were able to grow in HEp-2 cells to relatively 
high titer, which was consistent with our titration experiments (Table 2) and suggested 
that the aa substitutions in the glycine-rich motif did not abolish the L protein MTase 
function.  
Our hr studies with our initially rescued SeV mutants did not result in large 
Vero/HEp-2 ratios and we observed that the r1782A virus was attenuated in Vero cells. 
Therefore all infectious SeV mutants generated at a later date than our initial study, were 
tested for their ability to infect and produce CPE in Vero cells only. Infectious foci were 
visualized by crystal violet staining or IF at 48 or 72 h p.i. Several mutants behaved 
similarly to rWT, while some mutants had obvious defects in growth based on their 
inability to form visible infectious foci (Fig. 9A). All of the mutants with the substitutions 
between positions 1795 and 1800 (DKDKDR) were capable of forming visible infectious 
foci and grew to rWT-like titers (Fig. 9A and Table 3). The rG1804A, rE1805A, 
rG1806A mutants and the double-mutant rG1804A/G1806A behaved as described above, 
i.e., they showed similar growth to rWT. Even the rE1805A mutant, which had a slight 
delay in growth, still grew to high titers. Additional alanine mutants in or around the 
glycine-rich motif behaved with minor variations: the rG1808A and especially the triple 
mutant rG1804A/G1806A/G1808A had infectious foci smaller than rWT, but grew to a 
high titer (1.4 x 10
8
 CIU/ml), and the rY1802A mutant had small infectious foci 48 h p.i 
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but at 72 h p.i. had foci size and titer similar to rWT (Fig. 9B). In contrast to these 
mutants, leucine substitutions had dramatic effect on virus growth: E1805L and G1808L 
could not be recovered despite all efforts; rG1804L was dramatically attenuated in Vero 
cells and infectious foci could only be detected by IF (Fig. 9C); and rG1806L was 
severely attenuated in cell culture, and even after several passages on Vero cells, titers 
remained extremely low (<10
2
 CIU/ml) (Fig. 9C and Table 3). Thus, the GxGxG motif, 
which in the cases of homologous MTases with the known structure is invariably located 
in the loop between the first beta strand and the alpha helix of the Rossmann fold, 
tolerates substitutions to small side chain residue such as alanine, but the bulkier aliphatic 
side chain of leucine appears incompatible with the structure or function of this region. 
The rules for E1805 were similar: negative charge turned out to be unimportant for virus 
viability, even though this residue is conserved in all Mononegavirales, but a bulky 
aliphatic leucine residue was not tolerated.  
In our initial studies (described above), we observed that the SeV L mutant with 
an alanine substitution at the first position of the putative KDKE catalytic tetrad, 
rK1782A, was attenuated in cell culture. We went on to create alanine substitutions at the 
other positions of this motif and rescued viruses with substitutions at the D1901 and 
K1938 positions; however, we were not able to rescue a virus with a mutation at E1975. 
Interestingly, after sequencing, the K1938 position mutant had a substitution to serine and 
not alanine. This serine substitution apparently has been selected in vivo, as the input 
plasmids used for virus recovery were confirmed by sequencing to have the alanine 
substitution. In addition to targeting the KDKE tetrad, we created alanine mutants of two 
other positions invariant in Mononegavirales, S1777 and E1903, and a double mutant, 
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rK1938A/I1939L. All SeV L mutants with substitutions in and around this putative 
KDKE catalytic tetrad were attenuated when grown on Vero cells (Fig. 9A). rK1782A, 
rE1903A, and rK1938A/I1939L produced infectious foci detectable only by IF (Fig 9C).  
The aa of the KDKE tetrad are widely spaced in the sequence of virus MTase, but 
are brought into close proximity in the homologous MTases of the known structure and in 
the predicted spatial structures of the L domain VI proteins (Bujnicki and Rychlewski 
2002; Galloway et al. 2008). They form a semi-circle on the outer rim of the AdoMet 
binding pocket and are thought to work together in transferring the methyl group from 
that donor to the 5’ nucleotides of virus mRNA, though exact role of each residue, as well 
as the details of the reaction mechanism (and indeed, the native three-dimensional 
structures of MTases of Mononegavirales), remain to be investigated. Residues S1777 
and E1903 are predicted to be further outwards from the AdoMet-binding pocket, and 
may be expected not to interact with the methyl donor, but rather perhaps play a role in 
recognition of the RNA substrate.  Our results indicate that single alanine mutations in 
most of these residues result in attenuation of virus infection.  
We also recovered several mutants with alanine substitutions at other invariant 
positions of domain VI, i.e., W1876A, S1969A, and Y1977A.  These mutant viruses 
behaved similarly to rWT in Vero cells and grew to high titers (Fig. 5 and Table 3).  The 
corresponding residues are predicted to be located outside of the ligand-binding pocket 
and may not be involved in any intramolecular interactions. We, however, were unable to 
recover virus progeny in the mutants that had multiple alanine substitutions in these 
patches of amino acids predicted to face outwards, i.e., a triple substitution 
Y1825A/N1826A/S1827A or a double substitution T1875A/W1876A. These highly 
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conserved regions might be necessary for interactions of SeV MTase with other regions 
within the L protein or with other proteins.  
To further examine the growth characteristics of all rescued mutant viruses, a one-
step growth kinetics analysis was performed as described in Materials and Methods (Fig. 
10). rWT reached its highest titer at 48 h p.i. and then declined at 72 and 96 h p.i.  
Mutants with substitutions within the DKDKD sequence upstream of the glycine-rich 
motif had slightly lower titers than rWT overall, but still reached their highest titers at 48 
h p.i. (Fig. 10A). For mutants with substitutions in the glycine-rich motif, the majority 
behaved similarly to rWT with slightly lower titers overall and maximum titers (10
7
-10
8 
CIU/ml) reached at 48 h p.i. (Fig. 10C).
 
 rG1804L was severely attenuated with infectious 
particles detected only after 24 h p.i. and maximum titers reaching only 10
5
 CIU/ml at 96 
h p.i. L mutants with substitutions in and around the putative KDKE catalytic tetrad were 
delayed in growth and had dramatically lower maximum titers (10
4
-10
5 
CIU/ml) as 
compared to rWT. 
Correlation between virus attenuation in cell culture and defects in cap methylation. 
In addition to a phenotypic analysis of SeV mutants, we directly tested mutants 
for their ability to methylate viral mRNAs in vitro. The limitation of the described VV-
T7-based in vitro transcription assay with plasmid-expressed P and L proteins is its 
dependence on the vaccinia virus vector, which provides trans-active viral MTases 
(Horikami et al. 1984), thus making these systems unusable for our studies on the SeV 
MTase function. Therefore, the effects of the SeV L protein mutations on viral mRNA 
cap methylation were studied using detergent-activated purified viruses, naturally 
carrying active virion-bound polymerase, as was conducted previously for VSV 
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(Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). In addition to rSeV, we used rVSV 
wt and rVSV hr1 viruses as positive and negative controls for cap methylation 
throughout all these assays. It is important to note that in contrast to the VSV system, the 
reactions with detergent-activated purified SeV (and many other Mononegavirales) 
virions require the addition of cytoplasmic extracts to each reaction (Moyer et al. 1986; 
Moyer et al. 1990; De et al. 1991; Mizumoto et al. 1995). However, such addition would 
be undesirable for our experiments as these extracts might contain trans-active cellular 
cap MTases which could complement L protein defects in cap methylation and thus 
prevent discrimination between mutants based on their ability to methylate mRNA caps. 
Therefore, we optimized the SeV in vitro transcription conditions using purified tubulin 
which has been shown to stimulate SeV virion transcription even when other cellular 
components are absent (Moyer et al. 1986; Mizumoto et al. 1995).  Interestingly, our 
optimal reaction condition, producing similar amounts of viral mRNA to reactions with 
cell lysate from Vero cells (data not shown), generated about 200-fold less viral mRNA 
compared to VSV virions transcribed using the same conditions (Fig. 11A). Nevertheless, 
despite these big differences in the efficiency of mRNA synthesis, [α
32
P]UTP-labeled 
SeV mRNA was easily detectable (Fig.11A) and we proceeded to compare all our SeV 
mutants for their ability to i) synthesize and ii) methylate viral mRNAs in vitro.   
For our initially rescued infectious SeV mutants, Figure 11B  shows a 
representative gel with [α
32
P]UTP-labeled viral mRNA produced by detergent-activated 
purified SeV wt and mutant virions (all purified viruses were tested by SDS-PAGE 
analysis confirming that similar amounts of virus were used in each reaction, data not 
shown). We did not observe any dramatic reduction in mRNA synthesis for most 
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mutants, although r1782A produced about 60% less mRNA than rWT. Interestingly, the 
L-1782A protein produced viral mRNA levels similar to L-WT in the VV-T7-based in 
vitro transcription system. The decrease in mRNA synthesis by purified r1782A virions 
could be a result of a partial loss of virion activity as r1782A virus was collected for 
purification 5 days p.i. due to its slow growth (compare to 2-3 days p.i. for rWT and other 
mutants). Interestingly, r1804A, r1806A and r1804A/1806A showed a slight increase 
(10-20%) in viral mRNA synthesis compared to rWT (Fig. 11B). Next, we tested all our 
mutants for their ability to methylate cap structures using rVSV wt and rVSV hr1 viruses 
as positive and negative controls for mRNA cap methylation. For this assay, in vitro 
transcription by detergent-activated purified virions was conducted with cold NTPs and 
[
3
H]AdoMet (methyl group donor) in the presence or absence of  S-
adenosylhomocysteine (AdoHcy), a competitive inhibitor of AdoMet-dependent MTases. 
The total RNA was purified and used for measurement of [
3
H]AdoMet incorporation into 
mRNA as assayed by binding to DEAE-cellulose paper and scintillation counting. As 
shown in Figure 11C, most tested SeV virions produced a similar mRNA methylation 
pattern with cap methylation completely abolished in the presence of AdoHcy, as in the 
case of VSV wt. The only SeV mutant that showed no detectable methylation in the 
absence of AdoHcy (as for the VSV hr1 mutant) was SeV r1782A, which is consistent 
with its hr phenotype. Interestingly, the SeV r1805A mutant always showed an 
intermediate level of cap methylation (Fig. 11C) with about 60% reduction in 
[
3
H]AdoMet incorporation into viral mRNA. To test whether no mRNA methylation in 
r1782A and a decrease in cap methylation in r1805A were results of the inhibition of 
MTase activity rather than decreased mRNA synthesis, a portion of the total mRNA 
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produced with [
3
H]AdoMet (Figure 11C) was examined by Northern blot analysis using a 
specific riboprobe against the SeV NP gene. As shown in Fig. 11D, most SeV mutants 
produced mRNA levels similar to those of rWT (with about 40% for r1782A) further 
indicating that K1782A and E1805A mutations specifically affected mRNA cap 
methylation rather than viral mRNA synthesis. 
We performed similar experiments with all other rescued infectious SeV mutants 
to determine whether the L mutations affected the ability of viruses to methylate mRNA 
5’ cap structures. In vitro transcription was performed using detergent-activated purified 
virions in the presence of [H
3
]-AdoMet with or without AdoHcy, and RNA products were 
isolated and analyzed by scintillation counting for [H
3
]-AdoMet incorporation and by 
Northern blot for total mRNA levels (Table 3). Cap methylation activity of each L mutant 
protein was expressed as a ratio of [H
3
]-AdoMet incorporation into viral mRNA to the 
NP + P mRNA products (Table 3, columns 5 and 6). This normalization was done to 
account for variability in overall transcription levels between different viruses (Table 3, 
columns 3 and 4). This variability could be due to mutations specifically effecting viral 
mRNA synthesis or due to variability in the transcriptional activity of individual virion 
preparations (see below). 
Unfortunately, a high-resolution analysis of cap structure in SeV mRNA is 
beyond our reach due to the more than 200-fold lower abundance of mRNA produced by 
SeV virion-associated L protein as compared to VSV. However, to confirm that [H
3
]-
labeled SeV mRNA (Table 3) had methylated cap structures, we analyzed [H
3
]-AdoMet 
labeled mRNA generated as described above, using tobacco acid pyrophosphatase (TAP) 
(Fig. 12). TAP is commonly used to specifically remove the 5’-terminal guanosine 
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monophosphate from the cap of mRNA, while uncapped mRNA cannot serve as a 
substrate for the TAP (Shinshi et al. 1976). In addition to SeV mRNA, we used three 
different control mRNAs (described in detail in  Materials and Methods): i) [H
3
]-AdoMet 
labeled VSV mRNA generated using detergent-activated wt VSV virions using in vitro 
transcription conditions identical to SeV; ii) synthetic SeV NP mRNA containing Cap 0 
(m
7
GpppA...) structure labeled with [
3
H] at the G-N7 position, and iii) synthetic SeV NP 
mRNA containing Cap 1 structure (m
7
Gppp[m
2’-O
]A...) labeled with [H
3
]-AdoMet only at 
the 2’-O position (2’-O methylated by the vaccinia virus enzyme). For TAP analysis, all 
these mRNAs were normalized by [
3
H] counts and digested by TAP (or mock-treated 
using the same conditions without TAP). Figure 12 shows [
3
H] counts associated with the 
released 5’-terminal G (“m
7
G”) or with mRNA after TAP treatment and separation using 
Sephadex G-50 columns. As expected, TAP treatment did not affect an association of 
[
3
H] with the synthetic mRNA having Cap 1 structure (m
7
Gppp[m
2’-O
]A...) labeled only 
at the 2’-O position, but resulted in the release of [
3
H]-m
7
G from the synthetic Cap 0 
mRNA labeled at the G-N7 position (Fig. 12), confirming that TAP specifically 
hydrolyzed the phosphoric acid anhydride bonds in the triphosphate bridge of the cap 
structure. Importantly, TAP treatment clearly resulted in the release of [
3
H]-m
7
G from 
SeV mRNA produced by detergent-activated virions in vitro, indicating that SeV mRNA 
was at least partially methylated at the G-N7 position. A similar result was obtained for 
VSV virion-produced mRNA, which is consistent with the previous studies 
demonstrating that the fully-methylated VSV mRNA has Cap 1 structure (Abraham et al. 
1975; Testa and Banerjee 1977; Rahmeh et al. 2009).  
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Although our data (Fig. 12) demonstrate that SeV methylates its mRNA at least 
partially at the G-N7 position, at this point we cannot make any conclusions about cap 
structure of SeV mRNA produced under our experimental conditions. Figure 8 shows 
that TAP released more [
3
H]-m
7
G from SeV mRNA than from VSV mRNA, and similar 
amounts of [
3
H]-m
7
G were released from SeV mRNA and the synthetic Cap 0 mRNA, 
which could indicate that SeV was methylated exclusively at the G-N7 position. 
However, it would be premature to make this conclusion based solely on the TAP 
experiments. Thus, we did not observe a complete removal of [
3
H]-m
7
G from the 
synthetic Cap 0 mRNA labeled only at G-N7 position, indicating that under our 
experimental conditions TAP was only about 50% effective in hydrolyzing triphosphate 
bridges. Furthermore, mRNA products analyzed in Figure 12 were normalized by [
3
H] 
counts. However, it is likely that the efficiency of cap methylation is different for SeV, 
VSV and vaccinia virus MTases and, therefore, different molar amounts of capped 
mRNA were likely present in these reactions further complicating conclusions about cap 
structure. Further studies using alternative biochemical assays are needed to determine 
cap structure of SeV mRNA produced under our experimental conditions, although a 
dramatic improvement in our in vitro transcription conditions is needed to obtain 
sufficient amounts of viral mRNA for cap analysis.  Most of the SeV L mutants of the 
DKDKD sequence had methylation levels similar to rWT, while rD1795A and rR1800A 
had about a 50% decrease in cap methylation compared to rWT.  Consistent with our 
previous results, the SeV L mutant rG1804A/G1806A had only slightly decreased 
methylation compared to rWT and the rE1805A mutant had methylation levels about 
23% of rWT.  The other SeV L mutants of the glycine-rich motif all had lower levels of 
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methylation as compared to rWT ranging from about 10% for rY1802A and rG1804L to 
about 40% for rG1808A and rG1804A/G1806A/G1808A. Except for rS1777A, all SeV L 
mutants with substitutions in and around the KDKE tetrad (rK1782A, rD1901A, 
rE1903A, rK1938S, and rK1938A/I1939L) were severely defective in cap methylation 
(2-8% of rWT). In general, most of the SeV mutants defective in cap methylation were 
attenuated in Vero cells, indicating the importance of this function in the SeV life cycle. 
Interestingly, while rWT and most of our mutants showed only residual mRNA 
methylation in the presence of AdoHcy, this value was surprisingly high (12.5%) for 
rG1804A/G1806A. At this point, we do not have an explanation for this result, but it was 
consistently reproduced in several independent experiments. We cannot exclude an 
interesting possibility that this mutation improves the preference of L towards AdoMet 
over AdoHcy, making it less sensitive to the excess of this product. Further studies are 
needed to address this possibility. 
Superinfection analysis. 
To test whether SeV mutants with substitutions at different positions within 
domain VI could potentially complement each other when grown together, we infected 
Vero cells with various combinations of defective mutants at an MOI of 1 CIU/cell per 
virus (total MOI of 2). Under these conditions, most of the cells are co-infected with both 
viruses. In addition to viruses with the phenotypes described above, we included rWT 
and other mutants that behaved similarly to rWT as controls (rS1777A, rR1800A, 
rE1805A, rG1804A/G1806A/G1808A, and rY1977A). We did not see any increase in 
CPE when defective mutants were combined with other defective mutants (data not 
shown).  Instead, when two of the defective mutants (rK1938S and rK1938A/I1939L) 
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were combined with rWT, we observed an inhibition of CPE with less cell rounding and 
cells remaining attached to the plastic (data not shown), suggesting they interfered with 
rWT replication. To investigate this observation further, we repeated the experiment 
looking at all SeV L methylation defective mutants in combination with rWT only (Fig. 
13A). All combinations grew to titers comparable to supernatant collected from Vero 
cells infected with rWT only with the exception of K1938S and K1938A/I1939L which 
had 99% lower titers for rWT (rWT foci can be easily discriminated from those generated 
by mutants due to their significantly larger size and earlier appearance). We then 
compared growth kinetics of two mutants, K1938S and K1782A in combination with 
rWT by infecting Vero cells and collecting supernatants at 18-72 h p.i. Similar to our 
titration experiments (Fig. 13A), K1782A when combined with rWT had similar growth 
kinetics to rWT alone while K1938S in combination with rWT had delayed growth and 
lower maximal titers (Fig. 13B), indicating that cap methylation defect alone is not 
sufficient for the interference of rK1938S and rK1938A/I1939L with rWT replication and 
that some additional factors are involved in the dominant negative phenotype of these 
SeV mutants. At this time, we cannot explain why viruses containing aa substitution at 
the L position 1938 interfere with rWT replication. One possibility is that such inhibition 
may simply reflect elevated levels of DI particles generated by these mutants. To test this 
hypothesis, we infected Vero cells again (as in Fig. 13A), collected cells and the medium 
at 48 h p.i. Consistent with Figure 10A, both rK1938S and rK1938A/I1939L inhibited 
production of rWT as was determined by titration of the collected medium on fresh Vero 
cells (Fig. 13B). For analysis of RNA synthesized during superinfection, both collected 
supernatants and cells were analyzed by Northern blot as described in Materials and 
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Methods. To detect DI genomes, a probe complimentary to the first 54 5’-nucleotides of 
the SeV genomic RNA was used, which should be able to detect full-length genomic 
RNA of SeV as well as DI genomes independent on the mechanism of their generation. 
As shown in Figure 13D, we were unable to detect any DI genomes in Vero cells under 
our experimental conditions. Interestingly, despite clear inhibition of SeV rWT virion 
production (Fig. 13A-C), we did not see any statistically significant decrease in SeV NP 
mRNA accumulation in the superinfected cells (Fig. 13E) using a probe against coding 
NP gene sequences, although a modest decrease in the full-length genomic RNA (wt plus 
mutant) levels was observed (Fig. 13D, FL gRNA band). A similar lack of DI genomes 
and a very modest reduction in full-length genomic RNA levels was observed when virus 
particles from the medium were pelleted by ultracentrifugation, and RNA from these 
particles was analyzed by Northern blot as above (data not shown). Together, our data 
suggest that rK1938S and rK1938A/I1939L are able to over-compete rWT during 
superinfection and, while the mechanism is unclear, this effect is apparently DI-
independent. 
Role of SeV mRNA cap methylation in antiviral responses in primary cell cultures. 
Cap methylation defective viruses (VSV, SeV, or any other Mononegavirales) 
have never been tested in any animal system or primary cells. It has been well established 
that methylation of the 5’ cap at the G-N7 position is absolutely required for efficient 
translation, but significance of methylation at the 2’O-ribose has remained unclear 
(Daffis et al. 2010; Zust et al. 2011). Recent studies have demonstrated that the presence 
or absence of 2’O-ribose methylation has an evolutionary basis and plays a role in 
distinguishing self from non-self mRNA (Daffis et al. 2010; Zust et al. 2011). Therefore 
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several viruses have evolved strategies for ensuring that their viral mRNAs are capped 
and methylated, mimicking host mRNAs and evading antiviral responses (Daffis et al. 
2010; Zust et al. 2011). Two separate research groups demonstrated that lack of 2’O-
ribose methylation in positive strand RNA viruses led to increased immune responses in 
host cells thus indicating the importance of methylation at this position of the mRNA cap 
structure (Daffis et al. 2010; Zust et al. 2011). The relationship between 2’O-ribose cap 
methylation and host immune responses in negative strand RNA viruses has not been 
explored. We analyzed the ability of infectious recombinant SeV mutants with varying 
defects in viral cap methylation to infect and replicate in primary mouse fibroblasts 
(MEFs). It is important to note that our SeV mutants have been characterized for their 
ability to produce cap structures with or without methylation however due to limitations 
in our assays we have not been able to characterize whether defects occur at the 2’O-
ribose, G-N7 or both positions of the cap structure. To evaluate the significance of 
general cap methylation in SeV infection, MEFs, wt as well as several cell types that are 
deficient in immune components important for antiviral responses against RNA viruses 
(RIG-I KO, MDA5 KO, IRF3 KO, IRF7 KO), were used. Three SeV mutants were 
selected based on our described cap methylation studies: (i) the rK1782A virus which is 
completely defective in viral mRNA cap methylation (a single K to A substitution in the 
putative KDKE catalytic tetrad of the L protein), (ii) the rE1805A virus with intermediate 
levels of cap methylation (a single E to A substitution in the glycine-rich motif GEGAG 
of the L protein), or (iii) the rG1806A virus with wt levels of cap methylation (a single G 
to A substitution in the glycine-rich motif GEGAG of the L protein). 
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 Monolayer cultures were infected with SeV wt and mutants at an MOI of 10 
CIU/cell. Twenty-four h p.i. supernatant was collected, cell lysates were prepared and 
RNA was isolated. Supernatant was analyzed for infectious virus particles budding from 
the cells by standard plaque assay on Vero cells (Fig 14). In general, rK1782A and 
rE1805A were more attenuated in all cell types compared to wt and rG1806A. 
Interestingly, all viruses were able to replicate to higher titers in the RIG-I KO MEFs 
compared to all other cell types. Western blots were performed to analyze viral protein 
expression levels and induction of ISGs as a downstream indicator of recognition of SeV. 
In wt MEFs and IRF7 KO MEFs, rE1805A had lower viral protein expression than the 
other SeV. In MDA5 KO MEFs, rK1782A had lower viral protein expression than the 
other SeV. And in RIG-I KO and IRF3 KO MEFs, viral protein expression for all SeV 
mutants was comparable (Fig 15A). We also analyzed lysates for expression of the 
interferon-stimulated gene ISG56/IFIT-1 to examine if certain cell types have increased 
expression following infection with cap methylation defective SeV. As expected, 
ISG56/IFIT-1 was not expressed in RIG-I and IRF3 KO MEFs and for the other cell 
types there was no difference in expression when infected with any of the tested SeV (Fig 
15B). Overall, in our preliminary experiments we did not observe any increased immune 
responses to SeV mutants lacking cap methylation in wt MEFs. However, in MEFs 
lacking the viral RNA sensor, RIG-I, viral protein expression was equivalent for all 
mutant viruses and the wt virus which indicates that RIG-I possibly plays a role in 
detecting viral RNA lacking specific cap methylation. Future experiments are needed to 
further investigate the importance of RIG-I in the recognition of SeV mRNA lacking 
2’O-ribose methylation. 
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2.4 Conclusions 
In this study, we conducted site-directed mutagenesis of the SeV L polymerase 
protein by targeting several aa residues within the L domain VI, homologous to those 
previously shown to be important for mRNA cap methylation in VSV (Grdzelishvili et al. 
2005; Li et al. 2005; Grdzelishvili et al. 2006; Li et al. 2006). The present study is the 
first mutagenic analysis of the L protein domain VI conducted for any Mononegavirales 
other than VSV. In addition to the VSV L protein domain VI, a previous study identified 
a new region between VSV L aa 1450-1481 which was critical for mRNA cap 
methylation (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). However, we did not 
find any significant homology between rhabdo- and paramyxoviruses in this variable 
region between conserved domains V and VI, and in this study we targeted only those aa 
that were homologous between VSV and SeV. Therefore, we initially set out to generate 
six mutant SeV L genes: K1782A, G1804A, E1805A, E1805V, G1806A, and a double 
mutant G1804A/G1806A; in addition, we made the L-∆VI mutant with a deletion of the 
entire domain VI to confirm that the SeV L protein has similar sensitivity to a loss of this 
region as previously shown for the VSV L protein (Canter and Perrault 1996).  
When these mutant proteins were tested for their ability to synthesize mRNA 
using a VV-T7 expression system, we found that, while most mutants retained normal 
RNA polymerase activity, two mutants, L-E1805V (but not L-E1805A) and L-∆VI, were 
completely inactive. The loss of activity in L-∆VI was not surprising as an even smaller 
deletion within domain VI abolished RNA synthesis by the VSV L protein as a result of 
an inability of this mutant to form the P-L complex required for normal L RNA 
polymerase activity (Canter and Perrault 1996). Unlike mRNA capping, which is tightly 
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coupled with mRNA transcription, viral mRNA synthesis proceeds with a similar 
efficiency in the absence or presence of the methyl group donor, AdoMet (Abraham et al. 
1975), and, therefore, cap methylation is not required for  mRNA synthesis in 
Mononegavirales. Thus, we think that the inactivation of L-∆VI transcription had no 
relation to the cap methylation function of this protein but that the deletion negatively 
affected the overall conformation of the L protein resulting in a defect in P protein 
binding (Canter and Perrault 1996) or other functions important for normal L protein 
RNA polymerization activity. The inactivation of the L-E1805V protein was more 
surprising as a similar substitution in the VSV hr1 mutant (D1671V), while abolishing 
cap methylation, had no effect on VSV mRNA synthesis (Grdzelishvili et al. 2005). It is 
likely that the aa substitution in the L-E1805V protein negatively affected L protein 
folding resulting in a complete inactivation of this protein.  
All mutations that passed the in vitro transcription test were cloned into the SeV 
full-length infectious cDNA plasmid, and initially, recombinant infectious viruses 
r1782A, r1804A, r1805A, r1806A, and a double mutant rG1804A/G1806A were 
successfully recovered and characterized. We conducted a phenotypic and biochemical 
analysis of these mutants using VSV wt and hr1 recombinant viruses as convenient 
positive and negative controls, respectively, for the hr and ts virus growth phenotypes 
and mRNA cap methylation activities.  
First, we conducted the phenotypic analysis of SeV mutants by testing their 
relative growth at 34ºC in Vero against HEp-2 cells by virus titration or by multistep 
growth kinetics analysis using these cell lines. Previous studies linked the inability of 
VSV cap methylation defective mutants to grow in HEp-2 cells to a viral defect in 
64 
mRNA cap guanine-N7 methylation and consequent nontranslatability of primary VSV 
transcripts (Horikami and Moyer 1982; Horikami et al. 1984; Grdzelishvili et al. 2005; 
Grdzelishvili et al. 2006). It was also suggested that host cells methylate viral mRNA in 
permissive cell lines through an unknown mechanism (Horikami et al. 1984). It should be 
noted that VSV hr1, while unable to grow in HEp-2 cells, was also attenuated in Vero 
cells (titer on Vero cells: 2.4 x 10
9
 CIU/ml for VSV wt against 6.0 x 10
7
 for VSV hr1). 
Therefore, while a Vero/HEp-2 titer ratio could serve as a good indicator of a possible 
defect in cap methylation (e.g., for VSV hr1), we expected an attenuation of cap 
methylation defective SeV mutants in both, Vero and HEp-2, cells. In agreement with a 
possible role of the lysine 1782 as an active site of the L protein MTase domain, the SeV 
r1782A mutant was attenuated in both, Vero and HEp-2 cells and showed a hr phenotype 
with a Vero/HEp-2 titer ratio of 100 (compared to 2.3 for rWT). Given the importance of 
the glycine-rich motif in VSV and other MTases and the homology of the substituted aa 
in SeV to those shown to be critical for guanine-N7 methylation in VSV (Grdzelishvili et 
al. 2005; Li et al. 2005; Grdzelishvili et al. 2006; Li et al. 2006), we expected that all 
other tested SeV mutants would also be hr restricted. To our surprise, most of the mutant 
viruses with aa substitutions in the glycine-rich motif grew normally not only in Vero but 
also in HEp-2 cells indicating that they were not defective in cap methylation. r1805A 
displayed slow growth in both Vero and HEp-2 cells with about a 24 h delay in infectious 
foci formation and noticeably smaller foci on both Vero and HEp2 cells. However, we 
did not observe differences in the relative ability of r1805A (or r1805A-GFP) to grow on 
HEp-2 cells versus Vero cells by CIU counts indicating that r1805A retained at least 
some MTase activity.  
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We also tested SeV mutants for their temperature sensitivity in Vero cells at 34ºC 
against Vero cells at 40ºC. Although ts phenotype alone could not indicate whether SeV 
mutations affected viral MTase activities, our previously tested VSV mutants defective in 
cap methylation were also ts (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). Again, 
most of the initially tested SeV mutants were not ts with the exception of r1782A and 
r1805A displaying a clear ts phenotype similar to that of VSV hr1. Together, our 
phenotypic analysis of recombinant SeV mutants identified only one mutant, r1782A, 
that behaved similarly to VSV hr1 (hr and ts) indicating that all other tested SeV L 
mutants retain at least some cap methylation function.  
To directly test SeV mutants for their MTase function, we conducted mRNA cap 
methylation analyses using an in vitro transcription assay with detergent-activated SeV 
virions and tested viral mRNA products for the presence of methyl groups. 
Unfortunately, in contrast to our previous VSV studies (Grdzelishvili et al. 2005; 
Grdzelishvili et al. 2006), we were unable to conduct a very detailed analysis of the SeV 
cap structure because of very low levels of viral mRNA produced in vitro (about 200-fold 
less viral mRNA compared to VSV in vitro transcription system). Nevertheless, our 
assays (supported by the described virus growth analysis) allowed us to make general 
conclusions about cap methylation function in all tested SeV mutants. Thus, consistent 
with the described phenotypic analyses, the r1782A mutant was completely defective in 
cap methylation, while r1805A displayed about a 60% decrease in cap methylation. Our 
data is the first study experimentally supporting the previous computational predictions 
(Bujnicki and Rychlewski 2002; Ferron et al. 2002) suggesting the importance of the 
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invariant lysine (position 1782 in the SeV L protein) and the glycine-rich motif in 
different Mononegavirales.  
The invariant lysine (L position 1782 in the SeV, 1651 in VSV) is conserved in 
most Mononegavirales, is also present in the known 2’-O cap MTases including NS5 
protein of flaviviruses (Fig. 5) and nonstructural protein 16 of coronaviruses (Decroly et 
al. 2008), and was predicted to be the first lysine within so called KDKE tetrad catalyzing 
an SN2-reaction-mediated 2’-O methyl transfer in 2’-O MTases (Hodel et al. 1998; Egloff 
et al. 2002; Hager et al. 2002). In West Nile virus (WNV, a flavivirus), a similar 
substitution of K61A (K61 is a putative functional analog of K1782 in SeV L) in the NS5 
protein, which also carries both guanine-N7 and ribose  2’-O MTase activities, 
specifically inhibited 2’-O cap methylation (Ray et al. 2006; Zhou et al. 2007). In 
contrast, the K1782A mutation in SeV L (this study) and the previously analyzed VSV 
K1651A (homologous to SeV K1782A) substitutions abolished both G-N7 and 2’-O 
methylation (Li et al. 2005). This discrepancy between WNV and Mononegavirales can 
be explained by the different order of cap methylation previously shown for flaviruses 
(GpppA → m7GpppA → m7GpppAm) (Zhou et al. 2007) and proposed for VSV 
(GpppA → GpppAm → m7GpppAm) (Testa and Banerjee 1977; Li et al. 2006). While 
the inactivation of 2’-O methylation by substitution of the catalytic lysine (K61) could 
not affect G-N7 methylation in WNV due to the order of cap methylation (Ray et al. 
2006; Zhou et al. 2007), it prevented G-N7 methylation in VSV (Li et al. 2006) and in 
SeV (K1782A mutation in this study), suggesting that paramyxoviruses may use the same 
order of cap methylation as VSV. It is important to note that that the cap methylation 
order for Mononegavirales is still controversial with some evidence pointing to both 
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orders. The in vitro results using detergent-activated VSV (Indiana strain) virions 
proposed the following order of MTase reactions:  GpppA + AdoMet (low concentration) 
→ GpppAm  + AdoMet (high concentration) → 7mGpppAm (Testa and Banerjee 1977; 
Li et al. 2006). However, the previous in vivo data on VSV (Indiana strain) mRNA 
synthesis in the presence of the methylation inhibitor cycloleucine (Moyer 1981) and in 
vitro transcription data on VSV New Jersey serotype (Hammond and Lesnaw 1987) 
suggest that the reverse order of VSV mRNA methylation 
(GpppA→7mGpppA→7mGpppAm) can also occur. Moreover, a previous study showed 
that SeV produces mRNAs methylated at both the G-N7 and 2’-O-adenosine positions or 
at G-N7 only (7mGpppA), but did not detect any mRNAs methylated only at the 2’-O-
adenosine position (Takagi et al. 1995). Finally, a previous study showed that Newcastle 
disease virus (NDV), another paramyxovirus, produces viral mRNAs that are not 2’-O-
methylated at all (Colonno and Stone 1976). 
While our results show clear similarities between VSV K1651A and SeV 
K1782A mutants (both completely defective in cap methylation), the aa substitutions in 
the L protein glycine-rich motif had milder (E1805A) or non-significant effects (G1804A 
and G1806A) on viral mRNA cap methylation. Generally, this region, especially the 
second glycine residue (G1806 in the SeV L), is sensitive to aa substitutions as 
demonstrated in VSV and many other known AdoMet-dependent MTases (Martin and 
McMillan 2002), including cap mRNA MTases of vaccinia virus (Mao and Shuman 
1996; Saha et al. 2003), reovirus (Luongo et al. 1998) and eukaryotic cells (Wang and 
Shuman 1997; Yamada-Okabe et al. 1999). The previously characterized VSV mutants 
with homologous changes in the glycine-rich motif showed the following cap 
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methylation phenotypes: 1) VSV G1670A (homologous to SeV G1804A): <1 to 20% for 
guanine-N7 (depending on in vitro conditions) and about 40% overall methylation 
compared to wt VSV (Li et al. 2006); 2) VSV D1671V [similar to E1805V (not rescued) 
and E1805A]: <1% for G-N7 and 2’-O methylation compared to wt VSV (Grdzelishvili 
et al. 2005; Li et al. 2006); 3) VSV G1672A [similar to SeV G1806A]: <1 to 20% for G-
N7 (depending on in vitro conditions) and about 40% overall compared to wt VSV  
(Grdzelishvili, Smallwood et al. 2006; Li, Wang et al. 2006). Although VSV G1670A 
and G1672A mutants retained a substantial 2’-O MTase activity, they were severely 
inhibited for their G-N7 MTase activity (Li et al. 2006). Importantly, under the in vitro 
conditions similar to those utilized in this study, these VSV mutants showed no 
detectable G-N7 methylation, while SeV G1804A and G1806A did not significantly 
affect G-N7 or 2’-O cap methylation. The tolerance of SeV L protein to aa substitutions 
G1804A and G1806A is also supported by the fact that double substitution 
G1804A/G1806A had little effect on virus growth or mRNA methylation in vitro. 
Interestingly, we found that, while both r1804A and r1806A had normal mRNA synthesis 
and cap methylation, they behaved very unusually during multistep growth in HEp-2 
cells with r1804A growing considerably faster than rWT and r1806A slower than rWT. 
The presence of both mutations in r1804A/1806A produced an intermediate growth 
phenotype suggesting that these mutations had a reciprocal effect when present together. 
Further experiments are needed to elucidate molecular basis for the differences between 
r1804A and r1806A in HEp-2 cells.  
While we still do not understand the exact mechanism of hr restriction of cap 
methylation mutants of VSV, the hr analysis of SeV mutants justifies future use of this 
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approach as a supporting assay to determine cap methylation status of SeV mutants in 
addition to the direct cap methylation analysis. Thus, although none of the tested SeV 
mutants showed Vero/HEp-2 titer ratio as dramatic as in VSV hr1 (more than 60,000), 
the only SeV mutant with asymmetric attenuation in HEp-2 was the rK1782A virus (with 
Vero/HEp-2 ratio of 100), and this mutant was also completely defective in cap 
methylation. The only other SeV mutant attenuated in HEp-2 cells (although equally in 
Vero cells) was r1805A, which also showed 60% reduction in cap methylation. 
Therefore, while the ability of a mutant (VSV or SeV) to grow in HEp-2 cells may not be 
sufficient by itself to determine methylation status of viral mutants, our data on SeV 
r1782A and r1805A mutants show that this assay can be successfully used to complement 
an in vitro cap methylation analysis of the SeV mutants. 
Although we did not find dramatic differences between SeV r1804A, r1806A, 
r1804A/1806A and rWT using our experimental conditions, the wt glycine-rich motif 
sequence may be beneficial during normal viral infection, and we believe that there must 
be some evolutionary basis for sequence conservation of this motif among 
paramyxoviruses and Mononegavirales in general. To further analyze the importance of 
L protein domain VI of paramyxoviruses we performed a more detailed sequence-
function analysis.  
We conducted site-directed mutagenesis targeting the residues highly conserved 
among Mononegavirales, including the KDKE tetrad and glycine-rich motif. Similar to 
VSV, alanine substitutions in the putative KDKE catalytic tetrad of SeV generated 
mutant viruses defective in cap methylation. Our data also confirms the importance of the 
glycine-rich motif (putative AdoMet binding site of domain VI) in SeV cap methylation 
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but with different effect of mutations in the glycine-rich motif in SeV as compared to 
VSV. For VSV, it was shown that virions with alanine substitutions at the first two 
glycines had decreased cap methylation, while alanine substitution at the third glycine did 
not affect MTase activity (Li et al. 2006). Here, we determined that the third glycine of 
the glycine-rich motif seems to play a more significant role in cap methylation in SeV 
than VSV, decreasing cap methylation by about 70% (compared to rWT). As further 
confirmation of the importance of this position, a triple mutant with all three glycines 
substituted to alanines also had low methylation levels (37% of rWT) while a double 
mutant with only the first two glycines substituted to alanines had rWT-like levels of 
growth and higher methylation. Our initial results described above, showed so much 
tolerance to substitution in the first two glycines in the glycine-rich motif as to even 
doubt that this is a functional AdoMet-binding site. Our further analysis of the glycine-
rich motif, including the role of the third glycine in the SeV cap methylation and dramatic 
effect of glycine to leucine substitutions in this motif restore a more conventional view of 
the role of this conserved sequence motif.  
Another mutation resulting in defective cap methylation (10% of wt SeV) and 
virus attenuation was Y1802A. This residue has never been studied before in any 
Mononegavirales and is highly conserved in most paramyxoviruses. It possesses a 
hydroxyl group and may substitute for the aspartic or glutamic acid residues frequently 
found in the middle of the first beta-strand of the Rossmann fold. It has been proposed 
(Kozbial and Mushegian 2005) that the side chain of this residue makes either direct or 
water molecule-mediated contact with the methionine portion of AdoMet and may be 
directly involved in catalysis. In several paramyxoviruses, just next to this residue there is 
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a motif DKDKD1799 with potential importance in catalysis due to the high concentration 
of aspartates and lysines and its close proximity to the glycine-rich motif. We targeted 
these positions for substitution to alanines, but all these SeV L mutants were easily 
recovered, grew to high titers with similar kinetics to rWT in Vero cells and had high 
levels of cap methylation.  
Consistent with the role of cap methylation in the translatability of mRNA, SeV 
mutants with decreased methylation (<10%) were attenuated in Vero cells. The majority 
of these mutants had substitutions in and around the putative KDKE catalytic tetrad. In 
agreement with our initial study, we observed that alanine substitutions at positions in 
and around the glycine-rich motif were well tolerated; however, a triple mutant with all 
three glycines replaced with alanines did show slight attenuation, confirming the 
importance of this motif for SeV L function and virus replication. We also observed that 
two cap methylation defective mutants, rK1938S and rK1938A/I1939L, had strong 
interfering effect on replication of wt SeV during superinfection. Interestingly, another 
cap methylation defective mutant, rK1782A, did not interfere with rWT replication 
indicating that cap methylation defect alone is not sufficient for this dominant-negative 
mutant phenotype and that some additional factors are involved.  Currently, we cannot 
explain how K1938S mutation could inhibit the growth of rWT and further studies are 
warranted to explore this interesting observation.  
Interestingly, a single alanine substitution at the putative catalytic K1938 position 
was successfully introduced into plasmids containing the SeV L gene and the full-length 
antigenome of SeV. However, when infectious virus particles, recovered using a reverse 
genetics system, were sequenced, the substitution was to serine rather than alanine. Based 
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on the importance of this position in the catalytic tetrad, we speculate that the change to 
the polar serine residue led to a more favorable configuration of hydrogen bond network 
linking catalytic residues to AdoMet and perhaps additionally supporting proper 
conformation of the L protein, which may be important for its function. When tested in a 
VV-T7 in vitro transcription or replication systems, the K1938A mutant L had slightly 
lower transcription (~80%) and lower replication levels (~60%) as compared to rWT. 
Mutant virions with the K1938S substitution were defective in cap methylation (8% of 
rWT), but had high transcription levels (91% of rWT): apparently, a serine substitution is 
more favorable for the overall activity of the L protein (although not necessarily for cap 
methylation).  
We propose two main theories explaining the tolerance of the SeV L protein to 
the G1804A, G1806A and double G1804A/1806A substitutions. First, it is possible that, 
despite a homology between VSV and SeV at the glycine-rich motif, this region is not an 
AdoMet-binding site in SeV and possibly other paramyxoviruses, and that an actual 
AdoMet-binding site could be located at a different position in the SeV L protein. 
Importantly, even in VSV, a putative role of this motif as an AdoMet-binding site was 
postulated based on computational predictions and site-directed mutagenesis studies, but 
no experimental biochemical data are available to date for the L protein of any 
Mononegavirales directly demonstrating that this or any other L region actually binds 
AdoMet. While a different AdoMet-binding site location in SeV and VSV is a possibility, 
the complete inactivation of L cap methylation by K1782A (the first lysine of the 
catalytic KDKE tetrad in 2’-O MTases is generally positioned upstream and in a close 
proximity to the AdoMet-binding site) and about 60% decrease in methylation by 
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E1805A support another hypothesis that, while the glycine-rich motif is likely to be the 
SeV L protein AdoMet-binding site, SeV and possibly other paramyxoviruses are far 
more flexible than VSV to the aa substitutions in this motif. Such tolerance may explain 
why, while most Mononegavirales, including VSV and SeV, have the motif 
G(D/E)G(S/A)G (glycines important for VSV cap methylation are underlined; Fig. 1), 
more variation in this motif can be found in the members of the family Paramyxoviridae, 
especially in the genera Rubulavirus (subfamily Paramyxovirinae) and Avulavirus 
(subfamily Pneumovirinae), which have the motif AEG(S/A)G very similar to the 
sequence in our mutant SeV r1804A (AEGAG). Interestingly, the avian pneumovirus L 
protein has a motif AEASG which is similar to our double mutant SeV r1804A/1806A 
(AEAAG), which had a wt growth phenotype and normal mRNA cap methylation pattern. 
Previously, Li et al. (Li, Wang et al. 2006) speculated that these differences at the 
glycine-rich motif between NDV (genus Avulavirus) and VSV may account for the 
differences of these viruses in cap methylation pattern [the NDV caps are not 2’-O-
methylated at all (Colonno and Stone 1976)]. However, our data suggest that these 
sequence variations among paramyxoviruses reflect their tolerance to aa substitutions and 
are not functionally important as r1804A, r1806A and r1804A/1806A mutants displayed 
a normal cap methylation pattern. 
Despite some observed differences between VSV and SeV (more tolerance of 
SeV to aa substitutions in the glycine-rich motif), our results do clearly show the 
importance of the putative KDKE catalytic tetrad and glycine-rich motif, thus confirming 
previous computational predictions that these regions are important for MTase function 
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across different families of the order Mononegavirales (Bujnicki and Rychlewski 2002; 
Ferron et al. 2002; Martin and McMillan 2002). 
Cap methylation defective viruses (VSV, SeV, or any other Mononegavirales) 
have never been tested in any animal system or primary cells. Our preliminary analysis of 
select SeV mutants in primary MEFs demonstrate attenuation in wt MEFs which could 
indicate that these mutants lack 2’O-ribose methylation. Recent studies have 
demonstrated that the presence or absence of 2’O-ribose methylation plays a role in 
distinguishing self from non-self mRNA (Daffis et al. 2010; Zust et al. 2011). Therefore 
several viruses have evolved strategies for ensuring that their viral mRNAs are capped 
and methylated, mimicking host mRNAs and evading antiviral responses (Daffis et al. 
2010; Zust et al. 2011). Two separate research groups demonstrated that lack of 2’O-
ribose methylation in positive strand RNA viruses led to increased immune responses in 
host cells thus indicating the importance of methylation at this position of the mRNA cap 
structure (Daffis et al. 2010; Zust et al. 2011). Our SeV mutants have been characterized 
for their ability to produce cap structures with or without methylation however due to 
limitations in our assays we have not been able to characterize whether defects occur at 
the 2’O-ribose, G-N7 or both positions of the cap structure. Interestingly, although the 
r1782A mutant was attenuated in wt MEFs, protein expression levels in these cells was 
similar to rWT and r1806A while r1805A had lower protein levels.  This could indicate 
that r1805A, which exhibits intermediate levels of cap methylation, could be defective in 
2’O-ribose methylation and the cells are recognizing this defect and mounting a robust 
antiviral response against this mutant. It is unclear at this time why r1782A which is 
completely defective in cap methylation did not have lower viral protein levels than the 
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rWT and r1806A viruses that have normal cap methylation function. When cells infected 
with these viruses were analyzed for ISG56/IFIT-1 expression,an IFN-stimulated gene 
and a downstream indicator of an antiviral response, there was no difference in protein 
levels at the 24 h p.i. time point in wt MEFs. SeV cap methylation defective mutants 
grew to higher titers in RIG-I KO primary MEFs (but still lower than rWT in RIG I KO 
MEFs). Analysis of viral protein expression in RIG-I KO MEFs showed similar protein 
levels for all viruses which could indicate a role for RIG-I in detecting cap methylation 
defective mutants. Future experiments are needed to further investigate the importance of 
RIG-I in the recognition of SeV mRNA lacking 2’O-ribose methylation.  
Future experiments will include a comparative pathogenesis study in mice (the 
natural host for SeV) to determine the role of the mutated aa residues during normal 
infection and thus to understand why the glycine-rich motif is conserved in 
paramyxoviruses (and other Mononegavirales) if it can be mutated without serious 
consequences to virus fitness. Mutants defective in cap methylation could possibly be 
attenuated in vivo, however it is unclear if infectious viruses carrying these specific 
mutations will exhibit any unusual tissue specificity as compared to their wt counterpart. 
In addition to better understanding the biology of these viruses, these experiments would 
have important practical implications because targeting aa residues critical for cap MTase 
function in VSV, SeV and other Mononegavirales could be used to rationally attenuate 
these viruses (or manipulate their hr)  for development of live attenuated viruses and their 
use as vaccine (Bukreyev et al. 2006), oncolytic (von Messling and Cattaneo 2004) and 
gene therapy (Finke and Conzelmann 2005) vectors. 
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Figure 6.  In vitro mRNA synthesis and genome replication with SeV mutant L proteins 
using a VVT7 expression system. Plasmids expressing P and wt or mutant L proteins 
were transfected into VV-T7 infected A549 cells. N protein was also expressed for DI 
replication. Total RNA was isolated from cell lysates and in vitro transcription (A) or DI 
replication (B) reactions were performed in the presence of [α
32
P]-CTP.  Western blot 
analyses of cell lysates used in (A) or (B) demonstrate relative expression of the SeV L, P 
and N (for DI replication) proteins in A549 cells. Transcription and DI replication data 
represent the mean ± standard deviation of two independent experiments. 
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Figure 7. Host range and temperature sensitivity analysis of SeV mutants. (A) IF 
infectious focus assay to analyze SeV r1782A (compare to SeV rWT) for hr and ts 
phenotypes. Virus infectious foci were visualized by IF using anti-SeV antibodies and 
IgG-FITC secondary antibodies on fixed and permeabilized Vero or HEp-2 cells infected 
with SeV r1782A or rWT at 34°C or 40°C. (B) GFP fluorescence focus assay to analyze 
SeV rWT-GFP, r1805A-GFP and r1806A-GFP viruses encoding the GFP gene upstream 
of the NP gene for hr and ts phenotypes. Assays were done on Vero or HEp-2 cells at 
34°C or 40°C. Virus infectious foci were visualized by microscopy at 48 or 72 h p.i. as 
indicated using fluorescence (upper panels) or bright-field (lower panels) channels.  
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Figure 8. Multistep growth kinetics of wt and recombinant SeV in Vero and HEp-2 cells 
at 34°C.  SeV wt or recombinant viruses were used to infect (A) Vero or (B) HEp2 cells 
at MOI 0.001 CIU/cell.  Supernatants were harvested at 12 h (A) or 24 h (B) intervals and 
flash frozen.  Supernatants were assayed on Vero cells and virus titers were determined 
for each time interval. 
 
A 
B 
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Figure 9. Growth analysis of recombinant SeV mutants in Vero cells. (A) Crystal violet 
staining of infectious foci of all rescued SeV L mutants. Plaque assays were performed 
on Vero cells and infectious foci from the lowest dilution displaying infectious foci were 
stained 48 h p.i. Wells with no visual infectious foci at 48 h p.i. were analyzed at 72 h p.i. 
or by IF. (B) For delayed mutants (indicated by *), plaque assays were again performed 
and crystal violet staining of infectious foci was done at 72 h p.i. (C) For severely 
attenuated mutants that had no visible infectious foci at 48 or 72 h p.i. an IF assay was 
performed at 72 h p.i. Upper panels represent cells stained with an anti-SeV primary 
antibody and an IgG secondary antibody conjugated to FITC. Lower panels represent 
Hoeschst staining of nuclei from the same fields shown in upper panels. 
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Figure 10. One-step growth kinetics of 
SeV mutants in Vero cells. Monolayer 
cultures of Vero cells were infected at an 
MOI of 3 CIU/cell with each mutant 
SeV. Vero cells were incubated with 
viruses for 1 h, then unabsorbed viruses 
were aspirated, cells were washed two 
times with PBS and fresh was added to 
each well.  Supernatants were collected 
at 6, 24, 36, 48, 72, and 96 h p.i. and 
flash frozen. Plaque assays were 
performed on Vero cells and virus titers 
were determined for each time interval. 
* Zero titer indicates that virus titer at 
the indicated time point was below our 
detection threshold (50 CIU/ml). (A) 
SeV mutants with alanine substitutions 
in a DKDKD motif upstream of the 
glycine-rich motif. (B) SeV mutants that 
showed delayed growth in Vero cells or 
lower titers as compared to rWT. (C) 
SeV mutants with substitutions in and 
around the glycine-rich motif. The data 
represent the mean ± standard deviation 
of two independent experiments. 
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Figure 11. In vitro mRNA synthesis with 
purified mutant SeV. (A) Optimization 
of SeV virion transcription. In vitro 
transcription by detergent-activated 
purified SeV and VSV virions was 
performed using the same conditions in 
the presence of [α
32
P]UTP and varying 
amounts of virus and purified tubulin. 
1/225 or 1/15 of a 25 µl transcription 
reaction was loaded for wt VSV, while 
the entire product of a 25 µl transcription 
reaction was loaded for SeV. The mock 
sample had all reaction components 
except for virus. The positions of the 
SeV NP and VSV N mRNAs are 
indicated.  For all reactions total RNA 
was purified and analyzed by urea-
agarose gel electrophoresis and 
visualized by autoradiography. (B) 10 
µg of purified wt or mutant SeV were 
detergent activated and used for in vitro 
mRNA synthesis in a 50 µl transcription 
reaction in the presence of [α
32
P]UTP.  
The mRNA products were purified, 
separated by urea-agarose gel 
electrophoresis and visualized by 
autoradiography. The position of the 
SeV NP mRNA is indicated. “% Txn” 
shows mRNA levels relative to wt SeV 
(100%) using PhosphorImager and 
represents the average of two or three 
experiments where variation was less 
than 15%. (C) 80 µg of purified wt SeV 
(lane 1) or mutant SeV (lanes 2-5) were 
detergent activated and used for in vitro 
mRNA synthesis in a 200 µl 
transcription reaction in the presence of 
[
3
H]AdoMet with (gray bars) or without 
(black bars) addition of AdoHcy. For all 
conditions, RNA was purified, separated 
from nucleotides using gel filtration 
columns and used for the measurement 
of [
3
H]AdoMet incorporation into 
mRNA by scintillation counting. (D). 
Northern blot analysis to compare viral 
mRNA levels produced by SeV mutants 
in the absence of AdoHcy (upper panel) 
or to compare mRNA levels produced 
with and without AdoHcy (lower panel). 
For Northern blotting, 1/10 of the 
mRNA produced in (C) was separated in 
a 1.2% agarose formaldehyde gel 
system, transferred to a nylon membrane 
and incubated with an RNA probe 
complementary to the SeV NP gene. 
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Figure 12. Cap methylation analysis using tobacco acid pyrophosphotase. SeV rWT 
(“SeV mRNA) and VSV rWT (“VSV mRNA”) were produced in vitro transcription by 
detergent-activated purified virions in the presence of [
3
H]AdoMet. Synthetic SeV NP 
mRNA controls were synthesized in vitro using T7 RNA polymerase and then used to 
make mRNA containing Cap 0 (m
7
GpppA...) labeled with [
3
H]AdoMet at the G-N-7 
position, or mRNA containing Cap 1 (m
7
Gppp[m
2’-O
]A...) labeled with [
3
H]AdoMet only 
at the 2’-O position using vaccinia virus enzymes as described in Materials and methods. 
For TAP analysis, all RNAs were normalized by [
3
H] counts and digested by TAP 
(“+TAP”) or mock-treated using the same reactions but without TAP (“-TAP”). mRNA 
was then separated from [
3
H]m
7
G using Sephadex G-50 mini-columns. [
3
H]Met 
incorporation into the G-N-7 or 2’-O cap positions was measured by scintillation 
counting of the entire flow through (for mRNA containing [
3
H-m
2’-O
]A) and columns (for 
removed [
3
H]m
7
G). The data represent the mean ± standard deviation of two independent 
experiments. 
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Figure 13. Superinfection of Vero cells 
with SeV mutants. (A) Vero cells were 
infected with combinations of SeV 
mutants and rWT at an MOI of 1 
CIU/cell (total MOI of 2). Cells were 
observed and CPE was visualized by 
light microscopy at 24, 48, and 72 h p.i. 
The supernatant was collected at the 
same time points and each sample was 
further analyzed by plaque assays 
performed on Vero cells. Data represent 
the mean of three independent infections 
± standard deviation. (B) One-step 
growth kinetics for rWT grown in 
combination with K1782A and K1938S 
mutant viruses. Vero cells were infected 
at MOI 1 CIU/cell (total MOI of 2), 
supernatants collected at 18, 24, 48, and 
72 h p.i. and titered on Vero cells. (C-E) 
Vero cells were infected with 
combinations of SeV mutant viruses plus 
rWT at an MOI of 1 CIU/cell for each 
virus (total MOI of 2). 48 h p.i., cells 
were analyzed by Northern blot (D-E) 
and the medium was titered on fresh 
Vero cells (C). Titration was done on 6-
well plates with the rWT infection foci 
visualized 48 h p.i. using 4 CN 
Peroxidase Substrate staining Kit (KPL) 
and anti-SeV primary antibodies. 
Representative plates are shown. Only 
large SeV rWT (but not mutant) 
infectious foci are visible at this time 
point.  (D-E) Cell pellets were analyzed 
by Northern blot analysis for genomic 
RNA using a probe for FL genomic 
RNA (gRNA) as well as DI genomic 
RNA (D) or a riboprobe for the SeV NP 
mRNA as well as the FL antigenomic 
RNA (agRNA) (E), as described in 
Materials and Methods. “Vero Mock” 
sample: total RNA isolated from mock-
infected Vero cells. 7 μg of total RNA 
was used for each sample. “Vero wt 
SeV” sample: total RNA isolated from 
Vero cells infected with SeV rWT and 
collected at 48 h p.i. “DI gRNA” 
sample: total RNA isolated from a 
preparation of SeV DI particles (DI-H).  
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Figure 14. SeV infectivity of MEFs. SeV infectivity, expressed as cell infectious units/ml 
(CIU/ml), was measured by virus titration on Vero cells and counting infectious foci 
using immunofluorescence (IF). SFM media from 6-well plates was aspirated 2 or 3 days 
post infection, cells were washed with PBS, fixed with 3% paraformaldehyde (Sigma) for 
10 minutes, and permeabilized for 2 minutes 0.5% Triton-X-100.  Cells were then 
blocked in PBS with 5% bovine serum albumin (BSA, Sigma) for 20 minutes and 
incubated with anti-SeV primary antibodies (1:100) for 1 h.  Cells were washed, 
incubated with goat anti-rabbit IgG-Alexafluor antibodies (Santa Cruz) for 1 h in the 
dark, and viewed under a fluorescent microscope to determine virus titer. 
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Figure 15. Western blot analysis of MEFs infected with SeV mutants. Six well plates of 
MEFs were infected at an MOI of 10 CIU/cell and cells were harvested for lysates at 24 h 
p.i. Lysates were prepared directly in the 6 well plates in 1X SDS sample buffer and 5 µl 
(of a total of 150 µl) of each sample was separated by 10% SDS-PAGE and 
electroblotted onto PVDF membranes. Membranes were blocked with 5% non-fat dry 
milk and membranes were incubated with (A)  rabbit anti-SeV antibodies (1:5000) or (B)  
rabbit anti-IFIT-1 (ISG56, 1:500) followed by incubation with goat anti-rabbit IgG-HRP 
secondary antibodies (1:5000). 
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2.6 Table 1. Sequences of primers used in this study to generate SeV mutant L genes. 
Capital letters show substituted nucleotides resulting in the aa change. 
L mutant L changes Silent 
Site 
Primer sequences 
L-1777A S1777A AatII (+) ctctttggcatcaacGCGacgtcctgcttgaaagcacttg 
(-) caagtgctttcaagcaggacgtcgcgttgatgccaaagag 
L-1782A K1782A AfeI (+) catcaacagtactagctgcttgGCagcgcttgaacttacctacctatt 
(-)  caataggtaggtaagttcaagcgctgccaagcagctagtactgttgat 
L-1795A D1795A StyI (+) gagccccttagttgCcaaggataaagataggc 
(-) gcctatctttatccttggcaactaaggggctc 
L-1796A K1796A SalI (+) ctattgagccccttagtcgacGCggataaagataggc 
(-) gcctatctttatccgcgtcgactaaggggctcaatag 
L-1797A D1797A SalI (+) gagccccttagtcgacaaggCtaaagataggctatatttagggg 
(-) cccctaaatatagcctatctttagccttgtcgactaaggggctc 
L-1798A K1798A RsrII (+) ccccttagttgacaaggatGCGgaccggctatatttagg 
(-) cctaaatatagccggtccgcatccttgtcaactaagggg 
L-1799A D1799A StyI (+) gttgacaaggataaagCtaggctatacctaggggaaggagctg 
(-) cagctccttcccctaggtatagcctagctttatccttgtcaac 
L-1800A R1800A MluI (+) gttgacaaggataaagacGCgttatatttaggggaag 
(-) cttcccctaaatataacgcgtctttatccttgtcaac 
L-1802A Y1802A StyI (+) ggataaagataggctcGCCttgggggaaggagctggggc 
(- ) gccccagctccttcccccaaggcgagcctatctttatcc 
L-1804A G1804A EaeI (+) gataggctatatttggCCgaaggagctggggccatg 
(-)  catggccccagctccttcggccaaatatagcctatc 
L-1804L G1804L XbaI (+) gataaagataggctatatcttCTAgaaggagctggggccatg 
(-) catggccccagctccttctagaagatatagcctatctttatc 
L-1805A E1805A AvrII (+) gataaagataggctatacctaggggCaggagctggggccatg 
(-)  gcatggccccagctcctgcccctaggtatagcctatctttat 
L-1805L E1805L StyI (+) gataggctatatttaggcCTaggagctggggccatgc 
(-) gcatggccccagctcctaggcctaaatatagcctatc 
L-1805V E1805V AvrII (+) gataaagataggctatacctaggggTaggagctggggccatg 
(-)  gcatggccccagctcctacccctaggtatagcctatctttat 
L-1806A G1806A AvrII (+) gataaagataggctatacctaggggaagCagctggggccatgctttc 
(-)  gaaagcatggccccagcttcccctaggtatagcctatctttatc 
L-1806L G1806L SacI (+) ggctatatttaggggagCTCgctggggccatgctttc 
(-) gaaagcatggccccagcgagctcccctaaatatagcc 
L-1804A/ 
1806A 
G1804A/ 
G1806A 
PstI (+) gataggctatatttagCggaagCTgcaggggccatgctttc 
(-)  gaaagcatggcccctgcagcttccgctaaatatagcctatc 
L-1808A G1808A PstI (+) tttaggggaaggagctgCAgccatgctttcctgtt 
(-) aacaggaaagcatggctgcagctccttcccctaaa 
L-1808L G1808L HaeII (+) tatttaggggaaggagcgCTggccatgctttcctgttatg 
(-) cataacaggaaagcatggccagcgctccttcccctaaat 
L-1804A/ 
1806A/ 
1808A 
G1804A/ 
G1806A/ 
G1808A 
PstI (+) gataggctatatttagCggaagCagctgCAgccatgctttcctgtt 
(-) aacaggaaagcatggctgcagctgcttccgctaaatatagcctatc 
L-1810A M1810A AfeI (+) gaaggagctggggcaGCgctttcctgttatgacg 
(-) cgtcataacaggaaagcgctgccccagctccttc 
L-1825A/ 
1826A/ 
1827A 
Y1825A/ 
N1826A/ 
S1827A 
NotI (+) gcccatgcatcaactatGCGGCcGcaggggtatactcttgtg 
(-) cacaagagtatacccctgcggccgcatagttgatgcatgggc 
 
L-1876A W1876A HincII (+) gaatcctgggtcgacaGCgattgggaatgatgagtg 
(-) cactcatcattcccaatcgctgtcgacccaggatt 
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L mutant L changes Silent 
Site 
Primer sequences 
L-1875A/ 
1876A 
T1875A/W187
6A 
PstI (+) cgggaatcctggctctGcaGCgattgggaatgatgagtg 
(-) cactcatcattcccaatcgctgcagagccaggattcccg 
L-1901A D1901A FspI (+) aggcctagtccactgcgCAatggagggaggagatc 
(-)gatctcctccctccattgcgcagtggactaggcct 
L-1903A E1903A NaeI (+) gtccactgtgacatggCCggcggagatcataaggatg 
(-)catccttatgatctccgccggccatgtcacagtggac 
L-1938A K1938A AfeI (+) gttgtgcttataagcGCTattgctcccaggctgg 
(-) ccagcctgggagcaatagcgcttataagcacaac 
L-1969A S1969A AflII (+) cctaatagtgcttaagacaGctaaccctgcttccacag 
(-) ctgtggaagcagggttagctgtcttaagcactattagg 
L-1975A E1975A EaeI (+) ctaaccctgcttccacggCCatgtatcttctatcgag 
(-) ctcgatagaagatacatggccgtggaagcagggttag 
L-1977A Y1977A HaeII (+) ctgcttccacagagatgGCGcttctatcgaggcacc 
(-) ggtgcctcgatagaagcgccatctctgtggaagcag 
L- VI deletion of aa 
1777-1976 
none (+) ggctctttggcatcaaccttctatcgaggcacccc 
(-)  ggggtgcctcgatagaaggttgatgccaaagagcc 
Upstream primer VG19 for cloning and 
sequencing 
(+) catacctatgcagcttggcagaga 
 
Downstream primer VG20 for cloning and 
sequencing 
(-)  taaccctcaggttcctgatctcac 
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2.6 Table 2. Comparative titers of recombinant Sendai viruses in Vero or HEp2 cells at 
34°C or 40°C 
 
Virus 
Virus titer (CIU/ml) 
in Vero cells 
Virus titer 
(CIU/ml) 
in HEp-2  
Titer ratio 
34ºC/40ºC 
in Vero 
Titer  ratio 
at 34°C 
Vero/HEp-2 
 
34°C 
 
40°C 
 
34°C 
SeV rWT 2.0 x 108 3.4 x 107 8.8 x 107 5.9 2.3 
SeV r1782A 4.0 x 105 <103 4.0 x 103 >1.2 x 103 100 
SeV r1804A 1.5 x 107 3.2 x 106 5.3 x 106 4.7 2.8 
SeV r1805A 3.6 x 108 <103 1.6 x 108 >3.6 x 105 2.3 
SeV r1806A 2.4 x 108 1.6 x 107 1 x 108 15 2.4 
SeV r1804A/1806A 5.0 x 107 8.0 x 106 2.5 x 107 6.3 2.0 
SeV r WT-GFP 1.9 x 108 7.0 x 106 1.0 x 108 27.1 1.9 
SeV r1805A-GFP 8.3 x 107 <103 3.3 x 107 >8.3 x 104 2.5 
SeV r1806A-GFP 1.3 x 108 4.6 x 106 4.4 x 107 28.3 3.0 
rVSV wt 2.4 x 109 1.0 x 107 3.2 x 107 240 75 
rVSV hr1 6.0 x 107 <103 <103 > 6 x 104 > 6 x 104 
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2.6 Table 3. Cap methylation analysis using SeV detergent-activated purified virions 
 
VIRUSES 
Virus stock 
infectivity  
(CIU/ml) 
Txn 
- AdoHcy 
 
(% of rWT 
- AdoHcy) 
Txn 
+ AdoHcy 
 
(% of rWT 
- AdoHcy) 
† Cap 
Methylation  
- AdoHcy  
(% of rWT 
- AdoHcy) 
† Cap 
Methylation  
+ AdoHcy  
  (% of rWT 
- AdoHcy) 
rWT 3.8 x 108 100.0 67.0 ± 26.0 100.0 2.7 ± 0.2 
rS1777A 4 x 107 100.0 ± 25.8 70.3 ± 5.2 45.8 ± 11.9 0.7 ± 0.2 
rK1782A 2 x 105 25.8 ± 2.6 32.8 ± 11.7 6.6 ± 1.2 1.4 ± 0.7 
rD1795A 8 x 107 55.4 ± 12.4 51.3 ± 17.0 51.6 ± 16.9 1.7 ± 0.6 
rK1796A 8 x 107 54.0 ± 13.5 41.6 ± 3.9 82.2 ± 13.2 1.7 ± 0.3 
rD1797A 8 x 107 79.4 ± 0.5 64.4 ± 25.2 120.9 ± 20.8 2.7 ± 0.1 
rK1798A 1 x 108 48.9 ± 7.1 24.8 ± 0.5 104.0 ± 0.8 4.2 ± 0.6 
rD1799A 1.4 x 107 64.2 ± 12.7 53.1 ± 15.1 80.2 ± 19.8 2.7 ± 0.4 
rR1800A 4.8 x 107 70.1 ± 7.3 70.7 ± 9.9 48.5 ± 17.8 1.5 ± 1.0 
rY1802A 1.4 x 108 14.6 ± 5.6 15.4 ± 3.0 7.2 ± 0.5 1.8 ± 1.7 
rG1804A 3.4 x 107 nd nd nd nd 
rG1804L 1 x 106 27.9 ± 4.6 30.1 ± 5.8 9.9 ± 0.7 1.2 ± 0.5 
rE1805A 3.2 x 107 34.0 ± 15.8 50.0 ± 2.8 22.8 ± 5.2 5.3 ± 5.7 
rE1805L NR NR NR NR NR 
rG1806A 2.2 x 108 nd nd nd nd 
rG1806L <102 nd nd nd nd 
rG1808A 8 x 107 21.8 ± 8.2 18.1 ± 6.3 31.4 ± 0.1 1.8 ± 1.5 
rG1808L NR NR NR NR NR 
rG1804A/G1806A 8 x 107 114.8 ± 5.9 86.8 ± 12.8 50.9 ± 1.6 12.5 ± 0.3 
rG1804A/G1806A/
G1808A 1.4 x 108 
25.0 ± 5.0 17.2 ± 3.1 36.8 ± 5.0 2.1 ± 0.5 
rY1825A/N1826A/ 
S1827A NR 
 
NR 
 
NR NR NR 
rW1876A 1.6 x 108 20.3 ± 2.8 21.9 ± 6.2 46.8 ± 10.3 1.5 ± 0.3 
rT1875A/W1876A NR NR NR NR NR 
rD1901A 1.4 x 107 37.4 ± 5.7 27.3 ± 4.9 2.1 ± 0.5 0.2 ± 0.3 
rE1903A 4 x 105 26.1 ± 4.4 27.3 ± 3.5 7.3 ± 2.4 0.2 ± 0.5 
rK1938S 1.2 x 106 91.0 ± 12.7 60.1 ± 3.1 8.1 ± 0.9 2.2 ± 0.6 
rK1938A/I1939L 1.2 x 10
6
 46.9 ± 23.2 28.4 ± 16.1 2.4 ± 0.5 1.1 ± 0.4 
rS1969A 4.4 x 107 71.5 ± 10.1 67.0 ± 12.4 73.7 ± 20.9 2.1 ± 0.1 
rE1975A NR NR NR NR NR 
rY1977A 8 x 107 55.5 ± 16.7 48.5 ± 23.2 28.6 ± 5.7 5.1 ± 3.3 
- AdoHcy: in vitro transcription in the absence of S-adenosylhomocysteine (AdoHcy) 
+ AdoHcy: in vitro transcription in the presence of 100 µM AdoHcy 
† methylation of viral mRNA (NP + P) produced in vitro is expressed as the ratio (% of rWT) of [H3]-
AdoMet incorporation into viral mRNA by scintillation counting to the mRNA levels determined analyzed 
by Northern blot (mRNA levels are shown in the “Txn” columns ) . 
NR = not rescued (unable to rescue after multiple attempts)  
nd = not determined  
CIU = cell infectious units 
The data represent the mean ± standard deviation of two independent experiments. 
 
CHAPTER 3: VESICULAR STOMATITIS VIRUS AS AN ONCOLYTIC AGENT 
AGAINST PANCREATIC DUCTAL ADENOCARCINOMA 
 
3.1 Objective of the Study 
Oncolytic virus (OV) therapy is an anticancer approach that utilizes replication-
competent viruses to specifically kill tumor cells (Russell and Peng 2007; Vähä-Koskela 
et al. 2007; Breitbach et al. 2010). Such selectivity is possible because many tumors are 
characterized by defective innate immune responses or tumor-related abnormalities in 
regulation of mRNA translation or certain cellular signaling pathways, facilitating 
selective replication of viruses in cancer cells. OV can infect, replicate within and kill 
tumor cells and successful virus replication in leads to the release of newly formed 
infectious virus particles that go on to infect neighboring tumor cells.  
VSV is a promising OV and has demonstrated preclinical success against a 
variety of malignancies, including prostate (Ahmed et al. 2004; Chang et al. 2010; 
Moussavi et al. 2010), breast (Fernandez et al. 2002; Obuchi et al. 2003; Shi et al. 2009; 
Ahmed et al. 2010), melanoma (Fernandez et al. 2002; Galivo et al. 2010), colorectal 
(Huang et al. 2003; Shinozaki et al. 2005; Edge et al. 2008), liver (Wu 2008; Altomonte 
et al. 2009; Ausubel et al. 2011), glioblastoma (Ozduman et al. 2008; Wollmann 2010; 
Cary et al. 2011) and other cancers (Barber 2004). However, VSV oncolytic potential has 
never been studied in any pancreatic cancer models. Pancreatic ductal adenocarcinoma 
(PDA) is the most common form of pancreatic cancer and is characterized as being 
locally invasive with aggressive local growth and rapid metastases to surrounding tissues 
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(Stathis and Moore 2010). PDA is considered one of the most lethal abdominal 
malignancies with annual deaths closely matching the annual incidence of the disease 
(Lindsay et al. 2005; Farrow et al. 2008), resulting in a 5-year survival rate of merely 8-
20%. Several cancer therapies proven successful in other tumor types have shown little 
efficacy in treating PDA. Chemotherapy is the primary treatment available; however, 
patients exhibit little improvement or develop chemoresistance (Stathis and Moore 2010). 
Therefore, development of new treatment strategies for patients suffering from PDA is of 
utmost importance.  
OV therapy with several viruses, including adenoviruses (Kuhlmann et al. 2008; 
He et al. 2009; Huch 2009), herpesviruses (Sarinella et al. 2006; Kasuya et al. 2007; 
Nakao et al. 2007; Watanabe et al. 2008; Eisenberg et al. 2010) and reoviruses (Etoh et 
al. 2003; Himeno et al. 2005; Hirano et al. 2009), has recently shown promise in several 
PDA tumor models. However, there are several advantages of using VSV as an 
anticancer therapy. VSV is the prototypic nonsegmented negative-strand RNA (NNS) 
virus (order Mononegavirales, family Rhabdoviridae), and its basic biology and 
interactions with host immune responses have been extensively studied (Lyles 2007). 
This knowledge has led to the development of rationally designed VSV vectors for use in 
vaccines, gene therapy and OV therapy (Barber 2004; von Messling and Cattaneo 2004). 
While VSV is very sensitive to IFN-mediated antiviral responses (and therefore unable to 
productively infect healthy cells), it can specifically infect and kill tumor cells, majority 
of which are believed to be defective in Type I IFN production and responses (Barber 
2004; Lichty et al. 2004). Also, the mechanisms of VSV-mediated killing by apoptosis 
have been established (Gaddy and Lyles 2007). In addition to tumor specificity, VSV has 
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several important advantages as an OV: (i) replication occurs in the cytoplasm of host 
cells with no risk of host cell transformation, (ii) cellular uptake in many mammalian cell 
types occurs rapidly and there is no cell cycle dependency, (iii) the genome is easily 
manipulated with the possibility for strong and adjustable levels of foreign gene 
expression to enhance oncolysis and specificity, and (iv) there is no preexisting immunity 
against VSV in humans (Barber 2004). While VSV is not considered a significant human 
pathogen, it can cause neurotoxicity in mice, nonhuman primates and even humans 
(Quiroz et al. 1988). However, several VSV mutants have been generated which are not 
neurotropic but retain their oncolytic activity (Ahmed 2008; Kelly et al. 2010; Wollmann 
2010). In this study, we focused on two such VSV mutants, VSV-∆M51-GFP and VSV-
p1-GFP (Wollmann 2010). VSV-p1-GFP has the green fluorescent protein (GFP) open 
reading frame (ORF) inserted at position one of the viral genome resulting in slower viral 
replication kinetics reducing VSV-p1-GFP abilities to evade innate immune responses 
(Wollmann 2010). VSV-∆M51-GFP has a deletion at amino acid position 51 of the 
matrix (M) protein, as well as the GFP ORF inserted in position 5 of the viral genome 
(Wollmann 2010). The wt M protein plays a role in inhibiting transport of host mRNAs 
from the nucleus to the cytoplasm and thereby downregulating IFN production. The 
single deletion at the M51 position knocks out this important function of M and allows 
for a more robust IFN response from normal healthy tissue while the M51 deletion 
mutant is still affective against tumor cells. Both attenuated VSV recombinants have 
shown a desirable phenotype characterized by retention of their oncolytic activities but 
lack of neurotoxicity in vivo (Ahmed 2008; Wollmann 2010). 
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 In our study, the oncolytic potential of VSV variants was analyzed in a panel of 
13 clinically relevant human PDA cell lines and compared to conditionally replicative 
adenoviruses (CRAds), SeV, and respiratory syncytial virus (RSV). VSV showed 
superior oncolytic abilities compared to all other viruses tested, and was effective in 
killing the majority of tested PDA cell lines. However, we identified some PDA cell lines 
that showed general resistance to oncolysis by all tested viruses. These results were 
confirmed for several PDA cell lines in vivo in nude mice. We also conducted initial 
analysis of PDA resistance to virus-induced cell death. Our in vitro and in vivo results 
demonstrate that VSV has good potential as an OV against PDA, while further studies are 
needed to better understand the molecular mechanisms of resistance of some PDA cell 
lines to virotherapy. 
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3.2 Materials and Methods 
Cell lines. 
Human PDA cell lines used in this study: CFPAC-1 (ATCC CRL-1918), Hs766T 
(ATCC HTB-134), Capan-2 (ATCC HTB-80), T3M4 (Okabe et al. 1983), AsPC-1 
(ATCC CRL-1682), HPAF-II (ATCC CRL-1997), Suit2 (Iwamura et al. 1987), HPAC 
(ATCC CRL-2119), BxPC-3 (ATCC CRL-1687), MIA PaCa2 (ATCC CRL-1420), 
SU.86.86 (ATCC CRL-1837), Capan-1 (ATCC HTB-79), and Panc-1 (ATCC CRL-
1469) (Table 4). In addition, the immortal human pancreatic duct epithelial cell line 
(HPDE) (Furukawa et al. 1996) was used in this study and maintained in Keratinocyte-
SFM (Gibco). This cell line, which was generated by introduction of the E6 and E7 genes 
of human papillomavirus 16 into normal adult pancreas epithelia, retains a genotype 
similar to pancreatic duct epithelia and is non-tumorigenic in nude mice (Furukawa et al. 
1996). The mouse breast cancer cell line 4T1 (ATCC CRL-2539), the baby hamster 
kidney fibroblasts BHK-21 (ATCC CCL-10), the human cervix adenocarcinoma cell line 
HeLa (ATCC CCL-2), the African green monkey kidney cells Vero (ATCC CCL-81) and 
the human epidermoid cancer cells Hep-2 (ATCC CCL-23) were used to grow viruses 
and/or as controls for viral replication. CFPAC-1, Suit2, HPAC, MIA PaCa2, Capan-1, 
Panc-1, 4T1, and Vero cells were all maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Cellgro). Capan-2, T3M4, AsPC-1, BxPC-3 and SU.86.86 cells were 
maintained in Roswell Park Institute medium-1640 (RPMI, Hyclone). HPAF-II, Hs766T, 
BHK-21, A549 and HeLa cells were maintained in modified Eagle’s medium (MEM, 
Cellgro). All cell lines were supplemented with 9% fetal bovine serum (Gibco). For all 
experiments, PDA cell lines were passaged no more than 10 times. 
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Viruses. 
The following viruses were used in this study: recombinant wild-type (wt) VSV 
(Indiana serotype) (Lawson et al. 1995); VSV-p1-GFP; VSV-∆M51-GFP (p5); CRAd-
dl1520 (“ONYX-015”); CRAd-hTERT (Adv-TERTp-E1A); SeV-GFP; and RSV-GFP. 
VSV-p1-GFP has GFP ORF inserted at position one of the viral genome (Wollmann 
2010). VSV-∆M51-GFP has a deletion at amino acid position 51 of the matrix (M) 
protein, as well as the GFP ORF inserted in position 5 of the viral genome (Wollmann  
2010). Both attenuated VSV recombinants have been shown to retain their oncolytic 
activity while lacking neurotoxicity in vivo (Ahmed 2008; Wollmann 2010). CRAd-
dl1520 is attenuated by deletion of a large part of the coding sequence for the E1b55k 
viral gene product and selectively replicates in and kills cancer cells (Bischoff et al. 1996; 
Crompton and Kirn 2007). CRAd-hTERT is a human telomerase reverse transcriptase 
(hTERT)-promoter-dependent CRAd, which selectively replicates in and kill cells with 
active hTERT (85–90% of tumor cells) (Huang et al. 2003). SeV-GFP (SeV-GFP-Fmut) 
has the GFP ORF at position one of the viral genome and a mutation in the cleavage site 
of the fusion (F) protein allowing for F activation and production of infectious virus 
particles in cells without acetylated trypsin in the medium through a ubiquitous furin-like 
protease  (Wiegand et al. 2007). RSV-GFP has the GFP ORF at position one of the viral 
genome (Hallak et al. 2000) (Fig. 16). All VSV variants were grown in BHK-21 cells, 
SeV-GFP was grown in Vero, CRAds were grown in HeLa, and RSV-GFP was grown in 
Hep-2 cells. For animal experiments, VSV-∆M51-GFP was dialyzed (Slide-A-Lyzer, 
Pierce) in 2 L chilled dialysis buffer [25 mM Tris pH 7.4, 140 mM NaCl, 5 mM KCl, 0.6 
mM Na2HPO4, 0.5 mM MgCl2, 0.9 mM CaCl2, and 5% (w/v) sucrose] for 2 hour (h) at 
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4°C and then 4 h at 4°C in fresh dialysis buffer. CRAd-dl1520 was dialyzed in 10 mM 
Tris pH 8, 135 mM NaCl, 1 mM MgCl2 and 50% (v/v) glycerol three times for 1 h each 
at 4°C. Dialyzed viruses were tested for infectivity on A549 cells. 
Cell viability assay. 
Cells were seeded in 96-well plates so that they reached 80% confluency at 24 h, 
and then virus-infected at a multiplicity of infection (MOI) of 1 or 0.01 CIU (cell 
infectious units) per cell (based on VSV titration on 4T1 cells) or mock infected in 
MegaVir HyQSFM4 serum-free media (SFM, Hyclone). One h post infection (p.i.) virus 
was aspirated and cells were incubated in growth media containing 5% FBS. Cell 
viability was analyzed at 5 days (d) p.i. by an MTT cell viability assay (Biotium). To 
determine the kinetics of virus-associated cytopathogenicity, cells were seeded in 96-well 
plates so that they reached 50% confluency at 24 h. Cells were then mock infected or 
infected with VSV-∆M51-GFP at low (0.001 CIU/cell), intermediate (0.1 CIU/cell), or 
high MOI (1 CIU/cell).  At 1 h p.i., virus was aspirated and cells were overlaid with 
growth media containing 5% FBS.  An MTT cell viability assay was performed at 1, 16, 
24, 48, and 72 h p.i. 
Permissiveness of cells to virus infection. 
Cells were incubated with serial dilutions of VSV-wt, VSV-GFP(p1), VSV-
∆M51-GFP, SeV-GFP, CRAd-dl1520, or CRAd-hTERT in SFM for 1 h. At 1 h p.i., virus 
was aspirated and growth media containing 5% FBS was added to each well. The 
infectious foci of VSV-∆M51-GFP, VSV-GFP(p1) and SeV-GFP were analyzed by 
fluorescent microscopy at 24 and 48 h p.i. respectively. The infectious foci of CRAd-
dl1520 and CRAd-hTERT were analyzed by immunocytochemistry (ICC) at 5 d p.i. 
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Briefly, cells were washed with phosphate buffered saline (PBS) and fixed in 3% 
paraformaldehyde (PFA, Sigma) for 10 min followed by permeabilization for 2 min on 
ice with a solution containing 20 mM HEPES (pH 7.5), 300 mM sucrose, 50 mM NaCl, 3 
mM MgCl2, and 0.5% Triton X-100. Cells were then blocked with 5% bovine serum 
albumin (BSA, Sigma) in PBS for 20 min and incubated with anti-adenovirus hexon 
primary antibodies (1:600, US Biologicals, Cat # A0880-14) for 1.5 h. Cells were 
washed, incubated with peroxidase conjugated goat anti-mouse IgG antibodies (1:300, 
Jackson ImmunoResearch) for 1.5 h, and detected by addition of the peroxidase substrate 
3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB, Amresco). The infectious foci 
of VSV-wt were also analyzed by ICC as described above but using 1:100 rabbit 
polyclonal anti-VSV antibodies (raised against VSV virions) and anti-rabbit secondary 
antibodies. Cells were infected with serial dilutions of VSV-wt in triplicate and infectious 
foci were analyzed by ICC at 48 h p.i.  
One-step virus growth kinetics. 
Selected PDA cells were seeded in 96-well plates to reach confluency at 24 h. 
They were infected in duplicate with VSV-wt, VSV-∆M51-GFP, or VSV-p1-GFP at 
MOI 10 CIU/cell based on the reference cell line 4T1. At 1 h p.i. virus was aspirated, 
cells were washed twice with PBS (to prevent carryover of virions) and overlaid with 
growth media containing 5% FBS. At 1, 24, 50 and 72 h p.i. supernatant was collected 
from wells and flash frozen at -80°C. Virus titers were later determined by plaque assay 
analysis. Briefly, BHK-21 cells were incubated with serial dilutions of the samples for 1 
h. Virus was aspirated and cells were overlaid with a SFM / 2% BactoAgar mixture to 
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limit virus spread. Infectious foci were counted by light and fluorescence microscopy at 
16 h p.i. 
Type I interferon sensitivity and production. 
Cells were seeded in 96-well plates so that they reached 80% confluency at 24 h. 
For Type I interferon sensitivity, cells were either treated with 5000 U/ml interferon 
alpha (IFN-α, Calbiochem, Cat # 407294) in SFM or with SFM only. Twenty-four h post 
treatment, cells were infected with serial dilutions of VSV-∆M51-GFP, and infectious 
foci were analyzed 16 h p.i. by fluorescent microscopy. Treatments and infections were 
performed in duplicate. For Type I interferon production, cells were infected with VSV-
∆M51-GFP at MOI 10 CIU/cell or mock-treated with SFM only. One h p.i. virus was 
aspirated and cells were incubated in SFM. Eighteen h p.i. supernatant was harvested and 
analyzed by ELISA for production of human IFN-β (PBL, Cat # 41410-1) or human IFN-
α (multi-subtype, PBL, Cat # 41105-1) per manufacturer’s instructions (PBL 
InterferonSource). Infections were performed in triplicate. 
Western blot. 
Cellular lysates were prepared by mock infecting cells or infecting them with 
VSV-∆M51-GFP at MOI 1 or 10 CIU/cell.  One h p.i. virus was aspirated, cells were 
extensively washed and incubated in growth media containing 5% FBS. Cells were 
harvested at 16 h p.i. and lysed in lysis buffer containing 1% Triton-X-100, 20mM 
Hepes, 0.15 M NaCl, 2 mM EDTA and supplemented with c-inhibitor (2X, Roche).  
Total protein concentration was determined by Bradford assay.  Three µg (for VSV 
detection) or 30 µg (for GFP detection) of total protein was separated by electrophoresis 
on 10% or 12% SDS-PAGE gels respectively, and electroblotted to polyvinylidene 
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difluoride (PVDF) membranes. Membranes were blocked using 5% non-fat powdered 
milk in TBS-T [0.5 M NaCl, 20 mM Tris (pH 7.5), 0.1%Tween20], which was also used 
for antibody dilutions. Membranes were incubated with 1:10000 rabbit polyclonal anti-
VSV antibodies (raised against VSV virions) or 1:3000 mouse anti-GFP clone 9F9.F9 
(Rockland).  Detection was with 1:5000 goat anti-rabbit or 1:5000 goat anti-mouse 
horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) 
using the Enhanced Chemiluminescence Plus (ECL+) protein detection system (GE 
Healthcare). Membranes were reprobed with mouse anti-actin clone C4 (Moyer et al. 
1986) to verify sample loading.  Image capture and densitometry analysis were 
performed using VisionWorksLS v6.8 software (UVP).   
Northern blot. 
The pVSVFL(+)g.1 plasmid, which encodes a complete cDNA copy of the VSV 
(Indiana strain) antigenome (Lawson et al. 1995), was used as a template for addition of a 
SP6-promotor to the 3’ end of a 279 bp fragment of N by PCR using the following 
primers: 5’-ATCCAGTGGAATACCCGGCAGATT-3’ and 5’-
ATTTAGGTGACACTATAGAAGTGCTCGTCAGATTCAAGCTCAGGCTG-3’. A 
probe for detection of N mRNA and VSV anti-genomic RNA was synthesized from the 
PCR product by in vitro transcription in the presence of 
32
P-UTP using the MAXIscript 
T7 kit (Ambion). Cells were mock treated or treated with 100 µg/ml cycloheximide for 
30 min prior to mock infection or infection with VSV-∆M51-GFP at MOI 10 and 
continuing treatment with cycloheximide. At 4 h p.i. cells were collected and total RNA 
extracted using the Quick-RNA MiniPrep kit (Zymo Research). For each sample, 1µg of 
RNA was separated on a 1.2% agarose-formaldehyde gel containing ethidium bromide 
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for confirmation of RNA loading by visualization of rRNA. The RNA was transferred to 
a nylon membrane and incubated with probe overnight at 58°C. Bands were detected 
using a phosphoimager and quantitated using Image Quant 5.2 (Molecular Dynamics). 
Surface expression of adenovirus CAR receptor. 
Single cell suspensions were obtained by detaching cells using cell scrapers 
without trypsin to rule out potential proteolytic effect of trypsin on surface proteins. Cells 
then were incubated with Fc block at a concentration of 0.5ug/mL at room temperature 
for 30 min. Cells were stained for cellular receptor for adenovirus and coxsackievirus 
(CAR) using anti-CAR antibody (clone RmCB, Millipore) for 30 min (or mock-treated), 
washed, and subsequently stained with secondary antibody, goat anti-mouse IgG-FITC 
(Santa Cruz, 0.5 ug/ml) for 30 min. Expression of CAR was determined by flow 
cytometry (Beckman Coulter). Analysis was conducted using FlowJo (Treestar, Ashland, 
OR).  
Animal experiments. 
Mice were handled and maintained under veterinary supervision in accordance 
with institutional guidelines and under a University of North Carolina at Charlotte 
Animal Care and Use Committee (IACUC) approved protocol.  6-8 week old, male, 
athymic nude mice (Hsd:Athymic Nude-Foxn1
nu
,  Harlan Laboratories, Inc., Fredrick 
MD) were subcutaneously injected with one of 4 human PDA cell lines. All cell lines 
used in animal experiments were tested negative for an extended panel of pathogens 
(MIA PaCa2, SU.86.86, and Panc-1 were tested by Charles River Laboratories and 
HPAF-II was tested by Bioreliance). Based on preceding titration experiments (data not 
shown), mice were injected with: 5x10
6 
 Mia PaCa2, 5x10
6 
Panc-1,  3x10
6 
HPAF-II, and 
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 3x10
6  
SU.86.86 cells  (in
 
 100 µl of PBS) into the right flank (n=18 per group). Two 
additional untreated age-matched mice were used in this experiment to compare body 
weights with the treated experimental mice. Mice were palpated starting at 9 d post tumor 
injection. Tumors were established by day 13 and mice were randomly divided into 3 
groups (n=6 per group). One group served as a control and received one intratumoral (IT) 
administration of 50 μl PBS only. The other two groups were administered once with 
VSV-∆M51-GFP or CRAd-dl1520 IT with a dose of 5x10
7
 CIU in 50 μl PBS. Dose was 
determined based on CIU established on A549 cells for both viruses. Tumor size was 
monitored by caliper measurements every other day, and body weight was measured once 
weekly. Tumor weight was calculated according to the formula: grams = [(length in cm) 
x (width in cm)
2
]/2. Upon sacrifice, tumor and brain tissue were harvested and tested for 
the presence of VSV-∆M51-GFP. Data were analyzed using GraphPad software and are 
expressed as mean ± standard deviation. 
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3.3 Results 
Susceptibility of PDA cell lines to viral oncolysis. 
The susceptibility of human PDA cells to virus-mediated oncolysis was tested in a 
panel of 13 clinically relevant PDA cell lines derived from primary PDA tumors or PDA 
metastases to the liver and lymph nodes. In addition to PDA cell lines, the immortal 
human pancreatic duct epithelial cell line (HPDE), which retains a genotype similar to 
pancreatic duct epithelia and is non-tumorigenic in nude mice (Furukawa et al. 1996), 
was employed as a “benign” control cell line to determine virus specificity towards PDA 
cells. In addition to VSV-wt, we tested two additional VSV variants: VSV-∆M51-GFP 
and VSV-p1-GFP (Fig. 16), with a particular focus on VSV-∆M51-GFP (Wollmann 
2010). Several previous studies showed that VSV mutants with the deletion of 
methionine at position 51 (∆M51) of the matrix (M) protein exhibited good oncolytic 
potential but lack undesirable neurotoxicity (Stojdl 2003; Ebert et al. 2005; Goel et al. 
2007; Ahmed 2008; Wu 2008; Wollmann 2010). A similar phenotype was recently 
demonstrated for VSV-p1-GFP (Wollmann 2010). To evaluate the relative efficacy of 
VSV as an OV, we compared VSV variants to four other viruses: SeV-GFP, RSV-GFP, 
CRAd-dl1520, and CRAd-hTERT (Fig. 16). SeV-GFP and RSV-GFP are also NNS RNA 
viruses shown to have oncolytic potential (Kinoh 2004; Kinoh 2008; Yonemitsu 2008; 
Echchgadda et al. 2009; Komaru 2009; Echchgadda et al. 2011), while CRAds have 
shown some success in several PDA cell lines in vitro and in vivo (Kuhlmann et al. 2008; 
He et al. 2009; Huch 2009), although they have not been tested in most of the PDA cell 
lines used in this study. The inclusion of additional viruses would also help to 
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discriminate between a virus-specific and general resistance phenotype if any PDA cell 
lines were identified as non-permissive to VSV. 
To analyze the ability of viruses to kill cancer cells, PDA cell lines were infected 
at either a low MOI (0.01 CIU/cell) or a higher MOI (1.0 CIU/cell) and at 5 d p.i. an 
MTT cell viability assay was performed. The MOI values for each virus/cell line 
combination are relative and calculated based on titration of all VSV variants and SeV on 
4T1 cells, and RSV and CRAds on HeLa cells.  These two reference cell lines (4T1 and 
HeLa) were selected based on their abilities to support robust replication of viruses used 
in this study. Therefore, for each MOI, the same amount of virus stock was added to each 
cell line. VSV-wt, VSV-∆M51-GFP, and VSV-p1-GFP all caused significant death in the 
majority of cell lines at both high (Fig. 17A) and low (Fig. 17B) MOI compared to mock 
infected cells. In general, at the higher MOI, VSVs and CRAds caused more significant 
cell death than to SeV-GFP and RSV-GFP (Fig. 17A). At the lower MOI VSVs caused 
more significant cell death compared to all other viruses including CRAds (Fig. 17B).  
Several PDA cell lines showed varying degrees of resistance to oncolysis by 
VSVs, with HPAF-II, Hs766T and BxPC-3 displaying the strongest resistance. 
Interestingly, we observed a substantial difference in susceptibilities of HPAF-II, Hs766T 
and “benign” HPDE to oncolysis with different VSV variants. These cell lines were 
effectively killed by VSV-wt (both MOIs) and VSV-p1-GFP (HPAF-II at high MOI 
only) at 5 d p.i. but were resistant to VSV-∆M51-GFP, even at MOI 1. Importantly, all 
these three PDA cell lines were also among the most resistant to other tested viruses 
suggesting that general antiviral mechanisms may contribute to their phenotype 
(addressed later). 
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To analyze the kinetics of PDA cell death following VSV-∆M51-GFP (Fig. 18) or 
VSV-wt (data not shown) infection, cells were infected at MOI 0.001, 0.1 or 1 CIU/cell 
(Fig. 18) and cell viability was analyzed at different time points. The majority of cell 
lines had significantly decreased viability after infection with VSV-∆M51-GFP at any 
tested MOI. Consistent with the data presented in Figure 17, HPAF-II, Hs766T and 
BxPC-3 were most resistant to VSV-mediated cell death in the presence of any amount of 
VSV-∆M51-GFP. CFPAC-1, HPAC and “benign” HPDE cells were resistant to VSV-
∆M51-GFP only when infected with the lowest MOI (0.001).  
Permissiveness of PDA cell lines to viral infection. 
The failure of OVs to kill cancer cells can be explained by their inability to infect 
and/or replicate in these cells, although cellular defects in apoptosis may also be 
responsible for the defect in virus-mediated oncolysis. To determine whether variations in 
viral oncolysis observed between different PDA cell lines were due to different 
permissiveness of these cell lines to virus infection, monolayer cultures of PDA cells 
were infected with serial virus dilutions. To test whether the differences between cell line 
permissiveness to virus infection were specific for VSVs or general (e.g. if they have 
intact antiviral responses), we examined all viruses (Fig. 16) except for RSV. The 
infectious foci of VSV-∆M51-GFP, VSV-p1-GFP and SeV-GFP were analyzed by 
fluorescent microscopy at 24 (VSV) or 48 (SeV) h p.i., respectively. The number and size 
of viral plaques produced by VSV-wt, CRAd-dl1520 and CRAd-hTERT were analyzed 
by ICC as described in Materials and Methods. Virus permissiveness in Figure 19 is 
expressed as the ratio of virus titer on the pancreatic cell line under study to the titer on a 
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reference cell line (4T1 or HeLa) such that higher numbers indicate greater 
permissiveness.  
The degree of curvature in Figure 19 indicates that that the adenoviruses have less 
variability among PDA cells than VSV and SeV. Interestingly, while BxPC-3 and 
Hs766T were resistant to all tested viruses, HPAF-II showed an intermediate 
permissiveness to infection by both adenoviruses (Fig. 19; Fig. 20 for CRAd-dl1520), 
although this PDA cell line was resistant to virus-mediated oncolysis by either CRAd 
(Fig. 17). As shown in Figure 19, the majority of cell lines were highly permissive to 
VSV-∆M51-GFP infection with a relative ratio greater than or close to 1 (log10=0) 
(AsPC-1, SU.86.86, Capan-1,  Panc-1, MIA PaCa2, Suit2 and Capan-2). In these cell 
lines, we observed rapid spread of VSV-∆M51-GFP forming large infectious foci (filled 
circle symbol in Fig. 19; large GFP foci in Fig. 20). Cell lines less permissive to VSV-
∆M51-GFP infection include “benign” HPDE cells (6.6 times less with very small foci) 
as well as T3M4 (2.2 times less than 4T1), CFPAC-1 (3.8 times less), and HPAC (10 
times less), all of which also formed smaller infectious foci at 16 h p.i. BxPC-3, HPAF-II 
and Hs766T appeared highly resistant to VSV-∆M51-GFP infection, with relative 
susceptibilities much less than 4T1 (62,971 and 25,385 times less, respectively) and 
infectious foci being much smaller in size than all other cell lines tested (Fig. 20). VSV-
∆M51-GFP was also analyzed at 5 d p.i., when the majority of cell lines highly 
permissive to VSV-∆M51-GFP infection were no longer viable and detached from the 
culture plastic. However, HPAF-II, BxPC-3 and Hs766T cells remained attached to the 
plastic with decreased GFP intensity; again indicating VSV-∆M51-GFP infection is 
restricted in these cell lines (data not shown).  
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SU.86.86 showed a very intriguing phenotype by being highly permissive to 
VSVs and SeV, but resistant to both CRAd-dl1520 and CRAd-hTERT. To test whether 
this cell line may lack Coxsackievirus and adenovirus receptor (CAR) required for 
adenovirus attachment (which would explain this phenotype) (Kuhlmann et al. 2008; He 
et al. 2009; Huch 2009), we analyzed all PDA cell lines for CAR expression by flow 
cytometry and found that SU.86.86 was the only cell line completely lacking CAR (Fig. 
21), while all other cell lines (including HPAF-II, Hs766T and BXPC-3 displaying 
general resistance phenotype) had varying but detectable levels of CAR (data not shown), 
which is in agreement with our data (Figures 19 and 20) that these cell lines (unlike 
SU.86.86) have reasonably good susceptibility to both adenoviruses, also indicating that 
they are not defective in CAR expression. Although other factors may also contribute to 
the resistance of SU86.86 to CRAds, the lack of CAR expression alone might be a 
sufficient factor responsible for this phenotype. 
To examine if reduced permissiveness to VSV-∆M51-GFP also resulted in a 
decrease in new viral protein synthesis, lysates were prepared from uninfected cells and 
from cells infected with VSV-∆M51-GFP at MOI 1 and 10 CIU/cell and harvested at 16 
h p.i.  Equal amounts of total protein were then examined by Western blot for both VSV 
proteins and GFP expression. Expression levels of viral proteins within the different cell 
lines were in agreement with GFP protein expression (Fig. 22). Protein expression (see 
GFP level measurements in Fig. 22) was also generally consistent with cell line 
permissiveness and oncolysis, especially when protein accumulation is compared after 
lower MOI infection. Viral protein expression was strongly reduced in BxPC-3, HPAF-II, 
Hs766T and “benign” HPDE cells which are the most “non-permissive” and all 
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demonstrated small foci sizes when infected with VSV-∆M51-GFP (Fig. 19). Viral 
protein expression was also reduced in CFPAC-1 and HPAC cells which had reduced 
permissiveness and medium foci sizes.  
To directly examine growth potential of VSVs in resistant cell lines, we tested all 
3 VSVs in the majority of PDA cell lines (and in “benign” HPDE cells) using a standard 
one-step growth kinetics assay (Fig. 23). In general, our data show that while all tested 
cell lines were able to support productive replication of VSVs, the lowest production was 
observed in “benign” HPDE cells and in most PDA cell lines displaying resistant 
phenotype. Also, most cells showed very similar growth kinetics for all 3 viruses, while 
HPAF-II supported significantly lower level of VSV-∆M51-GFP production compared to 
other VSVs. This result may explain at least partially why HPAF-II cells were 
particularly resistant to VSV-∆M51-GFP (Fig. 17A) BxPC-3 cells showed surprisingly 
high level of new particle production when infected at MOI 10. However, it is important 
to note that MOI 10 used for one-step growth kinetics is never attainable during oncolytic 
treatment in vivo. The experiments on virus-mediated cell death shown in Figures 73 and 
18 were conducted at more realistic MOIs 0.001 to 1 (maximum).  
Timing and cellular factors of resistance of PDA cell lines to VSV-∆M51-GFP 
To analyze why PDA cells differ in their permissiveness to VSV-∆M51-GFP, we 
looked at the early stages of virus infection and at cellular characteristics that could 
explain the observed differences. Antigenome and VSV N mRNA synthesis was 
determined by Northern blot of total RNA isolated at 4 h p.i. from cells untreated or 
treated with cycloheximide and infected with VSV-∆M51-GFP at MOI 10 (Fig. 24 and 
Table 5).  Cycloheximide blocks new protein synthesis and thereby viral genome 
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synthesis and secondary transcription. Expression of both VSV N mRNA and anti-
genomic RNA were strongly reduced in BxPC-3, HPAC, HPAF-II, Hs766T and 
somewhat reduced in CFPAC-1 cells, consistent with the reduced viral protein synthesis 
and permissiveness to VSV-∆M51-GFP infection seen in these cells lines. Interestingly, 
RNA synthesis in “benign” HPDE cells was quite robust despite low protein synthesis 16 
h p.i. (Fig. 22) and reduced permissiveness in this cell line, suggesting a block at a later 
stage of viral infection. In all cases where secondary transcription was reduced, primary 
transcription was reduced proportionately (Table 5). This suggests that in cell lines with 
lower mRNA synthesis, viral genome release into the cytoplasm was inhibited, and that 
for genomes that were released, early infection proceeded normally.   
VSV is sensitive to Type I IFN responses. However, many different tumor types 
are known to lack these responses, allowing VSV to productively infect cancer cells 
while sparing healthy cells (Lichty et al. 2004; Barber 2005). Here, we wanted to test the 
hypothesis that the resistance of some PDA cell lines to VSV (and other viruses) was a 
result of their intact IFN responses. To determine if PDA cell lines were sensitive to Type 
I IFN, all cells were mock treated or treated with 5000 U/ml IFN-α for 24 h prior to 
infection with serial dilutions of VSV-∆M51-GFP. A titer ratio for mock treated to IFN-α 
treated cells was determined for each PDA cell line (Fig. 25). We observed that certain 
cell lines did not significantly suppress VSV-∆M51-GFP infection in response to IFN-α. 
VSV-∆M51-GFP titers were no more than 26-fold reduced following IFN treatment in 
Panc-1, SU.86.86, MIA PaCa2, and HPAC cells, while Capan-2, Hs766T, T3M4 and 
“benign” HPDE cells showed an intermediate sensitivity to IFN-α. HPAC displayed an 
interesting phenotype with comparable titers with or without IFN treatment; however, 
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IFN treated HPAC cells required an additional day for visible foci to appear.  
Surprisingly, several PDA cancer cell lines were highly responsive to IFN-α (Capan-1, 
AsPC-1, HPAF-II, BxPC-3, Suit2 and CFPAC-1). Among these IFN-sensitive cells are 
AsPC-1, Capan-1 and Suit2, which support robust infection of VSV-∆M51-GFP in the 
absence of IFN-α pre-treatment.  
To further study the role of IFN in the resistance of PDA cells to VSV, we 
examined the abilities of PDA cell lines to produce IFN alpha and/or beta in response to 
VSV-∆M51-GFP infection (MOI of 10 CIU per cell) at 18 h p. i. As expected, significant 
amounts of IFN-beta were produced by “benign” HPDE cells, which are expected to 
retain normal antiviral responses (Fig. 26). Importantly, all three cell lines (HPAF-II, 
HPAC and Hs766T) producing significant amount of IFN-beta at 18 h p.i. were among 
the most resistant cell lines (Fig. 26). As illustrated in Table 6, except for BxPC-3, all 
PDA cell lines highly resistant to VSV show an HPDE-like phenotype characterized by 
both the production of IFN-beta and sensitivity to IFN treatment. In addition, our data 
experimentally explain the phenotypes AsPC-1, Suit2, and Capan-1 which are sensitive 
to IFN but support robust virus infection without added IFN, as they all are defective in 
IFN production. Interestingly, we were unable to detect any significant production of 
IFN-alpha in response to virus infection by any tested cell line at 18 h p.i. (data not 
shown), however it is produced later than IFN-beta. Future experiments will analyze 
PDA cells for production of various IFNs at different time points after infection. 
Together, our data show surprising diversity among PDA cells in regards to their 
ability to produce and respond to Type I IFN. Moreover, we demonstrate that a 
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combination of IFN sensitivity and IFN-beta production may be used to predict 
responsiveness of most PDA cells to oncolytic treatment. 
Efficacy of VSV-∆M51-GFP and CRAd-dl1520 in nude mice bearing human PDA 
tumors. 
To test the efficacy of VSV-∆M51-GFP in vivo and to determine the relevance of 
our in vitro results to an in vivo situation, we chose four cell lines for in vivo testing 
based on our in vitro virus permissiveness and oncolysis experiments. MIA PaCa2 and 
Panc-1 are highly permissive to both VSV-∆M51-GFP and CRAd-dl1520, SU.86.86 is 
highly permissive to VSV-∆M51-GFP but not CRAd-dl1520, and HPAF-II has limited 
permissiveness to both VSV-∆M51-GFP and CRAd-dl1520 (Fig. 17-20). These human 
pancreatic cancer cell lines were injected subcutaneously into the right flank of male 
nude mice (n=18 per cell line). Once the mice developed palpable tumors (5-7 mm) they 
were divided equally into three groups (n=6). A control group received an IT injection of 
PBS, one group received an IT injection of 5x10
7
 CIU VSV-∆M51-GFP, and one group 
received an IT injection of 5x10
7
 CIU CRAd-dl1520. The mice were monitored daily for 
signs of distress and tumor size was measured every other day for 14 days. VSV-∆M51-
GFP and CRAd-dl1520 had the greatest therapeutic effect in mice bearing Panc-1 and 
MIA PaCa2 tumors (Fig. 27). VSV-∆M51-GFP seemed to stabilize SU.86.86 tumor 
growth compared to treatment of SU.86.86 tumors with CRAd-dl1520 and PBS, which 
had no effect on tumor growth (Fig. 27). SU.86.86 grew more rapidly than all other cell 
lines in vivo and several tumors became ulcerated over the course of the experiment (Fig. 
27). While mice bearing SU.86.86 tumors showed no signs of distress at any point during 
the experiment, several were euthanized at an earlier time point due to large tumor size 
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(day 21 instead of day 25). Tumor growth continued in the presence or absence of VSV-
∆M51-GFP and CRAd-dl1520 for mice bearing HPAF-II tumors (Fig. 27). In general, 
our in vivo experiments closely mimicked our in vitro results. Fourteen days post 
injection with VSV-∆M51-GFP, CRAd-dl1520 or PBS, all mice were euthanized and 
tumors were harvested and wet weight and presence of virus was determined.  
It has been demonstrated that VSV-wt can cause encephalitis in mice; however, 
VSV-∆M51-GFP is a non-neurotropic OV (Wollmann 2010). In agreement with this, 
animals infected with VSV-∆M51-GFP showed no signs of encephalitis or distress over 
the course of the experiment. Nevertheless, brain tissues of VSV-∆M51-GFP-infected 
animals were analyzed for the presence of virus by standard plaque assay on BHK-21 
cells with no  VSV-∆M51-GFP being detected.  Interestingly, despite the robust oncolytic 
effect achieved for animals bearing Panc-1 and MIA PaCa2 following IT infection with 
VSV-∆M51-GFP, when a similar analysis was conducted on tumor samples, only two 
samples (one SU.86.86 and one MIA PaCa2 sample) had detectable VSV-∆M51-GFP 
present at 14 d p.i. (data not shown).  
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3.4 Conclusions 
In this study, we have evaluated for the first time VSV as an OV against 
pancreatic cancer cells. VSV variants showed superior oncolytic abilities compared to 
other viruses and were effective against the majority of the 13 tested human PDA cell 
lines. We also identified several cell lines highly resistant to oncolytic virotherapy by 
VSV and/or other tested viruses. 
Among VSV variants, we focused primarily on VSV-∆M51-GFP because several 
previous studies showed that VSV variants with ∆M51 mutation were effective OVs with 
no neurotoxicity in animals (Stojdl 2003; Ebert et al. 2005; Goel et al. 2007; Ahmed 
2008; Wu 2008; Wollmann 2010). To evaluate the relative efficacy of VSV as an OV, we 
initially compared VSV variants to four other viruses. We chose CRAd-dl1520 (also 
known as “ONYX-15”) as a relevant control for further in vitro and in vivo experiments, 
as this DNA virus is unrelated to VSV, has been tested in several clinical trials, and has 
shown some success in previous PDA studies (Kasuya et al. 2005; Crompton and Kirn 
2007). It is important to point out that although our in vitro data suggest a possible use of 
CRAds for PDA treatment, any viable strategy for treatment of patients using CRAds 
remains to be determined due to some of their reported limitations, including their 
dependence of CAR expression in target cells, their quick elimination from the 
bloodstream by the liver, inactivation by binding to blood cells and other components of 
the immune system, as well as their limited spread throughout the tumor (Kuhlman et al. 
2008; He et al. 2009; Huch 2009). 
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Our in vitro experiments indicated a great variability in permissiveness of PDA 
cell lines to all viruses. Overall, VSV variants were the most effective, but even for 
VSVs, some cell lines, including HPAF-II, Hs766T and CFPAC-1, were less effectively 
killed by VSV-∆M51-GFP than by VSV-wt and VSV-p1-GFP. There are two major 
hypotheses explaining varying susceptibility of PDA cell lines to oncolysis by a 
particular virus in vitro. First, PDA cells may differ in their susceptibility to virus 
infection and/or their ability to support virus replication. This may happen because PDA 
cells may lack key lack key cellular factors (e.g., receptors) required for successful virus 
infection or because resistant cells have intact antiviral responses preventing successful 
virus spread. Alternatively, some PDA cells may have defective apoptotic pathways, so 
that even if a virus can successfully infect and replicate in these cells, they are not 
efficiently killed by apoptosis.  
The oncolytic potential of viruses is generally contingent on their ability to infect 
and replicate in these cells. In our study, PDA cell permissiveness to all viruses closely 
mirrored our cell death analysis, with several cell lines (HPAF-II, Hs766T and BxPC-3) 
showing varying degrees of resistance to all tested viruses. The six least permissive cell 
lines were all defective in cell killing for at least some of the MOIs tested.  Five of these 
cell lines, BxPC-3, HPAF-II, HPAC, Hs766T and CFPAC showed low levels of early (4 
h p.i.) viral RNA synthesis (including primary transcription of viral genome) when 
infected with VSV-ΔM51-GFP compared to the more permissive cell lines, indicating a 
possible defect at very early stage in infection, such as attachment, entry or endosomal 
escape.  Experiments are underway in these PDA cell lines to further define the affected 
steps in viral infection and the responsible cellular mechanisms. In contrast to VSV-
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resistant PDA cell lines, in “benign” HPDE cells (also resistant to VSV), early viral 
mRNA and genome synthesis equaled that found in many permissive cell lines, but viral 
protein synthesis at 16 h p.i and virion production were sharply reduced, suggesting a 
defect at later stages of viral infection. This phenotype is expected for “benign” cells with 
intact innate antiviral responses.  
To address differences in permissiveness to VSV in PDA cell lines, we also 
looked at their abilities to produce and respond to Type I IFN. In general, many tumor 
cells are defective in producing Type I IFNs but may remain sensitive to Type I IFN, 
which could be produced by infected benign cells that surround the tumor. Still other 
tumor cells may retain the ability to produce their own IFN (Stojdl et al. 2000; Naik and 
Russell 2009). Responsiveness of cancer cells to IFN could be an important factor in 
predicting their behavior in vivo, where VSV infection would induce IFN production in 
surrounding healthy tissues, thus limiting oncolytic potential towards cancer cells 
sensitive to IFN.  Our data showed surprising diversity among PDA cells in regard to 
their ability to produce and respond to Type I IFN (Table 6). With the exception of 
BxPC-3, all other VSV-resistant PDA cell lines were characterized by both the 
production of IFN-beta and sensitivity to IFN treatment. The same phenotype was shown 
by “benign” HPDE cells, which are expected to retain normal antiviral responses. The 
VSV-resistant phenotype of BxPC-3 in vitro (sensitive to IFN but does not produce IFN-
beta) could be due to an IFN-independent block of virus infection. Interestingly, we 
identified some PDA cell lines (AsPC-1, Suit2, and Capan-1) that are responsive to IFN, 
but highly susceptible to infection in vitro (without added IFN) as they all are defective in 
IFN production. High heterogeneity in response to type I IFN has been reported in 
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several other cancer types, including mesothelioma (Saloura et al. 2010), melanomas 
(Linge et al. 1995; Wong et al. 1997), lymphomas (Sun et al. 1998), bladder cancers 
(Matin et al. 2001), renal cancers (Pfeffer et al. 1996), and likely in other types (Stojdl 
2003). Our data suggest that a combination of IFN sensitivity and IFN-beta production 
may be used to predict responsiveness of most PDA cells to oncolytic treatment.  
Together, our data suggest that VSV-resistant cell lines have more than one 
“defect” responsible for their virus resistant phenotype. If their resistance was solely 
dependent on their intact IFN pathway, we would expect them to have phenotype similar 
to “benign” HPDE cells. HPDE cells do not have any defects in early steps of VSV 
infection (demonstrated by “normal” RNA synthesis including primary transcription of 
viral genome at 4 h p.i.), but robust Type I IFN responses inhibit consequent virus 
replication resulting in very low protein accumulation at 16 h p.i. However, unlike HPDE 
cells, all PDA cell lines highly resistant to VSV also showed defective early viral RNA 
synthesis suggesting that they have some defects inhibiting early steps of VSV infection 
(e.g. attachment or entry).  
Most of our data show a correlation between permissibility of PDA cells to VSV 
infection and its oncolytic potential. However, if cells are successfully infected at high 
MOI (one-step infection), they are able to successfully produce new viral particles. 
BxPC-3 showed surprisingly high production of new particle when infected at MOI 10. 
Interestingly, it is also the only one of the most resistant cell lines that did not produce 
significant amounts of IFN-beta (Fig. 26 and Table 6). At the same time, BxPC-3 were 
characterized by deficient RNA synthesis at 4 h p.i. suggesting that BxPC-3 have some 
defects in virus attachment/internalization or other early step in VSV infection. It also 
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showed a low levels of viral (and GFP) protein synthesis when BxPC-3 were infected at 
lower MOI of 1 (compare Figure 18 for AsPC1 and BxPC-3 at MOI 1 and 10). It is 
important to note that MOI 10 infection used in Figure 23 for one-step growth kinetics is 
never attainable during oncolytic treatment in vivo. The experiments on virus-mediated 
cell death shown in Figures 17 and 18 were conducted at more realistic MOIs between 
0.001 and 1.  
Previous studies have shown that many cancer cells are able to inhibit apoptosis 
to allow for prolonged proliferation (Hamacher et al. 2008). As VSV has been shown to 
cause cell death by apoptosis via either the intrinsic or extrinsic pathway or both (Gaddy 
and Lyles 2005; Gaddy and Lyles 2007; Sharif-Askari et al. 2007; Cary et al. 2011), cell 
lines with decreased expression or activation of certain apoptotic proteins have the 
potential of limiting/delaying cell death following VSV infection. Furthermore, 
differences in permissiveness to the VSV variants could be due to differences in their 
mechanisms of cell death induction. It has been demonstrated that VSV-wt induces 
apoptosis via the mitochondrial pathway due to wt M protein inhibiting gene expression, 
while VSV-∆M51-GFP, with a mutant M protein, induces apoptosis primarily via the 
death receptor pathway (Gaddy and Lyles 2005). While we cannot fully address these 
possibilities at this point, our preliminary experiments show significant increases in 
caspase-3 cleavage following VSV-∆M51-GFP infection in all cell lines except Hs766T 
and HPAC at 17 h p.i. (data not shown). More studies are needed to determine whether 
reduced level of apoptotic response or the delayed induction of apoptosis in some of these 
cell lines plays a role in restricting VSV oncolysis. These defects could also (in addition 
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to intact IFN pathways) explain why cell lines resistant to VSV are also resistant to other, 
unrelated, viruses. 
Based on our in vitro studies we chose 4 cell lines with varying permissiveness to 
VSV-∆M51-GFP and CRAd-dl1520 to determine if our in vitro studies are relevant in 
vivo. We observed in vitro that MIA PaCa2 and Panc-1 are highly permissive to both 
VSV-∆M51-GFP and CRAd-dl1520, SU.86.86 is highly permissive to VSV-∆M51-GFP 
but not CRAd-dl1520, and HPAF-II has limited permissiveness to both. The induced 
tumors in nude mice showed the same permissiveness pattern as observed in vitro 
indicating in vitro testing can be used to identify cancers resistant to a particular virus. It 
is important to emphasize that the ability of a virus to kill cancer cells in vitro or even in 
vivo (in nude mice) would not guarantee its efficacy in cancer patients due to complex 
tumor microenvironments and compromised immune responses (Breitbach et al. 2010). 
However, our data clearly show that if cells are resistant to viral oncolysis in vitro, it is 
highly unlikely that they could be effectively eliminated in vivo, suggesting the 
importance of in vitro pretesting (when possible) in identifying virus-resistant cancers.  
There are several important characteristics of VSV which in combination make it 
more attractive candidate for PDA treatment compared to other tested viruses: (i) there 
are few if any restrictions to VSV attachment and entry as it is believed to be not 
dependent on any host receptor in target cells; (ii) there is no preexisting immunity 
against VSV in humans; iii) VSV is not considered a significant human pathogen, and 
several VSV mutants, including VSV-∆M51-GFP and VSV-p1-GFP, are not neurotropic 
but retain their oncolytic activity; (iv) cellular uptake in many mammalian cell types 
occurs very rapidly and there is no cell cycle dependency; vi) our comparative analysis 
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here demonstrated that VSV variants showed superior oncolytic abilities compared to 
other viruses, and some cell lines that exhibited resistance to other viruses were 
successfully killed by VSV. 
There are several potential options for virus-resistant cancer cells. Prescreening 
cells against an array of different OVs could identify the best option for treating a 
particular tumor. For example, VSV-∆M51-GFP is more suitable than CRAds for treating 
PDAs similar to SU.86.86 cells which showed a complete lack of CAR expression 
required for adenovirus attachment (data not shown). In the cases where cells are less 
permissive to VSV-∆M51-GFP than VSV-wt or VSV-p1-GFP (HPAF-II and Hs766T), 
the use of VSV-p1-GFP might be a better option, especially because this virus is also 
non-neurotoxic in vivo. Combination therapies have also demonstrated some success. 
Virotherapy in combination with chemotherapy can enhance the oncolytic effect 
compared to either treatment alone (Ottolino-Perry et al. 2010). Treating tumors with 
more than one OV (combined virotherapy) could also potentially lead to enhanced 
oncolysis (Le Boeuf et al. 2010). Importantly, understanding the mechanisms and 
identifying potential biomarkers of resistance is critical for the development of 
prescreening approaches and individualized oncolytic virotherapy against PDA. 
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3.5 Figure 16 
 
Figure 16. Viruses used in this study. VSV-p1-GFP has the GFP ORF inserted in position 
one of the viral genome resulting in attenuation of the virus. VSV-∆M51-GFP has a 
deletion at amino acid position 51 of the matrix (M) protein reducing its ability to 
suppress host immunity. In addition, VSV-∆M51-GFP has the GFP ORF inserted in 
position 5 of the viral genome. SeV-GFP has the GFP ORF inserted at position one of the 
viral genome and a mutation in the cleavage site of the fusion (F) protein allowing for F 
activation and production of infectious virus particles in cell without trypsin addition. 
RSV-GFP has GFP ORF inserted at position one of the viral genome. CRAd-dl1520 is 
attenuated by deletion of a large part of the coding sequence for the E1b55k viral gene 
product. CRAd-hTERT is a human telomerase reverse transcriptase (hTERT)-dependent 
CRAd. 
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3.5 Figure 17 
 
Figure 17. PDA cell viability following infection with viruses. PDA cell lines and HPDE 
were seeded in 96-well plates so that they reached 80% confluency at 24 h. The cells 
were infected with the indicated viruses at MOI of 1 (A) or 0.01 (B) CIU/cell or mock 
infected. Cell viability was analyzed at 5 d p.i. by an MTT cell viability assay and 
expressed as a ratio of virus-treated to mock-treated cells for each time point. All MTT 
assays were done in triplicate and the data represent the mean ± standard deviation. Cell 
lines are grouped arbitrarily based on their susceptibility to virus-induced oncolysis.   
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3.5 Figure 18 
 
Figure 18. Kinetics of cytopathogenicity of VSV-∆M51-GFP in PDA cells. Cells were 
seeded in 96-well plates so that they reached 50% confluency at 24 h. Cells were then 
mock infected or virus infected at low (0.001 CIU/cell), intermediate (0.1 CIU/cell), or 
high MOI (1 CIU/cell). An MTT cell viability assay was performed at 1, 16, 24, 48, and 
72 h p.i. Cell viability is expressed as the % of mock-infected at 1 h p.i. All MTT assays 
were done in triplicate and the data represent the mean ± standard deviation. 
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3.5 Figure 19 
 
Figure 19. Permissiveness of PDA cell lines to different viruses. PDA cell lines and 
HPDE were incubated with serial dilutions of viruses. The infectious foci of VSV-∆M51-
GFP, VSV-GFP(p1) (24 h p.i.) and SeV-GFP (48 h p.i.) were analyzed by fluorescent 
microscopy. The infectious foci of VSV-wt, CRAd-dl1520 and CRAd-hTERT were 
analyzed by ICC as described in Materials and Methods. Virus permissiveness (relative 
yield) is expressed as the log10 of the ratio of virus titer on the pancreatic cell line under 
study to the titer on a reference cell line (4T1 for VSV and SeV; HeLa for CRAds). The 
following titers were observed on reference cell lines: VSV-wt (1.6 x 10
9
 CIU/ml on 
4T1), VSV-∆M51-GFP (3.3 x 10
8
 CIU/ml on 4T1), VSV-p1-GFP (3 x 10
7
 CIU/ml on 
4T1), SeV-GFP (1.5 x 10
7
 CIU/ml on 4T1), CRAd-hTERT (1.5 x 10
7
 CIU/ml on HeLa) 
and CRAd-dl1520 (4 x 10
8
 CIU/ml on HeLa). Relative yield 0 indicates that the PDA cell 
line is equally permissive to the virus as a reference cell line, while higher numbers 
indicate greater permissiveness. Area of infectious foci was analyzed using Image J 
software (NIH): "Small = area <10 (surface area units); Medium = area  10-30; Large = 
area >30. nd = not done. 
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3.5 Figure 20 
 
Figure 20. Permissiveness of selected PDA cell lines to virus infection. Representative 
PDA cell lines (not all shown) were incubated with serial dilutions of VSV-∆M51-GFP 
and CRAd-dl1520. The infectious foci of VSV-∆M51-GFP were analyzed by fluorescent 
microscopy at 24 h p.i. The infectious foci of CRAd-dl1520 were analyzed by ICC at 5 d 
p.i as described in Materials and Methods.  
 
126 
3.5 Figure 21 
 
Figure 21. Surface expression of adenovirus CAR receptor. Single cell suspensions of 
HeLa (positive control) and SU.86.86 cells (obtained without trypsin) were analyzed for 
adenovirus CAR receptor using anti-CAR antibody and secondary IgG-FITC antibody 
(solid lines) or secondary IgG-FITC antibody only (gray area). Expression of CAR was 
determined by flow cytometry (Beckman Coulter) and analyzed using FlowJo (Treestar, 
Ashland, OR) as described in Materials and Methods. 
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3.5 Figure 22 
 
Figure 22. Analysis of viral protein accumulation in cells at 16 h p.i. Cells were mock 
infected or infected them with VSV-∆M51-GFP at MOI 1 or 10 CIU/cell.  Cells were 
harvested at 16 h p.i. and cell lysates were analyzed by western blot for VSV proteins, 
GFP or actin.  
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3.5 Figure 23 
 
Figure 23. Early viral RNA levels in infected cells. Cells were mock treated or treated 
with 100 µg/ml cycloheximide (CHX) for 30 min prior to mock infection or infection 
with VSV-∆M51-GFP at MOI 10 and continuing treatment with CHX. At 4 h p.i., cells 
were collected and total RNA extracted and analyzed by Northern blot for VSV 
antigenome RNA (upper panel) or N mRNA (lower panel).   
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3.5 Figure 24 
 
Figure 24. One-step growth kinetics of VSVs in PDA cell lines. PDA cells were infected 
with VSV-wt, VSV-∆M51-GFP, or VSV-p1-GFP at MOI 10 CIU/cell that was calculated 
based on the reference cell line 4T1. At 1 h p.i. virus was aspirated and cells were washed 
and overlaid with 5% growth media. At 1, 24, 50 and 72 h p.i. supernatant was collected 
and virus titers determined by plaque assay on BHK-21 cells. All infections were done in 
duplicate and the data represent the mean ± standard deviation. 
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3.5 Figure 25 
 
Figure 25. Type I interferon sensitivity of PDA cell lines. PDA cell lines and HPDE were 
either treated with 5000 U/ml IFN-α in SFM or mock-treated with SFM only. Twenty-
four h post treatment, cells were infected with serial dilutions of VSV-∆M51-GFP, and 
infectious foci were analyzed 16 h p.i. by fluorescent microscopy to calculate virus titer 
under these conditions. Treatments and infections were performed in duplicate and 
average values are shown. For HPAC cells pretreated with IFN-α, virus-driven GFP 
signal was delayed by 24 h p.i. 
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3.5 Figure 26 
 
Figure 26. Type I interferon production by PDA cell lines. Cells were infected with VSV-
∆M51-GFP at MOI of 10 CIU/cell or mock-treated with SFM only. One h p.i. virus was 
aspirated and supernatant was harvested and analyzed by ELISA for production of human 
IFN-β. Infections were performed in triplicate and the data represent the mean ± standard 
deviation. Comparison of groups was done by using 2-way ANOVA followed by the 
Bonferroni posttest for multiple comparisons (***, P < 0.001). 
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3.5 Figure 27 
 
Figure 27. Efficacy of VSV-∆M51-GFP and CRAd-dl1520 in nude mice bearing human 
PDA tumors. 6-8 week old, male, athymic nude mice were subcutaneously injected with 
Mia PaCa2, Panc-1, HPAF-II, or Su.86.86 cells into the right flank (n=18 per group). 
Tumors were established by day 13 and mice were randomly divided into 3 groups (n=6 
per group). One group served as a control and received one IT administration of 50 μl 
PBS only. The other two groups were administered IT once with VSV-∆M51-GFP or 
CRAd-dl1520 at a dose of 5x10
7
 CIU in 50 μl PBS. Tumor size was monitored by caliper 
measurements and tumor weight was calculated according to the formula: grams = 
(length in centimeters x (width)
2
)/2. Comparison of groups was done by using 2-way 
ANOVA followed by the Bonferroni posttest for multiple comparisons (*, P < 0.05, **, P 
< 0.01, ***, P < 0.001).  
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3.6 Table 4. PDA cell lines used in this study. 
PDA cell line Origin Tumor type 
AsPC-1 Human Ascites 
BxPC-3 Human Primary 
CFPAC Human Primary 
Capan-1 Human Liver metastasis 
Capan-2 Human Primary 
HPAC Human Primary 
HPAF-II Human Primary 
Hs766T Human Lymph node metastasis 
MIA PaCa2 Human Primary 
Panc-1 Human Primary 
Su.86.86 Human Liver metastasis 
Suit2 Human Liver metastasis 
T3M4 Human Lymph node metastasis 
HPDE 
Human Non-malignant pancreatic 
ductal epithelia 
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3.6 Table 5.  Early viral RNA synthesis in cells infected with VSV-∆M51-GFP. 
Cell Line 
Primary 
TXN
a
 
Total  
TXN
b
 
Total TXN 
/  Primary 
TXN 
Antigeno
me 
RNA
c
  
Total TXN 
/ 
Antigenom
e RNA 
AsPC-1 668 29232 44 1276 23 
BxPC-3 37 1517 41 40 38 
CFPAC 172 10911 63 230 47 
Capan-1 1728 31394 18 2205* 14 
Capan-2 249 14807 59 1401* 11 
HPAC 56 1549 28 60* 26 
HPAF-II 27 899 34 18* 49 
Hs766T 181 3891 22 86 45 
MIA 
PaCa2 1520 31434 21 1857 17 
Panc-1 1126 34698 31 1401 25 
Su.86.86 5162 46195 9 1428 32 
Suit2 854* 41203* 48 2988* 14 
T3M4 378 14363 38 1051 14 
HPDE 1682 32759 19 1803 18 
 
a
 VSV N mRNA transcription (TXN) level  4 h p.i. in the presence of cycloheximide 
b
 VSV N mRNA transcription (TXN) level 4 h p.i. in the absence of cycloheximide 
c
 VSV antigenome RNA synthesis level 4 h p.i. in the absence of cycloheximide 
*values are for RNA bands detected using a phosphoimager and quantitated using Image 
Quant software, the average of two independent repeats except as indicated  
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3.6 Table 6. Correlation between IFN sensitivity, production and resistance of PDA cells 
to VSV. 
 IFN 
sensitivity 
(24 h p.i.) 
IFN-β 
production 
(18 h p.i.) 
In vitro 
resistance to 
VSV-∆M51-
GFP  
AsPC-1 +++ - - 
Su.86.86 - - - 
Capan-1 +++ - - 
Panc-1 - - - 
MIA PaCa2 - - - 
Suit2 ++ - - 
Capan-2 + - - 
T3M4 + - - 
CFPAC ++ - ++ 
HPDE + +++ +++ 
HPAC - +++ ++ 
BxPC-3 +++ - +++ 
HPAF-II +++ +++ +++ 
Hs766T + +++ +++ 
+++  high levels of IFN sensitivity, IFN production, or virus resistance 
++     intermediate levels of IFN sensitivity, IFN production, or virus resistance 
+       low levels of IFN sensitivity, IFN production, or virus resistance 
-        no detectible levels of IFN sensitivity, IFN production, or virus resistance 
 
 
CHAPTER 4: DISSERTATION SUMMARY 
 
 
VSV and SeV are the prototypic members of the NNS RNA viruses of the order 
Mononegavirales and are related to many medically important human and animal 
pathogens. Understanding the molecular biology of VSV and SeV is an important step in 
understanding the biology of these more dangerous viruses, and additionally VSV and 
SeV have great potential as vectors for vaccine development, gene therapy and oncolytic 
virus (OV) therapy. This dissertation analyzed the cap methylation function of the SeV L 
protein in comparison to what has been previously shown for the VSV L protein we 
identified several aa residues required for SeV cap methylation function. In addition, we 
analyzed for the first time, the oncolytic potential of VSV in a pancreatic ductal 
adenocarcinoma (PDA) model and we observed that VSV can be a highly effective 
oncolytic agent against PDA. 
Sequence-function analysis of the Sendai virus L protein domain VI 
 To begin our comparative analysis of domain VI of the VSV and SeV L proteins, 
we hypothesized that domain VI of VSV and SeV had similar importance in cap 
methylation function. We performed a sequence alignment and targeted aa residues that 
are highly conserved in Mononegavirales, were shown to effect cap methylation function 
in VSV (positions of the KDKE catalytic tetrad and glycine-rich motif), and are present 
in other MTases. Using site-directed mutagenesis, targeted aa residues were substituted 
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for alanines (and in some cases leucines) and twenty-nine mutant SeV L proteins were 
generated (all mutations were in domain VI). Our focus was on the aa residues of the 
KDKE catalytic tetrad and the glycine-rich motif (the putative methyl donor binding 
site), in addition to several other highly conserved aa residues in domain VI of the L 
protein. We targeted residues D1799 and Y1802 located just upstream of the glycine-rich 
motif and conserved only in some paramyxoviruses. Many classes of MTases of known 
structure contain either a conserved aspartate or glutamate, or a tyrosine residue within 
the beta strand that precedes the conserved glycine-rich motif, but rarely do they contain 
both these residues. A polar residue in this position has been implicated in reaction 
mechanism as the fifth catalytic entity (Kozbial and Mushegian 2005), and we were 
interested in determining whether one or both of these aa may play a functional role in 
SeV MTase. We also targeted the unusual DKDKD sequence located immediately 
upstream of the residue D1799. Although this DKDKD sequence is present only in some 
paramyxoviruses, we wanted to determine whether such high concentration of aspartates 
and lysines and its close proximity to the glycine-rich motif may play some role in cap 
methylation catalysis. All viruses with mutations in this motif were easily rescued and 
had wt-like levels of transcription, replication and cap methylation functions indicating 
these individual positions do not play an important role in L protein function.  
All L protein mutations were cloned into a SeV FL genomic plasmid and using a 
reverse genetics system, this plasmid along with plasmids encoding L, P, and N (the 
proteins necessary for an successful virus replication cycle) were transfected into a 
mammalian cell line (BSR-T7). Twenty-four infectious mutant SeV were generated using 
this system and these mutant viruses contained the specific mutations in their L proteins 
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within the infectious virus particles. We were unable to generate infectious viruses 
containing certain specific L mutations, therefore we tested these mutant L proteins for 
their ability to catalyze genome replication and mRNA synthesis. We found that certain 
mutations completely inactivated the enzymatic function of these L proteins and therefore 
infectious virus particles could not be recovered. We were not surprised that the L-∆VI 
mutant was not functional because deletion of an entire portion of the L would affect 
protein folding, allosteric interactions with other domains, or interactions with other viral 
proteins. The inactivation of the L-E1805V protein was more surprising as a similar 
substitution in the VSV hr1 mutant (D1671V), while abolishing cap methylation, had no 
effect on VSV mRNA synthesis (Grdzelishvili et al. 2005). It is likely that the aa 
substitution in the L-E1805V protein negatively affected L protein folding resulting in a 
complete inactivation of this protein. Interestingly, we also observed varying 
transcription and replication levels for other mutants which indicates these specific 
mutations also negatively affected L protein folding or allosteric interactions with other 
domains.    
Infectious SeV with specific mutations within domain VI of the L protein were 
further characterized in cell culture and analyzed for their ability to infect and replicate in 
Vero cells, which are known to support robust replication of SeV. It was shown 
previously for VSV that defects in cap methylation led to attenuation in certain 
nonpermissive cell lines while still retaining the ability to grow to high titers in 
permissive cell lines. We expected to see similar levels of virus replication between 
different SeV mutant viruses in Vero cells because these cells are known to be highly 
permissive to SeV. We found that several SeV mutants had similar infectivity as rWT, 
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however several mutants also exhibited no cytopathic effects in Vero cells. Infection of 
Vero cells by these mutants could be detected by immunofluorescence and were shown to 
be highly attenuated compared to rWT. This result was confirmed in a virus replication 
kinetics experiment. The same SeV mutants that were attenuated in Vero cells 
demonstrated lower titers and delayed infection compared to rWT. We had hypothesized 
that SeV infection in Vero cells would mimic what has been shown for VSV infection in 
BHK cells. Previous studies linked the inability of VSV cap methylation defective 
mutants to grow in nonpermissive cells to a viral defect in mRNA cap G-N7 methylation 
and consequent nontranslatability of primary VSV transcripts (Horikami and Moyer 
1982; Horikami et al. 1984; Grdzelishvili et al. 2005; Grdzelishvili et al. 2006). It was 
also suggested that host cells methylate viral mRNA in permissive cell lines through an 
unknown mechanism (Horikami et al. 1984). The exact mechanism is unknown; 
however, permissive cells can have trans acting MTases present in the cytoplasm 
possibly due to contamination with other viruses or bacteria present in these cells. 
Therefore, SeV mutants being attenuated in Vero cells indicates that this cell line lacks 
the ability to complement cap methylation function as was observed in BHK cells.  
We performed a biochemical analysis of cap methylation status of our mutant 
SeV using an in vitro transcription assay with purified virions in the presence of a 
radiolabeled methyl donor (AdoMet). We observed a correlation between mutant SeV 
attenuation in Vero cells and defective cap methylation especially for viruses carrying 
mutations in the KDKE catalytic tetrad. We also observed that SeV exhibits more 
tolerance to aa substitutions to alanine in the glycine-rich motif as compared to VSV. The 
slight differences in aa residues surrounding the glycine-rich motif of SeV might play a 
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role in the observed tolerance. However, this motif was still shown to be important to 
SeV cap methylation function when we generated mutant viruses with substitutions to 
leucines and observed severe attenuation in cell culture. Unfortunately, in contrast to our 
previous VSV studies (Grdzelishvili et al. 2005; Grdzelishvili et al. 2006), we were 
unable to conduct a very detailed analysis of the SeV cap structure because of very low 
levels of viral mRNA produced in vitro (about 200-fold less viral mRNA compared to 
VSV in vitro transcription system). Nevertheless, our assays (supported by the described 
virus growth analysis) allowed us to make general conclusions about cap methylation 
function in all tested SeV mutants.  
Cap methylation defective viruses (VSV, SeV, or any other Mononegavirales) 
have never been tested in any animal system or primary cells. It is possible that cap 
methylation defective viruses will be attenuated in vivo; however, it is unclear if 
infectious viruses carrying these specific mutations will exhibit any unusual tissue 
specificity as compared to their wild type counterpart. Further studies of cap methylation 
defective viruses in vivo can lead to the rational design of vectors for vaccine, gene 
therapy and oncolytic virotherapy development. Additionally, studying cap methylation 
defective SeV mutants in mice (the natural host of SeV) would provide the unique ability 
to analyze the effect of defective cap methylation over the course of natural infection at 
the organismal level. 
Despite some observed differences between VSV and SeV (more tolerance of 
SeV to aa substitutions in the glycine-rich motif), our analysis identified several aa 
residues required for successful cap methylation and virus replication and clearly showed 
the importance of a putative catalytic tetrad and methyl donor binding site in SeV cap 
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methylation. This study is the first extensive sequence analysis of the L protein domain 
VI in the family Paramyxoviridae, and it confirms structural and functional similarity of 
this domain across different families of the order Mononegavirales. 
VSV as an oncolytic agent against pancreatic ductal adenocarcinoma 
We also analyzed for the first time VSV as an oncolytic agent against pancreatic 
ductal adenocarcinoma (PDA). PDA remains one of the most challenging malignancies to 
treat due to aggressive growth and rapid metastases to surrounding tissues. Other 
oncolytic viruses have had preclinical success in pancreatic cancer however VSV (or any 
VSV variants) has never been tested in any pancreatic cancer model. We chose to focus 
on VSV-∆M51-GFP, a recombinant VSV that retains its oncolytic activities but lacks 
neurotoxicity in vivo (Ahmed 2008; Wollmann 2010) and is being widely used in other 
oncolytic VSV studies. In addition, we compared VSV to other oncolytic viruses 
(CRAds, SeV, and RSV).  There are several important characteristics of VSV which in 
combination make it a more attractive candidate for PDA treatment compared to other 
tested viruses: (i) there are few if any restrictions to VSV attachment and entry as it is 
believed to be not dependent on any specific host receptor in target cells; (ii) there is no 
preexisting immunity against VSV in humans; iii) VSV is not considered a significant 
human pathogen, and several VSV mutants, including VSV-∆M51-GFP and VSV-p1-
GFP, are not neurotropic but retain their oncolytic activity; (iv) cellular uptake in many 
mammalian cell types occurs very rapidly and there is no cell cycle dependency; vi) our 
comparative analysis here demonstrated that VSV variants showed superior oncolytic 
abilities compared to other tested viruses, and some cell lines that exhibited resistance to 
other viruses were successfully killed by VSV. Based on these characteristics, we 
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hypothesized that VSV would be an effective oncolytic agent against PDA. In this study, 
VSV variants and other oncolytic viruses were tested for their ability to infect, replicate 
and cause cell death in a panel of 13 clinically relevant PDA cell lines. VSV variants 
showed superior oncolytic abilities compared to other viruses, and some cell lines that 
exhibited resistance to other viruses were successfully killed by VSV. However, PDA 
cells were highly heterogeneous in their susceptibility to virus-induced oncolysis and 
several cell lines were resistant to all tested viruses (resistance discussed below).  
Four cell lines that varied in their permissiveness to VSV-∆M51-GFP and CRAd-
dl1520 were tested in nude mice, and in vivo results closely mimicked those in vitro, 
indicating in vitro testing can be used to identify cancers resistant to a particular virus. 
However, the ability of a virus to kill cancer cells in vitro or even in vivo (in nude mice) 
would not guarantee its efficacy in cancer patients due to complex tumor 
microenvironments and compromised immune responses (Breitbach et al. 2010). Lack of 
relevant mouse models has contributed to the challenge of developing effective therapies 
for patients suffering from PDA. Until recently, much PDA research has been conducted 
in immunocompromised mouse models that lack important immunologic components and 
signaling pathways which cannot give a clear picture of tumor growth with respect to an 
intact immune system (Clark et al. 2009). Currently there are strategies to better 
understand tumor-immune system interactions using immunocompetent mouse models. 
Mice with induced PDA tumors are created by injecting malignant murine PDA cell lines 
into a particular immunocompetent strain of mice which then develop palpable tumors at 
the site of injection. This system is useful in studying the interactions between the tumor 
microenvironment and host immunity however it is an artificial system in the sense that 
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tumors do not develop orthotopically and injected tumor cells need to be of mouse origin 
(human cell lines would most likely be rejected). In addition to induced mouse models, 
there are a variety of immunocompetent mouse models that have been recently described 
that mimic the natural progression of preinvasive to invasive PDA as observed in human 
patients. Studying these mice has led to a better understanding of the dynamics of the 
tumor microenvironment and host immune interactions (Hingorani et al. 2003). 
Hingorani et al. (2003) developed PDA mice which have a point mutation in one Kras 
allele (LSL-KRAS
G12D
) that is activated upon breeding with mice expressing Cre 
recombinase under control of the pancreas specific p48 promoter (P48-Cre) (Kawaguchi 
et al. 2002). Analyzing VSV-∆M51-based virotherapy in immunocompetent mice that 
closely mimic human progression of PDA would give a clearer picture of the efficacy of 
VSV-∆M51 against PDA. While VSV is one of the most promising oncolytic viruses, 
several obstacles remain to be addressed. Use of an orthotopic model of PDA would 
require intravenous delivery of VSV-∆M51. Intravenous delivery of VSV-∆M51 would 
ideally target only cancer cells (primary tumor and metastases), but there are several 
obstacles to this mode of virus delivery. Delivery of VSV-∆M51 into the bloodstream can 
lead to inactivation of the virus by neutralizing antibodies, complement molecules, and 
other immune components prior to delivery to the tumor. The dose of virus particles 
delivered will also play a major role in the efficacy of VSV-∆M51. There is little 
seroprevalence of VSV in the human population, therefore VSV-∆M51 would be most 
effective upon primary administration, but further administration can lead to faster 
neutralization and clearance of the virus before full oncolytic potential can be achieved. 
One strategy to overcome this would be to deliver multiple doses of VSV-∆M51 within a 
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few days prior to the induction of immune responses. Combination therapies with 
multiple oncolytic viruses might also achieve greater efficacy by eliminating the need to 
administer multiple doses of a single virus. Because of its preclinical success, at least two 
VSV OVs have been considered for clinical trials by the NIH Recombinant-DNA 
Advisory Committee (Cary et al. 2011) and these trials will determine the fate of VSV-
based oncolytic virotherapy.   
While our results demonstrate VSV is a promising oncolytic agent against PDA, 
further studies are needed to better understand the molecular mechanisms of resistance of 
some PDAs to oncolytic virotherapy. There are two major hypotheses explaining varying 
susceptibility of PDA cell lines to oncolysis by VSV in vitro. First, PDA cells may differ 
in their susceptibility to virus infection and/or their ability to support virus replication. 
This may happen because PDA cells may lack key cellular factors (e.g., receptors) 
required for successful virus infection or because resistant cells have intact antiviral 
responses preventing successful virus spread. Alternatively, some PDA cells may have 
defective apoptotic pathways, so that even if a virus can successfully infect and replicate 
in these cells, they are not efficiently killed by apoptosis.  
Resistant PDA cells in this study showed low levels of very early VSV RNA 
synthesis, indicating possible defects at initial stages of infection. VSV infects a wide 
range of cell types, and while there is no distinct receptor identified for VSV, it is thought 
that VSV enters cells through recognition of ubiquitous cell surface molecules or even 
electrostatic interactions (Schlegel et al. 1983; Bailey et al. 1984; Coil and Miller 2004). 
It is possible that VSV entry can be inhibited by steric hindrance by cell surface 
molecules such as mucins, large cell surface molecules that are highly glycosylated and 
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often overexpressed in human cancers (Tinder et al. 2008). Heavily glycosylated mucins 
in pancreatic cancer also create a highly acidic tumor microenvironment (Moniaux et al. 
2004; Wojton and Kaur 2010) which can inhibit the effects of oncolytic virotherapy.  
Unlike permissive PDA cell lines, most of the resistant cell lines were able to both 
produce and respond to Type I IFN, suggesting that intact IFN responses contributed to 
their resistance phenotype. A hallmark of many cancers is a loss of chromosome arm 9p 
where many important tumor suppressor genes, genes for cell cycle control, and the Type 
I IFN genes (IFN-α/β) reside (Vitale et al. 2007). The loss of these important gene 
products provide growth advantages to the tumor  however the inability to produce Type 
I IFN renders tumor cells susceptible to virus infections (Stojdl et al. 2000). While the 
majority of cancer cells lack Type I IFN signaling and production, certain cancer cell 
types retain this function and OVs such as VSV would not be an effective therapy. While 
VSV is an effective OV against tumors that lack Type I IFN, other OVs that utilize 
different mechanisms of oncolysis might be more effective for patients with tumors with 
intact IFN responses. For example, CRAds are OVs that target cancer cells that have 
dysfunctional p53 molecules (also a hallmark of many cancers).  However, our results 
demonstrate cells that are resistant to VSV are also resistant to other OVs, including 
CRAds, which indicates multiple mechanisms are involved in resistant cancer cells. 
Prescreening patient samples for production of Type I IFN would be a useful biomarker 
for determining patients that would respond to VSV-based OV therapy. 
Many cancer cells are also defective in apoptosis, which could delay or prevent 
cell death following infection (Hamacher et al. 2008). As VSV has been shown to cause 
cell death by apoptosis via either the intrinsic and/or extrinsic pathway (Gaddy and Lyles 
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2005; Gaddy and Lyles 2007; Sharif-Askari et al. 2007; Cary et al. 2011), cell lines with 
decreased expression or activation of certain apoptotic proteins have the potential of 
limiting/delaying cell death following VSV infection. Furthermore, differences in 
permissiveness to the VSV variants could be due to differences in their mechanisms of 
cell death induction. Our preliminary analysis of the apoptosis regulatory proteins Bax 
and Bcl-2 failed to show an association with resistance, and in most PDA cell lines 
caspase-3 was activated in a caspase-8 dependent manner following VSV-ΔM51 
infection (data not shown). More studies are needed to determine whether reduced level 
of apoptotic response or the delayed induction of apoptosis in some of these cell lines 
plays a role in restricting VSV oncolysis. These defects could also (in addition to intact 
IFN pathways) explain why cell lines resistant to VSV are also resistant to other, 
unrelated, viruses. 
Cancer cells exhibiting resistance might not be candidates for OV therapy, or 
alternative strategies can be employed to aggressively target resistant cells. There are 
several potential options for virus-resistant cancer cells. Prescreening cells against an 
array of different OVs could identify the best option for treating a particular tumor. 
Combination therapies have also demonstrated some success. Virotherapy in combination 
with chemotherapy can enhance the oncolytic effect compared to either treatment alone 
(Ottolino-Perry et al. 2010). Treating tumors with more than one OV (combined 
virotherapy) could also potentially lead to enhanced oncolysis (Le Boeuf et al. 2010). 
Importantly, understanding the mechanisms and identifying potential biomarkers of 
resistance is critical for the development of prescreening approaches and individualized 
oncolytic virotherapy against PDA. 
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 In summary, the current study analyzed for the first time domain VI of the L 
protein in SeV, and we demonstrated structural and functional similarities between two 
distantly related families of Mononegavirales – rhabdoviruses and paramyxoviruses. This 
region of the L protein plays a role in several aspects of cap methylation of viral mRNAs. 
Additionally, we analyzed the potential of using VSV as an oncolytic agent against PDA. 
While we demonstrated that VSV has superior oncolytic abilities compared to other 
viruses used in our study, further analysis of the molecular mechanisms of resistance of 
certain cell lines can lead to a better understanding of viral infection and oncolysis and 
development towards an improved anticancer therapy.  
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